<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id><journal-id journal-id-type="publisher-id">genes</journal-id><journal-title-group><journal-title>Genes</journal-title></journal-title-group><issn pub-type="epub">2073-4425</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6826991</article-id><article-id pub-id-type="doi">10.3390/genes10100770</article-id><article-id pub-id-type="publisher-id">genes-10-00770</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2166-8395</contrib-id><name><surname>Santos</surname><given-names>Sean M.</given-names></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref></contrib><contrib contrib-type="author"><name><surname>Icyuz</surname><given-names>Mert</given-names></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref></contrib><contrib contrib-type="author"><name><surname>Pound</surname><given-names>Ilya</given-names></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref></contrib><contrib contrib-type="author"><name><surname>William</surname><given-names>Doreen</given-names></name><xref ref-type="aff" rid="af2-genes-10-00770">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6498-9848</contrib-id><name><surname>Guo</surname><given-names>Jingyu</given-names></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref></contrib><contrib contrib-type="author"><name><surname>McKinney</surname><given-names>Brett A.</given-names></name><xref ref-type="aff" rid="af3-genes-10-00770">3</xref></contrib><contrib contrib-type="author"><name><surname>Niederweis</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af2-genes-10-00770">2</xref></contrib><contrib contrib-type="author"><name><surname>Rodgers</surname><given-names>John</given-names></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1176-6469</contrib-id><name><surname>Hartman</surname><given-names>John L.</given-names><suffix>IV</suffix></name><xref ref-type="aff" rid="af1-genes-10-00770">1</xref><xref rid="c1-genes-10-00770" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-genes-10-00770"><label>1</label>Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA<email>icyuz@uab.edu</email> (M.I.); <email>poundilya@yahoo.com</email> (I.P.); <email>guo.jingyu@gmail.com</email> (J.G.); <email>jwrodger@uab.edu</email> (J.R.)</aff><aff id="af2-genes-10-00770"><label>2</label>Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; <email>doreen.william@nct-dresden.de</email> (D.W.); <email>mnieder@uab.edu</email> (M.N.)</aff><aff id="af3-genes-10-00770"><label>3</label>Tandy School of Computer Science and Department of Mathematics, The University of Tulsa, Tulsa, OK 74104, USA; <email>brett.mckinney@gmail.com</email></aff><author-notes><corresp id="c1-genes-10-00770"><label>*</label>Correspondence: <email>jhartman@uab.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>10</volume><issue>10</issue><elocation-id>770</elocation-id><history><date date-type="received"><day>22</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Knowledge about synthetic lethality can be applied to enhance the efficacy of anticancer therapies in individual patients harboring genetic alterations in their cancer that specifically render it vulnerable. We investigated the potential for high-resolution phenomic analysis in yeast to predict such genetic vulnerabilities by systematic, comprehensive, and quantitative assessment of drug&#x02013;gene interaction for gemcitabine and cytarabine, substrates of deoxycytidine kinase that have similar molecular structures yet distinct antitumor efficacy. Human deoxycytidine kinase (dCK) was conditionally expressed in the <italic>Saccharomyces cerevisiae</italic> genomic library of knockout and knockdown (YKO/KD) strains, to globally and quantitatively characterize differential drug&#x02013;gene interaction for gemcitabine and cytarabine. Pathway enrichment analysis revealed that autophagy, histone modification, chromatin remodeling, and apoptosis-related processes influence gemcitabine specifically, while drug&#x02013;gene interaction specific to cytarabine was less enriched in gene ontology. Processes having influence over both drugs were DNA repair and integrity checkpoints and vesicle transport and fusion. Non-gene ontology (GO)-enriched genes were also informative. Yeast phenomic and cancer cell line pharmacogenomics data were integrated to identify yeast&#x02013;human homologs with correlated differential gene expression and drug efficacy, thus providing a unique resource to predict whether differential gene expression observed in cancer genetic profiles are causal in tumor-specific responses to cytotoxic agents.</p></abstract><kwd-group><kwd>yeast phenomics</kwd><kwd>gene&#x02013;drug interaction</kwd><kwd>genetic buffering</kwd><kwd>quantitative high throughput cell array phenotyping (Q-HTCP)</kwd><kwd>cell proliferation parameters (CPPs)</kwd><kwd>gemcitabine</kwd><kwd>cytarabine</kwd><kwd>recursive expectation-maximization clustering (REMc)</kwd><kwd>pharmacogenomics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-genes-10-00770"><title>1. Introduction</title><p>Genomics has enabled targeted therapy aimed at cancer driver genes and oncogenic addiction [<xref rid="B1-genes-10-00770" ref-type="bibr">1</xref>], yet traditional cytotoxic chemotherapeutic agents remain among the most widely used and efficacious anticancer therapies [<xref rid="B2-genes-10-00770" ref-type="bibr">2</xref>]. Changes in the genetic network underlying cancer can produce vulnerabilities to cytotoxic chemotherapy that further influence the therapeutic window and provide additional insight into their mechanisms of action [<xref rid="B3-genes-10-00770" ref-type="bibr">3</xref>,<xref rid="B4-genes-10-00770" ref-type="bibr">4</xref>]. A potential advantage of so-called synthetic lethality-based treatment strategies is that they could have efficacy against passenger gene mutation or compensatory gene expression, while classic targeted therapies are directed primarily at driver genes (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>A). Quantitative high throughput cell array phenotyping of the yeast knockout and knockdown libraries provides a phenomic means for systems level, high-resolution modeling of gene interaction [<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>,<xref rid="B6-genes-10-00770" ref-type="bibr">6</xref>,<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>], which is applied here to predict cancer-relevant drug&#x02013;gene interaction through integration with cancer pharmacogenomics resources (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>B). </p><p>Nucleoside analogs include a diverse group of compounds with anticancer, antiviral, and immunosuppressive efficacy [<xref rid="B10-genes-10-00770" ref-type="bibr">10</xref>]. The anticancer agents have tissue-specific efficacy ranging from solid tumors to leukemias, yet details about how these agents confer differential activity are unknown [<xref rid="B10-genes-10-00770" ref-type="bibr">10</xref>,<xref rid="B11-genes-10-00770" ref-type="bibr">11</xref>]. Gemcitabine (2&#x02032;,2&#x02032;-difluoro 2&#x02032;-deoxycytidine, dFdC) and cytarabine (Ara-C) are deoxycytidine analogs that undergo the first step of conversion to their active triphosphate forms by deoxycytidine kinase (dCK) (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>C). The nucleoside triphosphate analogs can be incorporated into DNA and inhibit the functions of polymerases and other enzymes involved in DNA metabolism. For example, gemcitabine inhibits ribonucleotide reductase (RNR), which limits the production of deoxyribonucleotides (dNTPs) that are needed for DNA synthesis and repair [<xref rid="B11-genes-10-00770" ref-type="bibr">11</xref>]. Gemcitabine has been used as a single agent in the treatment of some cancers, such as pancreatic, and in combination with platinum-based drugs in non-small-cell lung, breast, and ovarian cancers [<xref rid="B12-genes-10-00770" ref-type="bibr">12</xref>,<xref rid="B13-genes-10-00770" ref-type="bibr">13</xref>,<xref rid="B14-genes-10-00770" ref-type="bibr">14</xref>,<xref rid="B15-genes-10-00770" ref-type="bibr">15</xref>]. Cytarabine, on the other hand, has been an important agent in treatments for acute myeloid leukemia and acute lymphoblastic leukemia [<xref rid="B16-genes-10-00770" ref-type="bibr">16</xref>].</p><p>Deoxycytidine kinase (dCK) phosphorylates deoxycytidine to deoxycytidine monophosphate (dCMP), similarly phosphorylating gemcitabine and cytarabine to dFdCMP and AraCMP, respectively. UMP/CMP kinase and the nucleoside diphosphate kinase are subsequently involved in conversion to the triphosphate form (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>C). Reduced expression of dCK or high expression of RNR subunits <italic>RRM1</italic> and <italic>RRM2</italic> is associated with increased gemcitabine resistance [<xref rid="B10-genes-10-00770" ref-type="bibr">10</xref>,<xref rid="B12-genes-10-00770" ref-type="bibr">12</xref>,<xref rid="B17-genes-10-00770" ref-type="bibr">17</xref>,<xref rid="B18-genes-10-00770" ref-type="bibr">18</xref>,<xref rid="B19-genes-10-00770" ref-type="bibr">19</xref>,<xref rid="B20-genes-10-00770" ref-type="bibr">20</xref>,<xref rid="B21-genes-10-00770" ref-type="bibr">21</xref>]. Genomic analyses have suggested genetic influences on the efficacy of gemcitabine or cytarabine [<xref rid="B22-genes-10-00770" ref-type="bibr">22</xref>,<xref rid="B23-genes-10-00770" ref-type="bibr">23</xref>,<xref rid="B24-genes-10-00770" ref-type="bibr">24</xref>,<xref rid="B25-genes-10-00770" ref-type="bibr">25</xref>,<xref rid="B26-genes-10-00770" ref-type="bibr">26</xref>], which we model here at a systems level by surveying gene&#x02013;drug interaction to elucidate biology underlying differential anticancer efficacies of the respective drugs, and thereby aid in predicting treatment outcomes based on individual patient cancer genetic profiles. </p><p><italic>Saccharomyces cerevisiae</italic> does not have a dCK homolog and is thus naturally resistant to gemcitabine and cytarabine. To examine the gene&#x02013;drug interaction networks for gemcitabine and cytarabine in yeast, we introduced human dCK into the yeast knockout and knockdown (YKO/KD) library by the synthetic genetic array (SGA) method [<xref rid="B27-genes-10-00770" ref-type="bibr">27</xref>,<xref rid="B28-genes-10-00770" ref-type="bibr">28</xref>,<xref rid="B29-genes-10-00770" ref-type="bibr">29</xref>] and conducted phenomic analysis on the resulting double mutant library by quantitative high-throughput cell array phenotyping (Q-HTCP) [<xref rid="B6-genes-10-00770" ref-type="bibr">6</xref>,<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>] using multiple growth inhibitory concentrations of gemcitabine or cytarabine (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>B). Cell proliferation parameters (CPPs) obtained by Q-HTCP were used to quantify and compare drug&#x02013;gene interaction for gemcitabine vs. cytarabine. The unbiased results provide a systems-level resource of genetic and biological information about the cytotoxicity of these drugs, incorporating knowledge about genes that either buffer or promote their effects [<xref rid="B3-genes-10-00770" ref-type="bibr">3</xref>,<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>].</p><p>Recent advances in cancer pharmacogenomics have provided gene expression and drug sensitivity data from hundreds of cancer cell lines, establishing associations between gene expression and anticancer efficacy for many compounds, including gemcitabine and cytarabine [<xref rid="B30-genes-10-00770" ref-type="bibr">30</xref>,<xref rid="B31-genes-10-00770" ref-type="bibr">31</xref>,<xref rid="B32-genes-10-00770" ref-type="bibr">32</xref>]. We investigated the potential utility of a yeast phenomic model of chemotherapy sensitivity and resistance for predicting causality in correlations between differential gene expression and drug sensitivity by generating a network-level drug&#x02013;gene interaction resource. The resource integrates cancer pharmacogenomic and yeast phenomic data, using the results to query the cancer genetics literature in order to obtain systems-level biological insights about how yeast phenomic models help predict cytotoxic chemotherapy efficacy based on unique genetic alterations specific to each individual patient&#x02019;s cancer (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>A).</p></sec><sec id="sec2-genes-10-00770"><title>2. Materials and Methods</title><sec id="sec2dot1-genes-10-00770"><title>2.1. Strains, Media, and Drugs</title><p>We obtained the yeast gene knockout strain library (YKO) from Research Genetics (Huntsville, AL, USA) and the knockdown (KD) collection, also referred to as the decreased abundance of mRNA production (DAmP) library, from Open Biosystems (Huntsville, AL, USA). The YKO library is in the genetic background of BY4741 (S288C MATa <italic>ura3-&#x02206;0 his3-&#x02206;1 leu2-&#x02206;0 met17-&#x02206;0</italic>). Additional information and strains can be obtained at <uri xlink:href="https://dharmacon.horizondiscovery.com/cdnas-and-orfs/non-mammalian-cdnas-and-orfs/yeast/#all">https://dharmacon.horizondiscovery.com/cdnas-and-orfs/non-mammalian-cdnas-and-orfs/yeast/#all</uri>. Some mutants appear multiple times in the library and they are treated independently in our analysis. HLD is a modified synthetic complete medium [<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>] and was used with 2% dextrose (HLD) as the carbon source. Doxycycline hydrochloride (BP26535) was obtained from Fisher Scientific. Gemcitabine (Gemzar) was obtained from Eli Lilly and Company (0002-7502-01). Cytarabine was obtained from Bedford Laboratories (55390-131-10).</p><p>A tet-inducible dCK query allele was constructed in the SGA background in the following way: An integrating plasmid for doxycycline-inducible gene expression was constructed by subcloning 3&#x02032;UTR and 5&#x02032;ORF targeting sequences from the LYP1 locus into pJH023 [<xref rid="B33-genes-10-00770" ref-type="bibr">33</xref>], creating pJH023_UO_lyp1, and the reverse VP16 transactivator (Tet-ON), obtained by PCR from pCM176 [<xref rid="B34-genes-10-00770" ref-type="bibr">34</xref>], was fused to the <italic>ACT1</italic> promoter by overlap PCR and subcloned into pJH023_UO_lyp1, replacing the VP16 transactivator (Tet-OFF) and creating the &#x0201c;Tet-ON&#x0201d; construct, pML1055 [<xref rid="B35-genes-10-00770" ref-type="bibr">35</xref>]. pML1055 was digested with NOT1 and transformed into strain 15578-1.2b_LYP1 (<italic>MAT&#x003b1; his3&#x02206;1 leu2&#x02206;0 ura3&#x02206;0 can1&#x02206;0::P<sub>GAL1</sub>-T<sub>ADH1</sub>-P<sub>MFA1</sub>-his5<sup>+</sup><sub>sp</sub> hmr&#x02206;0::URA3ca</italic>), which was derived by backcrossing 15578-1.2b (<italic>MAT&#x003b1; his3&#x02206;1 leu2&#x02206;0 ura3&#x02206;0 can1&#x02206;0::P<sub>GAL1</sub>-T<sub>ADH1</sub>-P<sub>MFA1</sub>-his5<sup>+</sup><sub>sp</sub> lyp1&#x02206;0 hmr&#x02206;0::URA3ca</italic>) to restore the <italic>LYP1</italic> locus. The resulting chromosomal integration of pML1055 between the promoter and ORF at the <italic>LYP1</italic> locus was selected with nourseothricin, giving rise to DWY1 (<italic>MAT&#x003b1; his3&#x02206;1 leu2&#x02206;0 ura3&#x02206;0 can1&#x02206;0::P<sub>GAL1</sub>-T<sub>ADH1</sub>-P<sub>MFA1</sub>-his5<sup>+</sup><sub>sp</sub> hmr&#x02206;0::URA3ca Pact1-revTetR-VP16</italic>-natMX-<italic>PtetO7-LYP1</italic>). Tet-inducible <italic>LYP1</italic> in DWY1 was verified phenotypically by doxycycline-dependent SAEC sensitivity [<xref rid="B35-genes-10-00770" ref-type="bibr">35</xref>]. Overlap PCR was performed to fuse deoxycytidine kinase (from a plasmid, gift of Bo Xu and William Parker, Southern Research) and the HPH gene (from pFA6a-HBH-hphMX4) [<xref rid="B36-genes-10-00770" ref-type="bibr">36</xref>], introducing flanking sequences for replacement of the <italic>LYP1</italic> ORF (see <xref ref-type="app" rid="app1-genes-10-00770">Additional File 1, Table S1</xref> for primers). The PCR product was transformed into DWY1 (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 2, Figure S1</xref>) and transformants selected on hygromycin were confirmed by doxycycline-induced sensitivity to gemcitabine and cytarabine, yielding MIY16 (<italic>MAT&#x003b1; his3&#x02206;1 leu2&#x02206;0 ura3&#x02206;0 can1&#x02206;0::P<sub>GAL1</sub>-T<sub>ADH1</sub>-P<sub>MFA1</sub>-his5<sup>+</sup><sub>sp</sub> hmr&#x02206;0::URA3ca lyp1-&#x02206;0::Pact1-revTetR-VP16</italic>-natMX-<italic>PtetO7-DCK</italic>). </p><p>The synthetic genetic array (SGA) method, a way to introduce an allele of interest into the YKO/KD library and recover haploid double mutants [<xref rid="B28-genes-10-00770" ref-type="bibr">28</xref>,<xref rid="B29-genes-10-00770" ref-type="bibr">29</xref>], was used to derive a haploid YKO/KD collection with doxycycline-inducible dCK expression. </p></sec><sec id="sec2dot2-genes-10-00770"><title>2.2. Quantitative High Throughput Cell Array Phenotyping (Q-HTCP)</title><p>Q-HTCP, an automated method of collecting growth curve phenotypes for the YKO/KD library arrayed onto agar media, was used to obtain phenomic data [<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. A Caliper Sciclone 3000 liquid handling robot was used for cell array printing, integrated with a custom imaging robot (Hartman laboratory) and Cytomat 6001 (Thermo Fisher Scientific, Asheville, NC, USA) incubator. Images of the 384-culture arrays were obtained approximately every 2&#x02013;3 hours and analyzed as previously described [<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. To obtain CPPs, image analysis was performed in Matlab and data were fit to the logistic equation, G(t) = K/(1 + e<sup>&#x02212;r(t&#x02212;l)</sup>), assuming G(0) &#x0003c; K, where G(t) is the image intensity of a spotted culture vs. time, K is the carrying capacity, r is the maximum specific growth rate, and l is the moment of maximal absolute growth rate, occurring when G(t) = K/2 (the time to reach half of carrying capacity) [<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>]. The CPPs, primarily K and L, were used as phenotypes to measure drug&#x02013;gene interaction.</p></sec><sec id="sec2dot3-genes-10-00770"><title>2.3. Quantification of Drug&#x02013;Gene Interaction </title><p>Gene interaction was defined as departure of the corresponding YKO/KD strain from its expected phenotypic response to gemcitabine or cytarabine [<xref rid="B6-genes-10-00770" ref-type="bibr">6</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B38-genes-10-00770" ref-type="bibr">38</xref>]. The expected phenotype depends, in part, on the difference in cell proliferation phenotypes between the mutant and reference strain without gemcitabine or cytarabine, which we have termed shift. This difference is applied to the entire data series (hence the term, &#x02018;shift&#x02019;), when assessing differential response in cell proliferation phenotypes between the mutant and reference strain in the presence of escalating concentrations of gemcitabine or cytarabine [<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>,<xref rid="B6-genes-10-00770" ref-type="bibr">6</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B33-genes-10-00770" ref-type="bibr">33</xref>]. The concentrations of gemcitabine or cytarabine (&#x003bc;g/mL) were chosen based on phenotypic responses being functionally discriminating in the parental strain. Gemcitabine, cytarabine, or doxycycline, alone, did not alter cell proliferation (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>C&#x02013;F; <xref ref-type="app" rid="app1-genes-10-00770">Additional File 2, Figure S2A&#x02013;D</xref>). Thus, shift was calculated in the presence of 5 &#x003bc;g/mL doxycycline without nucleoside analog.</p><p>Interaction scores were calculated as previously described [<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B39-genes-10-00770" ref-type="bibr">39</xref>], with slight modifications, as summarized below. All media conditions used for interaction score calculation had 5 &#x003bc;g/mL doxycycline to express dCK. Variables were defined as:<list list-type="simple"><list-item><p>D<sub>i</sub> = concentration (dose) of gemcitabine or cytarabine;</p></list-item><list-item><p>R<sub>i</sub> = observed mean growth parameter for parental reference strain at D<sub>i</sub>;</p></list-item><list-item><p>Y<sub>i</sub> = observed growth parameter for the YKO/KD mutant strain at D<sub>i</sub>;</p></list-item><list-item><p>K<sub>i</sub> = Y<sub>i</sub> &#x02212; R<sub>i</sub>, the difference in growth parameter between the YKO/KD mutant (Y<sub>i</sub>) and reference (R<sub>i</sub>) at D<sub>i</sub>; </p></list-item><list-item><p>K<sub>0</sub> = Y<sub>0</sub> &#x02212; R<sub>0</sub>, the effect of gene KO/KD on the observed phenotype in the absence of gemcitabine or cytarabine&#x02014;this value is annotated as &#x02018;shift&#x02019; and is subtracted from all K<sub>i</sub> to obtain L<sub>i</sub>;</p></list-item><list-item><p>L<sub>i</sub> = K<sub>i</sub> &#x02212; K<sub>0</sub>, the interaction between (specific influence of) the KO/KD mutation on gemcitabine or cytarabine response, at D<sub>i</sub>;</p></list-item></list></p><p>For cultures not generating a growth curve, Y<sub>i</sub> = 0 for K and r. Note, however, that for cultures with extremely low growth, the L parameter asymptote is infinity and thus it was assigned Y<sub>i</sub> max, defined as the maximum observed Y<sub>i</sub> among all cultures exhibiting a minimum carrying capacity (K) within 2 standard deviation (SD) of the parental reference strain mean at D<sub>i</sub>. Y<sub>i</sub> max was also assigned to outlier values (i.e., if Y<sub>i</sub> &#x0003e; Y<sub>i</sub> max).</p><p>Interaction Was Calculated by the Following Steps:<list list-type="simple"><list-item><label>(1)</label><p>Compute the average value of the 768 reference cultures (R<sub>i</sub>) at each dose (D<sub>i</sub>):</p></list-item><list-item><label>(2)</label><p>Assign Y<sub>i</sub> max (defined above) if growth curve is observed at D<sub>0</sub>, but not at D<sub>i</sub>, or if observed Y<sub>i</sub> is greater than Y<sub>i</sub> max.</p></list-item><list-item><label>(3)</label><p>Calculate K<sub>i</sub> = Y<sub>i</sub> &#x02212; R<sub>i</sub>.</p></list-item><list-item><label>(4)</label><p>Calculate L<sub>i</sub> = K<sub>i</sub> &#x02212; K<sub>0</sub></p></list-item><list-item><label>(5)</label><p>Fit data by linear regression (least squares): L<sub>i</sub> = A + B*D<sub>i</sub></p></list-item><list-item><label>(6)</label><p>Compute the interaction value &#x02018;INT&#x02019; at the max dose: INT = L<sub>i</sub>-max = A + B*D<sub>max</sub></p></list-item><list-item><label>(7)</label><p>Calculate the mean and standard deviation of interaction scores for reference strains, mean(REF<sub>INT</sub>) and SD(REF<sub>INT</sub>); mean(REF<sub>INT</sub>) is expected to be approximately zero, with SD(REF<sub>INT</sub>) primarily useful for standardizing against variance (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 1, Tables S2&#x02013;S5; Additional Files 3&#x02013;4</xref>).</p></list-item><list-item><label>(8)</label><p>Calculate interaction z-scores:</p><p>z-score(YKO<sub>INT</sub>) = (YKO<sub>INT</sub> &#x02212; mean(REF<sub>INT</sub>))/SD(REF<sub>INT</sub>) </p><p>z-score(YKO<sub>INT</sub>) &#x0003e; 2 for L or &#x0003c; &#x02212;2 for K are referred to as gene deletion enhancers of gemcitabine or cytarabine cytotoxicity, and conversely, L interaction score &#x0003c; &#x02212;2 or K interaction scores &#x0003e;2 are considered gene deletion suppressors. Due to the fact that the CPP distributions for KD strains were different from the reference strain, we used the mean and standard deviation from the KD plates only as a conservative measure of variance where z-score(KD<sub>INT</sub>) = (KD<sub>INT</sub> &#x02013; mean(KD<sub>INT</sub>))/SD(KD<sub>INT</sub>).</p></list-item></list></p></sec><sec id="sec2dot4-genes-10-00770"><title>2.4. Recursive Expectation-Maximization Clustering (REMc) and Heatmap Generation</title><p>REMc is a probability-based clustering method and was performed as previously described [<xref rid="B40-genes-10-00770" ref-type="bibr">40</xref>]. Clusters obtained by Weka 3.5, an EM-optimized Gaussian mixture-clustering module, were subjected to hierarchical clustering in R (<uri xlink:href="http://www.r-project.org/">http://www.r-project.org/</uri>) to further aid visualization with heatmaps. REMc was performed using L and K interaction z-scores (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>A). The effect of gene deletion on the CPP (in the absence of drug), termed &#x02018;shift&#x02019; (K<sub>0</sub>), was not used for REMc, but was included for visualization in the final hierarchical clustering. <xref ref-type="app" rid="app1-genes-10-00770">Additional File 5</xref>, Files A&#x02013;B contain REMc results in text files with associated data also displayed as heatmaps. In cases where a culture did not grow in the absence of drug, 0.0001 was assigned as the interaction score, so that associated data (&#x02018;NA&#x02019;) could be easily indicated by red coloring in the shift columns of the heatmaps.</p></sec><sec id="sec2dot5-genes-10-00770"><title>2.5. Gene Ontology Term Finder (GTF)</title><p>A python script was used to format REMc clusters for analysis with the command line version of the GO Term Finder (GTF) tool downloaded from <uri xlink:href="http://search.cpan.org/dist/GO-TermFinder/">http://search.cpan.org/dist/GO-TermFinder/</uri> [<xref rid="B41-genes-10-00770" ref-type="bibr">41</xref>]. GTF reports on enrichment of gene ontology (GO) terms by comparing the ratio of genes assigned to a term within a cluster to the respective ratio involving all genes tested. <xref ref-type="app" rid="app1-genes-10-00770">Additional File 5</xref>, File C contains GTF analysis of all REMc clusters. GO-enriched terms from REMc were investigated with respect to genes representing the term and literature underlying their annotations [<xref rid="B42-genes-10-00770" ref-type="bibr">42</xref>]. </p></sec><sec id="sec2dot6-genes-10-00770"><title>2.6. Gene Ontology Term Averaging (GTA) Analysis </title><p>In addition to using GTF to survey functional enrichment in REMc clusters, we developed GTA as a complementary workflow, using the GO information on SGD at <uri xlink:href="https://downloads.yeastgenome.org/curation/literature/">https://downloads.yeastgenome.org/curation/literature/</uri> to perform the following analysis:<list list-type="order"><list-item><p>Calculate the average and SD for interaction values of all genes in a GO term.</p></list-item><list-item><p>Filter results to obtain terms having GTA value greater than 2 or less than &#x02212;2.</p></list-item><list-item><p>Obtain GTA scores defined as |GTA value| - gtaSD; filter for GTA score &#x0003e; 2.</p></list-item></list></p><p>The GTA analysis is contained in <xref ref-type="app" rid="app1-genes-10-00770">Additional File 6</xref> as tables and interactive plots created using the R plotly package <uri xlink:href="https://CRAN.R-project.org/package=plotly">https://CRAN.R-project.org/package=plotly</uri>. GTA results were analyzed using both the L and K interaction scores and are included in <xref ref-type="app" rid="app1-genes-10-00770">Additional File 6 (Files A&#x02013;C)</xref>.</p></sec><sec id="sec2dot7-genes-10-00770"><title>2.7. Prediction of Human Homologs that Influence Tumor Response to Gemcitabine or Cytarabine</title><p>PharmacoDB holds pharmacogenomics data from cancer cell lines, including transcriptomics and drug sensitivity [<xref rid="B32-genes-10-00770" ref-type="bibr">32</xref>]. The PharmacoGx R/Bioconductor package [<xref rid="B43-genes-10-00770" ref-type="bibr">43</xref>] was used to analyze the GDSC1000 (<uri xlink:href="https://pharmacodb.pmgenomics.ca/datasets/5">https://pharmacodb.pmgenomics.ca/datasets/5</uri>) and gCSI (<uri xlink:href="https://pharmacodb.pmgenomics.ca/datasets/4">https://pharmacodb.pmgenomics.ca/datasets/4</uri>) datasets, which contained transcriptomic and drug sensitivity results. A <italic>p</italic>-value &#x0003c; 0.05 was used for differential gene expression and drug sensitivity. For gene expression, the sign of the standardized coefficient denotes increased (+) or decreased (&#x02212;) expression. The biomaRt R package [<xref rid="B44-genes-10-00770" ref-type="bibr">44</xref>,<xref rid="B45-genes-10-00770" ref-type="bibr">45</xref>] was used with the Ensembl database [<xref rid="B46-genes-10-00770" ref-type="bibr">46</xref>] to match yeast and human homologs from the phenomic and transcriptomic data, classifying yeast&#x02013;human homology as one to one, one to many, and many to many. The Princeton Protein Orthology Database (PPOD) was also used to manually review homology in further consideration of whether or not to include particular genes in the results sections and whether or not cancer literature searches related to the homologs would be worthwhile [<xref rid="B47-genes-10-00770" ref-type="bibr">47</xref>].</p></sec></sec><sec sec-type="results" id="sec3-genes-10-00770"><title>3. Results</title><sec id="sec3dot1-genes-10-00770"><title>3.1. Quantitative Phenomic Characterization of Differential Gene&#x02013;Drug Interaction</title><p>The Q-HTCP workflow incorporates high-throughput kinetic imaging and analysis of proliferating 384-culture cell arrays plated on agar media to obtain CPPs for measuring gene&#x02013;drug interaction, as previously described [<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. To apply it for analysis of dCK substrates, a tetracycline-inducible human dCK allele was introduced into the complete YKO/KD library by the synthetic genetic array method [<xref rid="B29-genes-10-00770" ref-type="bibr">29</xref>,<xref rid="B48-genes-10-00770" ref-type="bibr">48</xref>] (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>B). The dependence of gemcitabine and cytarabine toxicity on dCK expression was demonstrated for the reference strain (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>A&#x02013;F), as the two nucleosides exerted cytotoxicity only if dCK was induced by the addition of doxycycline. Induction of dCK had no effect on proliferation in the absence of gemcitabine or cytarabine (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>C&#x02013;F).</p><p>Interaction scores were calculated by departure of the observed CPP for each YKO/KD strain from that expected based on the observed phenotypes for the reference strain treated and untreated with drugs and the YKO/KD strain in the absence of drugs, incorporating multiple drug concentrations, 768 replicate reference strain control cultures, and summarized by linear regression as z-scores [<xref rid="B6-genes-10-00770" ref-type="bibr">6</xref>,<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B33-genes-10-00770" ref-type="bibr">33</xref>,<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. Gene interaction scores with absolute value greater than two were selected for global analysis and termed deletion enhancers (z-score_L &#x02265; 2 or z-score_K &#x02264; &#x02212;2) or deletion suppressors (z-score_L &#x02264; &#x02212;2 or z-score_K &#x02265; 2) of drug cytotoxicity, revealing functions that buffer or promote drug cytotoxicity, respectively [<xref rid="B39-genes-10-00770" ref-type="bibr">39</xref>] (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>).</p><p>Growth inhibition was greater for gemcitabine than for cytarabine (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>A&#x02013;F), however, the phenotypic variance was also less for cytarabine, such that interactions of smaller effect size were detectable and the range of scores was greater (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 1, Table S6</xref>). The CPP, &#x02018;L&#x02019;, (the time at which half carrying capacity is reached), is most sensitive to growth inhibitory perturbation, while &#x02018;K&#x02019; (carrying capacity) reports on more extreme growth differences (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>A&#x02013;H). Low correlation between the gene&#x02013;drug interaction profiles suggested differential buffering of these two drugs, consistent with their distinct antitumor efficacies (<xref ref-type="fig" rid="genes-10-00770-f002">Figure 2</xref>I,J). </p></sec><sec id="sec3dot2-genes-10-00770"><title>3.2. Functional Analysis of Gene Interaction Modules</title><p>Recursive expectation-maximization clustering (REMc) was used to identify modules of genes that shared similar profiles of buffering or promoting nucleoside toxicity of gemcitabine or cytarabine [<xref rid="B40-genes-10-00770" ref-type="bibr">40</xref>] (see <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>A&#x02013;F; <xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref>; <xref ref-type="app" rid="app1-genes-10-00770">Additional File 5</xref>). As described previously, REMc results were assessed with GO Term Finder for gene ontology functional enrichment [<xref rid="B41-genes-10-00770" ref-type="bibr">41</xref>] and heatmaps generated by first adding data regarding the main effect of the gene knockout or knockdown (i.e., no drug) on cell proliferation, termed &#x02018;shift&#x02019; (see methods), followed by hierarchical clustering [<xref rid="B40-genes-10-00770" ref-type="bibr">40</xref>,<xref rid="B41-genes-10-00770" ref-type="bibr">41</xref>]. GO term average (GTA) scores, which are based on the average and standard deviation of drug&#x02013;gene interaction for all genes of each GO term [<xref rid="B39-genes-10-00770" ref-type="bibr">39</xref>], were used as a complement to REMc/GTF for identifying functions that buffer or promote drug effects (<xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="genes-10-00770-f004">Figure 4</xref>, and <xref ref-type="app" rid="app1-genes-10-00770">Additional File 6, Files A&#x02013;C</xref>). Yeast&#x02013;human homologs were judged, regarding causality of differential gene expression associated with sensitivity to gemcitabine or cytarabine, by the correspondence of yeast phenomic and cancer pharmacogenomics results, thus establishing a model resource to test the utility of yeast phenomics to inform cancer genetic profiling for predicting drug-specific, antitumor efficacy (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>G&#x02013;H). </p><p>Heatmaps were also produced systematically to visualize drug&#x02013;gene interaction profiles for all genes assigned to GO terms identified by REMc/GTF or GTA; these are referred to as term-specific heatmaps and are grouped by GO term parent&#x02013;child relationships (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 7</xref>).</p><p>Cancer pharmacogenomics data in PharmacoDB were mined using <italic>PharmacoGx</italic> [<xref rid="B43-genes-10-00770" ref-type="bibr">43</xref>] and <italic>biomaRt</italic> [<xref rid="B44-genes-10-00770" ref-type="bibr">44</xref>,<xref rid="B45-genes-10-00770" ref-type="bibr">45</xref>] with the Genomics of Drug Sensitivity in Cancer (GDSC) [<xref rid="B30-genes-10-00770" ref-type="bibr">30</xref>,<xref rid="B49-genes-10-00770" ref-type="bibr">49</xref>] or Genentech Cell Line Screening Initiative (gCSI) [<xref rid="B31-genes-10-00770" ref-type="bibr">31</xref>,<xref rid="B50-genes-10-00770" ref-type="bibr">50</xref>] datasets to match yeast drug&#x02013;gene interaction by homology to differential gene expression in gemcitabine or cytarabine sensitive cancer cell lines (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>G&#x02013;H; <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8</xref>). Yeast gene deletion enhancers identified human homologs underexpressed in gemcitabine- or cytarabine-sensitive cells, termed UES, while yeast gene deletion suppressors identified human homologs overexpressed in drug-sensitive cells, termed OES (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>G). </p><p>The analysis was focused on the GDSC database, because it had expression data available for both gemcitabine and cytarabine; however, analysis of the gCSI data was also conducted for gemcitabine (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File A</xref>). Differential expression was analyzed: (1) across all tissue types, to consider interactions that might be applicable in novel treatment settings; (2) in hematopoietic and lymphoid tissue (HaL); and (3) in lung tissue, as cytarabine and gemcitabine are used to treat HaL and lung cancers, respectively. Gemcitabine is also used for pancreatic cancer; however, the number of cell lines tested (30) was lower than for lung (156) or HaL (152). Thus, yeast genes that were deletion enhancing or suppressing were catalogued with human homologs that were UES or OES in PharmacoDB (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>G,H, <xref rid="genes-10-00770-t003" ref-type="table">Table 3</xref>, <xref rid="genes-10-00770-t004" ref-type="table">Table 4</xref> and <xref rid="genes-10-00770-t005" ref-type="table">Table 5</xref>, and <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File A</xref>). </p><p>In summary REMc, GTF, and GTA revealed functional genetic modules that alternatively buffer (deletion enhancing) or promote (deletion suppressing) drug cytotoxicity [<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>,<xref rid="B40-genes-10-00770" ref-type="bibr">40</xref>,<xref rid="B51-genes-10-00770" ref-type="bibr">51</xref>] and illustrated whether the effects were shared or differential between gemcitabine and cytarabine (<xref ref-type="fig" rid="genes-10-00770-f004">Figure 4</xref>). Yeast phenomic information was integrated with pharmacogenomics data results according to yeast&#x02013;human gene homology to identify correlated differential gene expression associated with drug sensitivity in cancer cell lines (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>, <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref> and <xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>). This approach serves to generate hypotheses regarding whether differential expression of a particular gene is causal for increased drug sensitivity [<xref rid="B52-genes-10-00770" ref-type="bibr">52</xref>] and ultimately whether yeast phenomic models can improve the predictive value of cancer pharmacogenomics data in the context of precision oncology [<xref rid="B53-genes-10-00770" ref-type="bibr">53</xref>,<xref rid="B54-genes-10-00770" ref-type="bibr">54</xref>,<xref rid="B55-genes-10-00770" ref-type="bibr">55</xref>,<xref rid="B56-genes-10-00770" ref-type="bibr">56</xref>,<xref rid="B57-genes-10-00770" ref-type="bibr">57</xref>,<xref rid="B58-genes-10-00770" ref-type="bibr">58</xref>].</p></sec></sec><sec id="sec4-genes-10-00770"><title>4. Functions that Respond to Gemcitabine and Cytarabine Similarly</title><sec id="sec4dot1-genes-10-00770"><title>4.1. Genetic Modules that Buffer Cytotoxicity of Both Gemcitabine and Cytarabine</title><p>To characterize gemcitabine and cytarabine, which have similar molecular structures and mechanisms of action, yet different spectra of antitumor efficacy, we first surveyed for buffering genes shared in common. Examples of genes with deletion-enhancing interactions for both drugs are displayed in clusters 2-0.2-0, 1-0-14, 2-0.2-2, and 2-0.16-1 (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>B). GO enrichment was observed in these clusters for the DNA integrity checkpoint; positive regulation of DNA replication; and the Mre11, RecQ helicase-Topo III, CORVET, HOPS, GET, and Ubp3-Bre5 deubiquitination complexes (<xref ref-type="fig" rid="genes-10-00770-f004">Figure 4</xref>, <xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref>). GTA identified many of the same functions and additionally revealed the terms vesicle fusion with vacuole and checkpoint clamp complex (<xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). We mapped yeast gene&#x02013;drug interactions to respective human homologs in PharmacoDB to find evidence for evolutionary conservation of gene&#x02013;drug interaction (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C,D, <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, Files B&#x02013;D</xref>) and buffering mechanisms.</p></sec><sec id="sec4dot2-genes-10-00770"><title>4.2. DNA Integrity Checkpoint and Repair-Related Complexes</title><p>As gemcitabine and cytarabine triphosphate analogs are incorporated into DNA, we anticipated shared interactions with genes functioning in DNA metabolism and repair. Overlap was observed, however there were differential effects between genes assigned to the same gene ontology terms, such that GO TermFinder enrichment in REMc clusters was less than might have been expected. For example, deletion-enhancing gene&#x02013;drug interaction for the GO term, DNA integrity checkpoint, was enriched in cluster 1-0-14, which displayed deletion enhancement for both gemcitabine and cytarabine (<xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref>, <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref> and <xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>A). However, its child term, intra-S DNA damage checkpoint, was not GO-enriched because of differential clustering among drug&#x02013;gene interactions associated with the term (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 5, File C</xref>). Similarly, intra-S DNA damage checkpoint was not identified by GTA due to variation in interaction between genes assigned to the term, highlighting the utility in displaying the phenomic data for each GO term for manual review (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>A). </p><p>Enriched complexes functionally related to the DNA integrity checkpoint function included the RecQ helicase-Topo III, the checkpoint clamp, and the Mre11 complexes (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B). Rmi1, Top3, and Sgs1 form the RecQ helicase Topo III complex, which is involved in Rad53 checkpoint activation and maintenance of genome integrity [<xref rid="B59-genes-10-00770" ref-type="bibr">59</xref>], and together with replication protein A function in DNA decatenation and disentangling of chromosomes [<xref rid="B60-genes-10-00770" ref-type="bibr">60</xref>]. <italic>RMI1</italic> and <italic>SGS1</italic> deletion-enhancement clustered together in 1-0-14, while <italic>TOP3</italic> had a similar, but slightly weaker interaction pattern in cluster 1-0-16 (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 5, File B</xref>). The human homolog of <italic>SGS1</italic>, <italic>RECQL5</italic>, was UES for cytarabine in lung cancer cells (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; see 1-0-14 in 5C, all cluster heatmaps available in <xref ref-type="app" rid="app1-genes-10-00770">Additional File 5, File B</xref>). <italic>RECQL5</italic> preserves genome stability during transcription elongation, and deletion of <italic>RECQL5</italic> increases cancer susceptibility [<xref rid="B61-genes-10-00770" ref-type="bibr">61</xref>,<xref rid="B62-genes-10-00770" ref-type="bibr">62</xref>]. Human <italic>TOP3A</italic> was also UES for cytarabine in lung tissue (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 2-0.16-1). <italic>TOP3A</italic> is underexpressed in ovarian cancer, and mutations in <italic>TOP3A</italic> are associated with increased risk for acute myeloid leukemia and myelodysplastic syndromes, suggesting potential cancer vulnerabilities if somatic, but they can also occur in the germline, which would lead to enhanced host toxicity [<xref rid="B63-genes-10-00770" ref-type="bibr">63</xref>,<xref rid="B64-genes-10-00770" ref-type="bibr">64</xref>,<xref rid="B65-genes-10-00770" ref-type="bibr">65</xref>].</p><table-wrap id="genes-10-00770-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t003_Table 3</object-id><label>Table 3</label><caption><p>Yeast&#x02013;human homologs predicted to similarly buffer or promote both gemcitabine and cytarabine toxicity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">yGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">hGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">H</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description (Human)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAM7</td><td align="center" valign="middle" rowspan="1" colspan="1">HELZ</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B66-genes-10-00770" ref-type="bibr">66</xref>,<xref rid="B67-genes-10-00770" ref-type="bibr">67</xref>,<xref rid="B68-genes-10-00770" ref-type="bibr">68</xref>,<xref rid="B69-genes-10-00770" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">helicase with zinc finger</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAM7</td><td align="center" valign="middle" rowspan="1" colspan="1">HELZ2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">helicase with zinc finger 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAM7</td><td align="center" valign="middle" rowspan="1" colspan="1">UPF1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B70-genes-10-00770" ref-type="bibr">70</xref>,<xref rid="B71-genes-10-00770" ref-type="bibr">71</xref>,<xref rid="B72-genes-10-00770" ref-type="bibr">72</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">UPF1, RNA helicase and ATPase</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PTC1</td><td align="center" valign="middle" rowspan="1" colspan="1">PPM1E</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.7</td><td align="center" valign="middle" rowspan="1" colspan="1">7.9</td><td align="center" valign="middle" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B73-genes-10-00770" ref-type="bibr">73</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">protein phosphatase, Mg2+/Mn2+ dependent 1E</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PTC1</td><td align="center" valign="middle" rowspan="1" colspan="1">PPM1L</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.7</td><td align="center" valign="middle" rowspan="1" colspan="1">7.9</td><td align="center" valign="middle" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B74-genes-10-00770" ref-type="bibr">74</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">protein phosphatase, Mg2+/Mn2+ dependent 1L</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD24</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD17</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">H, L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;27.6</td><td align="center" valign="middle" rowspan="1" colspan="1">14.2</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B75-genes-10-00770" ref-type="bibr">75</xref>,<xref rid="B76-genes-10-00770" ref-type="bibr">76</xref>,<xref rid="B77-genes-10-00770" ref-type="bibr">77</xref>,<xref rid="B78-genes-10-00770" ref-type="bibr">78</xref>,<xref rid="B79-genes-10-00770" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD17 checkpoint clamp loader component</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SGS1</td><td align="center" valign="middle" rowspan="1" colspan="1">RECQL5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;33.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">19.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B61-genes-10-00770" ref-type="bibr">61</xref>,<xref rid="B62-genes-10-00770" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RecQ like helicase 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KTI11_2</td><td align="center" valign="middle" rowspan="1" colspan="1">DPH3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;10.3</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-genes-10-00770" ref-type="bibr">80</xref>,<xref rid="B81-genes-10-00770" ref-type="bibr">81</xref>,<xref rid="B82-genes-10-00770" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">diphthamide biosynthesis 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BIM1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">MAPRE2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">16.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B83-genes-10-00770" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">microtubule associated protein RP/EB family member 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BIM1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">MAPRE2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">16.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B83-genes-10-00770" ref-type="bibr">83</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">microtubule associated protein RP/EB family member 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BIM1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">MAPRE3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">16.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B84-genes-10-00770" ref-type="bibr">84</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">microtubule associated protein RP/EB family member 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ASF1</td><td align="center" valign="middle" rowspan="1" colspan="1">ASF1B</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.5</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B85-genes-10-00770" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">anti-silencing function 1B histone chaperone</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AVL9</td><td align="center" valign="middle" rowspan="1" colspan="1">AVL9</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B86-genes-10-00770" ref-type="bibr">86</xref>,<xref rid="B87-genes-10-00770" ref-type="bibr">87</xref>,<xref rid="B88-genes-10-00770" ref-type="bibr">88</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">AVL9 cell migration associated</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP1A1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B89-genes-10-00770" ref-type="bibr">89</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase Na+/K+ transporting subunit &#x003b1; 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP1A2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B90-genes-10-00770" ref-type="bibr">90</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase Na+/K+ transporting subunit &#x003b1; 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP1A3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase Na+/K+ transporting subunit &#x003b1; 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP1A4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase Na+/K+ transporting subunit &#x003b1; 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP1A4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase Na+/K+ transporting subunit &#x003b1; 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP2C1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B91-genes-10-00770" ref-type="bibr">91</xref>,<xref rid="B92-genes-10-00770" ref-type="bibr">92</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase secretory pathway Ca2+ transporting 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PMR1</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP2C1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B91-genes-10-00770" ref-type="bibr">91</xref>,<xref rid="B92-genes-10-00770" ref-type="bibr">92</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase secretory pathway Ca2+ transporting 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TOP3</td><td align="center" valign="middle" rowspan="1" colspan="1">TOP3A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B63-genes-10-00770" ref-type="bibr">63</xref>,<xref rid="B64-genes-10-00770" ref-type="bibr">64</xref>,<xref rid="B65-genes-10-00770" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA topoisomerase III &#x003b1;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS21</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB21</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B93-genes-10-00770" ref-type="bibr">93</xref>,<xref rid="B94-genes-10-00770" ref-type="bibr">94</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB21, member RAS oncogene family</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS21</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB22A</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B95-genes-10-00770" ref-type="bibr">95</xref>,<xref rid="B96-genes-10-00770" ref-type="bibr">96</xref>,<xref rid="B97-genes-10-00770" ref-type="bibr">97</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB22A, member RAS oncogene family</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ACB1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">ACBD4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B98-genes-10-00770" ref-type="bibr">98</xref>,<xref rid="B99-genes-10-00770" ref-type="bibr">99</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">acyl-CoA binding domain containing 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ACB1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">ACBD5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B100-genes-10-00770" ref-type="bibr">100</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">acyl-CoA binding domain containing 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ACB1_2</td><td align="center" valign="middle" rowspan="1" colspan="1">DBI</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.16-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B101-genes-10-00770" ref-type="bibr">101</xref>,<xref rid="B102-genes-10-00770" ref-type="bibr">102</xref>,<xref rid="B103-genes-10-00770" ref-type="bibr">103</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">diazepam binding inhibitor, acyl-CoA binding protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CPR3</td><td align="center" valign="middle" rowspan="1" colspan="1">PPIA</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B104-genes-10-00770" ref-type="bibr">104</xref>,<xref rid="B105-genes-10-00770" ref-type="bibr">105</xref>,<xref rid="B106-genes-10-00770" ref-type="bibr">106</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">peptidylprolyl isomerase A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CPR3</td><td align="center" valign="middle" rowspan="1" colspan="1">RGPD4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">RANBP2-like and GRIP domain containing 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ELO3</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B107-genes-10-00770" ref-type="bibr">107</xref>,<xref rid="B108-genes-10-00770" ref-type="bibr">108</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL fatty acid elongase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ELO3</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B109-genes-10-00770" ref-type="bibr">109</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL fatty acid elongase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ELO3</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL fatty acid elongase 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ELO3</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL5</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL fatty acid elongase 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ELO3</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL6</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B110-genes-10-00770" ref-type="bibr">110</xref>,<xref rid="B111-genes-10-00770" ref-type="bibr">111</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ELOVL fatty acid elongase 6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MDL2</td><td align="center" valign="middle" rowspan="1" colspan="1">ABCB10</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B112-genes-10-00770" ref-type="bibr">112</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP binding cassette subfamily B member 10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MDL2</td><td align="center" valign="middle" rowspan="1" colspan="1">TAP1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">transporter 1, ATP binding cassette subfamily B member</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PIF1</td><td align="center" valign="middle" rowspan="1" colspan="1">PIF1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B113-genes-10-00770" ref-type="bibr">113</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">PIF1 5&#x02019;-to-3&#x02019; DNA helicase</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RPS1B</td><td align="center" valign="middle" rowspan="1" colspan="1">RPS3A</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B114-genes-10-00770" ref-type="bibr">114</xref>,<xref rid="B115-genes-10-00770" ref-type="bibr">115</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ribosomal protein S3A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAC3</td><td align="center" valign="middle" rowspan="1" colspan="1">MCM3AP</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B116-genes-10-00770" ref-type="bibr">116</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">minichromosome maintenance complex component 3 associated protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SAC3</td><td align="center" valign="middle" rowspan="1" colspan="1">SAC3D1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B117-genes-10-00770" ref-type="bibr">117</xref>,<xref rid="B118-genes-10-00770" ref-type="bibr">118</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">SAC3 domain containing 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YTA7</td><td align="center" valign="middle" rowspan="1" colspan="1">ATAD2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-genes-10-00770" ref-type="bibr">119</xref>,<xref rid="B120-genes-10-00770" ref-type="bibr">120</xref>,<xref rid="B121-genes-10-00770" ref-type="bibr">121</xref>,<xref rid="B122-genes-10-00770" ref-type="bibr">122</xref>,<xref rid="B123-genes-10-00770" ref-type="bibr">123</xref>,<xref rid="B124-genes-10-00770" ref-type="bibr">124</xref>,<xref rid="B125-genes-10-00770" ref-type="bibr">125</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase family, AAA domain containing 2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YTA7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATAD2B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-0.8-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATPase family, AAA domain containing 2B</td></tr></tbody></table><table-wrap-foot><fn><p>Genes selected for discussion in the results were included in the table. The homology types (H) are one to one (1), one to many (2), and many to many (3). Drugs (Gem, Cyt, or Both) with which the genes interacted in a UES or OES manner in the GDSC database are indicated. The REMc clusters 1-0-14 and 2-0.16-1 are deletion enhancing and 2-0.8-1 is deletion suppressing (see <xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C,D). Tissue types from which genes were UES or OES in the PharmacoDB data are indicated for across all tissue (A), lung (L), and hematopoietic (H). Related references cited (Ref), and gene descriptions are given. <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8</xref> contains other tables of this type.</p></fn></table-wrap-foot></table-wrap><p>The checkpoint clamp in yeast is comprised of Rad17/hRad1, Ddc1, and Mec3, which function downstream of Rad24/hRad17 in the DNA damage checkpoint pathway [<xref rid="B75-genes-10-00770" ref-type="bibr">75</xref>,<xref rid="B76-genes-10-00770" ref-type="bibr">76</xref>,<xref rid="B77-genes-10-00770" ref-type="bibr">77</xref>] to recruit yDpb11/hTopB1 to stalled replication forks and activate the yMec1/hATR protein kinase activity, initiating the DNA damage response [<xref rid="B78-genes-10-00770" ref-type="bibr">78</xref>]. The human homolog of yeast <italic>RAD24, RAD17</italic>, was UES for gemcitabine in both lung and hematopoietic and lymphoid tissue (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 1-0-14), representing a synthetic lethal relationship of potential therapeutic relevance. Consistent with this finding in yeast, depletion of <italic>hRAD17</italic> can sensitize pancreatic cancer cells to gemcitabine [<xref rid="B79-genes-10-00770" ref-type="bibr">79</xref>]. </p><p>Mre11, Xrs2, and Rad50 constitute the Mre11 complex, which participates in the formation and processing of double-strand DNA breaks involved in recombination and repair [<xref rid="B126-genes-10-00770" ref-type="bibr">126</xref>], and clustered together in 1-0-14 (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B,C). Deficiency in the Mre1 complex is known to sensitize human cells to nucleoside analog toxicity [<xref rid="B127-genes-10-00770" ref-type="bibr">127</xref>], as also seen in cancer cell lines deficient for other checkpoint-signaling genes, such as Rad9, Chk1, or ATR, [<xref rid="B128-genes-10-00770" ref-type="bibr">128</xref>]. Single nucleotide polymorphisms in DNA damage response (<italic>ATM</italic> and <italic>CHEK1</italic>) have been associated with overall survival in pancreatic cancer patients treated with gemcitabine and radiation therapy [<xref rid="B129-genes-10-00770" ref-type="bibr">129</xref>]. Taken together, the results highlight evolutionarily conserved genes that function in DNA replication and recombination-based repair and are required to buffer the cytotoxic effects of both cytarabine and gemcitabine.</p></sec><sec id="sec4dot3-genes-10-00770"><title>4.3. Positive Regulation of DNA-Dependent DNA Replication Initiation</title><p>The term, positive regulation of DNA-dependent DNA replication initiation, was identified by REMc/GTF and GTA for buffering interactions with both drugs, though stronger for gemcitabine (<xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref> and <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). Genes representing this term were <italic>FKH2, RFM1,</italic> and <italic>SUM1</italic> (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B). The origin binding protein, Sum1, is required for efficient replication initiation [<xref rid="B130-genes-10-00770" ref-type="bibr">130</xref>] and forms a complex with Rfm1 and the histone deacetylase, Hst1, which is recruited to replication origins to deacetylate H4K5 for initiation [<xref rid="B131-genes-10-00770" ref-type="bibr">131</xref>]. <italic>HST1</italic> was also a strong deletion enhancer but was observed only for the L parameter and clustered in 2-0.2-2. The forkhead box proteins, Fkh1 and Fkh2, contribute to proper replication origin timing and long range clustering of origins in G1 phase [<xref rid="B132-genes-10-00770" ref-type="bibr">132</xref>] and appear to buffer the cytotoxicity of gemcitabine more so than cytarabine, with <italic>FKH2</italic> deletion showing a stronger effect than its paralog (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B). Multiple human forkhead box protein homologs (<italic>yFKH2/hFOXJ1/FOXG1/FOXJ3/FOXH1</italic>) (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D) were observed as UES in PharmacoDB, of which <italic>FOXJ1</italic> underexpression is a marker of poor prognosis in gastric cancer [<xref rid="B133-genes-10-00770" ref-type="bibr">133</xref>], reduced expression of <italic>FOXG1</italic> is correlated with worse prognosis in breast cancer [<xref rid="B134-genes-10-00770" ref-type="bibr">134</xref>], <italic>FOXJ3</italic> is inhibited by miR-517a and associated with lung and colorectal cancer cell proliferation and invasion [<xref rid="B135-genes-10-00770" ref-type="bibr">135</xref>,<xref rid="B136-genes-10-00770" ref-type="bibr">136</xref>], and <italic>FOXH1</italic> is overexpressed in breast cancer and <italic>FOXH1</italic> inhibition reduces proliferation in breast cancer cell lines [<xref rid="B137-genes-10-00770" ref-type="bibr">137</xref>]. Although not UES in PharmacoDB, inhibition of the <italic>HST1</italic> homolog, <italic>SIRT1,</italic> by Tenovin-6 inhibits the growth of acute lymphoblastic leukemia cells and enhances cytarabine cytotoxicity [<xref rid="B138-genes-10-00770" ref-type="bibr">138</xref>], enhances gemcitabine efficacy in pancreatic cancer cell lines, and improves survival in a pancreatic cancer mouse model [<xref rid="B139-genes-10-00770" ref-type="bibr">139</xref>]. Thus, loss of this gene module that positively regulates DNA replication initiation appears to be robustly involved in oncogenesis and is also synthetic lethal with gemcitabine and cytarabine.</p></sec><sec id="sec4dot4-genes-10-00770"><title>4.4. Endosomal Transport and Related Processes</title><p>GO annotated processes, enriched by REMc/GTF and GTA, and having deletion enhancement profiles related to endosome transport included vesicle fusion with vacuole (<italic>VAM3</italic> and <italic>VPS33</italic>), the CORVET/HOPS (<italic>VPS41, VPS8, VPS16, PEP3, VPS33, VAM6,</italic> and <italic>VPS3</italic>), ESCRT (<italic>VPS27, VPS24, DID4, MVB12; HSE1</italic> and <italic>SRN2</italic> were gemcitabine specific), GET complex (<italic>GET1, GET2;</italic> 2-0.14-0), and Ubp3-Bre5 deubiquitination (<italic>UBP3</italic> and <italic>BRE5</italic>) complexes (<xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref> and <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>E). The CORVET and HOPS tethering complexes function in protein and lipid transport between endosomes and lysosomes/vacuoles, are required for vacuolar fusion, recognize SNARE complexes, help determine endomembrane identity, and interact with the ESCRT complex [<xref rid="B140-genes-10-00770" ref-type="bibr">140</xref>,<xref rid="B141-genes-10-00770" ref-type="bibr">141</xref>]. The ESCRT complex recognizes ubiquitinated endosomal proteins to mediate degradation through the multivesicular body pathway [<xref rid="B142-genes-10-00770" ref-type="bibr">142</xref>,<xref rid="B143-genes-10-00770" ref-type="bibr">143</xref>]. The Ubp3-Bre5 deubiquitination complex maintains Sec23, a subunit of COPII vesicles required for transport between the ER and Golgi, by cleaving its ubiquitinated form [<xref rid="B144-genes-10-00770" ref-type="bibr">144</xref>]. The GET complex (<italic>GET1-3</italic>) mediates insertion of tail-anchored proteins into the ER membrane, a critical process within the secretory pathway for vesicular trafficking [<xref rid="B145-genes-10-00770" ref-type="bibr">145</xref>,<xref rid="B146-genes-10-00770" ref-type="bibr">146</xref>,<xref rid="B147-genes-10-00770" ref-type="bibr">147</xref>]. Thus, these complexes, which function in processes related to endosomal transport, appear to be critical for buffering the toxicity of nucleoside analogs.</p><p>Several deletion-enhancing endosomal genes had human homologs associated with UES in cancer cell lines and/or reported roles in cancer biology (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>E and <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D), including: (1) <italic>VPS41/VPS41</italic>, in which a single nucleotide polymorphism is associated with familial melanoma [<xref rid="B148-genes-10-00770" ref-type="bibr">148</xref>]; (2) <italic>VPS27/WDFY1</italic>, which is regulated by <italic>NPR2</italic> to maintain the metastatic phenotype of cancer cells [<xref rid="B149-genes-10-00770" ref-type="bibr">149</xref>,<xref rid="B150-genes-10-00770" ref-type="bibr">150</xref>]; (3) human homologs of yeast <italic>HSE1</italic>, <italic>TOM1,</italic> and <italic>TOM1L2, TOM1L2</italic> hypomorphic mice having increased tumor incidence associated with alterations in endosomal trafficking [<xref rid="B151-genes-10-00770" ref-type="bibr">151</xref>]; (4) <italic>VPS8/VPS8</italic> and <italic>VAM6/VPS39,</italic> which are predicted to be homologous members of the CORVET complex [<xref rid="B152-genes-10-00770" ref-type="bibr">152</xref>]; and (5) <italic>VPS21/RAB21/RAB22A</italic>, where <italic>RAB21</italic> promotes carcinoma-associated fibroblast invasion and knockdown inhibits glioma cell proliferation [<xref rid="B93-genes-10-00770" ref-type="bibr">93</xref>,<xref rid="B94-genes-10-00770" ref-type="bibr">94</xref>], and <italic>RAB22A</italic> promotes oncogenesis in lung, breast, and ovarian cancer [<xref rid="B95-genes-10-00770" ref-type="bibr">95</xref>,<xref rid="B96-genes-10-00770" ref-type="bibr">96</xref>,<xref rid="B97-genes-10-00770" ref-type="bibr">97</xref>]. Thus, it seems tumors arising in the context of deficiencies in certain endosomal trafficking genes could be vulnerable to gemcitabine and/or cytarabine.</p></sec><sec id="sec4dot5-genes-10-00770"><title>4.5. &#x02018;Non-GO-enriched&#x02019; Homolog Pairs with Corresponding UES and Deletion Enhancement </title><p>We next explored yeast&#x02013;human homologs exhibiting yeast deletion enhancement and underexpression sensitivity in cancer, systematically and regardless of whether their functions were enriched within gene ontology (<xref rid="genes-10-00770-t003" ref-type="table">Table 3</xref>, <xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C). &#x02018;Non-enriched&#x02019; interaction can be explained by a small total number of genes performing the function, only select genes annotated to a term impacting the phenotype, by genes contributing to a function without yet being annotated to it, by novel functions, and other possibilities.</p><p>With regard to the above, human homologs of the yeast type 2C protein phosphatase, <italic>PTC1,</italic> included <italic>PPM1L</italic> and <italic>PPM1E</italic> (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 1-0-14)<italic>. PPM1L</italic> has reduced expression in familial adenomatous polyposis [<xref rid="B74-genes-10-00770" ref-type="bibr">74</xref>], while <italic>PPM1E</italic> upregulation has been associated with cell proliferation in gastric cancer [<xref rid="B73-genes-10-00770" ref-type="bibr">73</xref>]. Such differential interactions of paralogs could result from tissue specific expression and functional differentiation of regulatory proteins. Previously, we reported <italic>ptc1-&#x02206;0</italic> to buffer transcriptional repression of <italic>RNR1</italic> [<xref rid="B33-genes-10-00770" ref-type="bibr">33</xref>], which is upregulated as part of the DNA damage response to increase dNTP pools [<xref rid="B153-genes-10-00770" ref-type="bibr">153</xref>]. </p><p>The microtubule binding proteins, <italic>yBIM1/hMAPRE2/hMAPRE3</italic>, were deletion enhancing in yeast and UES in cancer for gemcitabine (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 1-0-14), of which frameshift mutations were reported in <italic>MAPRE3</italic> for gastric and colorectal cancers [<xref rid="B84-genes-10-00770" ref-type="bibr">84</xref>], however, <italic>MAPRE2</italic> is upregulated in invasive pancreatic cancer cells [<xref rid="B83-genes-10-00770" ref-type="bibr">83</xref>], demonstrating that the yeast phenomic model could help distinguish causal influence in cases of paralogous gene expression having what appear to be opposing effects on phenotypic response of cancer cells to cytotoxic chemotherapy.</p><p><italic>NAM7</italic> is a yeast RNA helicase that was deletion-enhancing for both drugs, though slightly stronger for cytarabine, while its human homologs <italic>HELZ, HELZ2</italic>, and <italic>UPF1</italic>, were UES only with cytarabine (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 1-0-14). <italic>HELZ</italic> has differential influence in cancer, acting as a tumor suppressor or oncogene [<xref rid="B66-genes-10-00770" ref-type="bibr">66</xref>,<xref rid="B67-genes-10-00770" ref-type="bibr">67</xref>,<xref rid="B68-genes-10-00770" ref-type="bibr">68</xref>,<xref rid="B69-genes-10-00770" ref-type="bibr">69</xref>]. <italic>UPF1</italic> downregulation is associated with poor prognosis in gastric cancer and hepatocellular carcinoma, and mutations often occur in pancreatic adenosquamous carcinoma [<xref rid="B70-genes-10-00770" ref-type="bibr">70</xref>,<xref rid="B71-genes-10-00770" ref-type="bibr">71</xref>,<xref rid="B72-genes-10-00770" ref-type="bibr">72</xref>]. Thus, it is possible cytarabine could have efficacy for patients with mutational loss of function in members of this helicase family. </p><p><italic>ASF1/ASF1B</italic> (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 2-0.16-1) functions in nucleosome assembly as an anti-silencing factor and is one of the most overexpressed histone chaperones in cancer [<xref rid="B85-genes-10-00770" ref-type="bibr">85</xref>]. The yeast phenomic data suggest that anticancer approaches that target ASF1 as a driver [<xref rid="B154-genes-10-00770" ref-type="bibr">154</xref>] could be augmented by combination with gemcitabine or cytarabine. </p><p><italic>AVL9/AVL9</italic> (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 2-0.16-1) functions in exocytic transport from the Golgi [<xref rid="B86-genes-10-00770" ref-type="bibr">86</xref>]. <italic>AVL9</italic> knockdown resulted in abnormal mitoses associated with defective protein trafficking and increased cell migration with development of cysts [<xref rid="B87-genes-10-00770" ref-type="bibr">87</xref>], but also reduced cell proliferation and migration in other studies [<xref rid="B88-genes-10-00770" ref-type="bibr">88</xref>]. Regardless, the yeast phenomic model together with pharmacogenomics data would predict that functional loss of AVL9 renders cells vulnerable to cytarabine.</p><p><italic>PMR1</italic> is a P-type ATPase that transports Mn++ and Ca++ into the Golgi. Several of its human homologs, <italic>ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP2C1,</italic> were UES, either for gemcitabine or cytarabine, in the PharmacoDB analysis (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 2-0.16-1). Reduced expression of <italic>ATP1A1</italic> can promote development of renal cell carcinoma [<xref rid="B89-genes-10-00770" ref-type="bibr">89</xref>], reduced expression of <italic>ATP1A2</italic> is associated with breast cancer [<xref rid="B90-genes-10-00770" ref-type="bibr">90</xref>], and mutations in <italic>ATP2C1</italic> impair the DNA damage response and increase the incidence of squamous cell tumors in mice [<xref rid="B91-genes-10-00770" ref-type="bibr">91</xref>,<xref rid="B92-genes-10-00770" ref-type="bibr">92</xref>]. Like with <italic>FKH2</italic> (described above), <italic>PMR1</italic> deletion-enhancement points to multiple human homologs that are both implicated in the cancer literature to promote cancer when underexpressed, yet are also UES in the pharmacogenomics data, suggesting a potentially clinically useful synthetic lethal vulnerability.</p><p><italic>KTI11/DPH3</italic> (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 1-0-14), is a multi-functional protein involved in the biosynthesis of dipthamide and tRNA modifications important for regulation of translation, development and stress response [<xref rid="B80-genes-10-00770" ref-type="bibr">80</xref>,<xref rid="B81-genes-10-00770" ref-type="bibr">81</xref>], and has promoter mutations associated with skin cancer [<xref rid="B82-genes-10-00770" ref-type="bibr">82</xref>]. It was observed to be UES only for cytarabine and in hematopoietic and lymphoid cancer (the context cytarabine is used clinically). </p><p><italic>ACB1</italic> binds acyl-CoA esters and transports them to acyl-CoA-consuming processes, which is upregulated in response to DNA replication stress [<xref rid="B155-genes-10-00770" ref-type="bibr">155</xref>]. Human homologs of <italic>ACB1</italic> exhibiting UES (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>C; 2-0.16-1) included: (1) <italic>DBI</italic>, which is upregulated in hepatocellular carcinoma and lung cancer, and its expression is negatively associated with multidrug resistance in breast cancer [<xref rid="B101-genes-10-00770" ref-type="bibr">101</xref>,<xref rid="B102-genes-10-00770" ref-type="bibr">102</xref>,<xref rid="B103-genes-10-00770" ref-type="bibr">103</xref>]; (2) <italic>ACBD4,</italic> which promotes ER-peroxisome associations [<xref rid="B98-genes-10-00770" ref-type="bibr">98</xref>] and is upregulated by a histone deacetylase inhibitor, valproic acid, in a panel of cancer cell lines [<xref rid="B99-genes-10-00770" ref-type="bibr">99</xref>]; and (3) <italic>ACBD5,</italic> which also promotes ER-peroxisome associations, but its link to cancer is unclear [<xref rid="B100-genes-10-00770" ref-type="bibr">100</xref>]. Thus, it appears this gene family may influence epigenetic processes that buffer the cytotoxic effects of gemcitabine and cytarabine.</p></sec><sec id="sec4dot6-genes-10-00770"><title>4.6. Deletion Suppression of Toxicity for Both Nucleosides </title><p>As opposed to deletion-enhancing interactions, which represent functions that buffer the cytotoxic effects of the drugs, deletion suppression identifies genes that promote toxicity, thus predicting overexpression sensitivity (OES) in pharmacogenomics data that represent causal tumor vulnerabilities. REMc/GTF identified as deletion-suppressing the GO terms glutaminyl-tRNA(Gln) biosynthesis (1-0-3), the nucleoplasmic THO (2-0.8-1), RNA cap binding (1-0-3), and the NuA3b histone acetyltransferase complexes (1-0-7) (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 5, File C</xref>), while GTA identified mitochondrial translational elongation and the nuclear cap binding complex (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 6, File A</xref>). However, the respective term-specific heatmaps revealed weak effects and high shift for many of the genes (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 2, Figure S3</xref>), highlighting the utility of this phenomic visualization tool for prioritizing findings and leading us to shift our focus to individual yeast&#x02013;human homologs identified in gene deletion suppressing clusters that were OES in the pharmacogenomics analysis, as detailed below.</p><p>In cluster 2-0.8-1, yeast-human homologs with correlated gene deletion suppression and OES for both gemcitabine and cytarabine (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D; <xref rid="genes-10-00770-t003" ref-type="table">Table 3</xref>) included: (1) <italic>YTA7/ATAD2/ATAD2B</italic>, which localizes to chromatin and regulates histone gene expression. <italic>ATAD2</italic> overexpression portends poor prognosis in gastric, colorectal, cervical, hepatocellular carcinoma, lung, and breast cancer, and thus overexpression sensitivity could represent the potential to target a driver gene [<xref rid="B119-genes-10-00770" ref-type="bibr">119</xref>,<xref rid="B120-genes-10-00770" ref-type="bibr">120</xref>,<xref rid="B121-genes-10-00770" ref-type="bibr">121</xref>,<xref rid="B122-genes-10-00770" ref-type="bibr">122</xref>,<xref rid="B123-genes-10-00770" ref-type="bibr">123</xref>,<xref rid="B124-genes-10-00770" ref-type="bibr">124</xref>,<xref rid="B125-genes-10-00770" ref-type="bibr">125</xref>]; (2) <italic>PIF1</italic>/<italic>PIF1</italic>, a DNA helicase, which is involved in telomere regulation and is required during oncogenic stress [<xref rid="B113-genes-10-00770" ref-type="bibr">113</xref>]; (3) <italic>RPS1B/RPS3A</italic>, which is a small subunit ribosomal protein that is overexpressed in hepatitis B-associated hepatocellular carcinoma and non-small-cell lung cancer [<xref rid="B114-genes-10-00770" ref-type="bibr">114</xref>,<xref rid="B115-genes-10-00770" ref-type="bibr">115</xref>]; (4) <italic>LEO1/LEO1</italic>, which associates with the RNA polymerase II and acts as an oncogene in acute myelogenous leukemia [<xref rid="B156-genes-10-00770" ref-type="bibr">156</xref>]; (5) <italic>ELO3/ELOVL1/ELOVL2/ELOVL4/ELOVL6</italic>, which constitutes a family of fatty acid elongases that function in sphingolipid biosynthesis, among which <italic>ELOVL1</italic> is overexpressed in breast and colorectal cancer tissue [<xref rid="B107-genes-10-00770" ref-type="bibr">107</xref>,<xref rid="B108-genes-10-00770" ref-type="bibr">108</xref>], <italic>ELOVL2</italic> is upregulated in hepatocellular carcinoma [<xref rid="B109-genes-10-00770" ref-type="bibr">109</xref>], and <italic>ELOVL6</italic> is overexpressed and associated with poor prognosis in liver and breast cancer [<xref rid="B110-genes-10-00770" ref-type="bibr">110</xref>,<xref rid="B111-genes-10-00770" ref-type="bibr">111</xref>]; (6) <italic>MDL2/ABCB10</italic>, which is a mitochondrial inner membrane ATP-binding cassette protein and is upregulated in breast cancer [<xref rid="B112-genes-10-00770" ref-type="bibr">112</xref>]; (7) <italic>CPR3/PPIA</italic>, which is a mitochondrial cyclophilin that is upregulated in lung cancer, esophageal, and pancreatic cancer [<xref rid="B104-genes-10-00770" ref-type="bibr">104</xref>,<xref rid="B105-genes-10-00770" ref-type="bibr">105</xref>,<xref rid="B106-genes-10-00770" ref-type="bibr">106</xref>]; and (8) <italic>SAC3/MCM3AP/SAC3D1</italic>, which is a nuclear pore-associated protein functioning in transcription and mRNA export, with <italic>MCM3AP</italic> being upregulated in glioma cells [<xref rid="B116-genes-10-00770" ref-type="bibr">116</xref>], while <italic>SAC3D1</italic> is upregulated in cervical cancer and hepatocellular carcinoma [<xref rid="B117-genes-10-00770" ref-type="bibr">117</xref>,<xref rid="B118-genes-10-00770" ref-type="bibr">118</xref>]. Yeast gene deletion suppression, together with overexpression sensitivity of human homologs in cancer, reveals potential therapeutic vulnerabilities that can be further explored in both systems.</p></sec></sec><sec id="sec5-genes-10-00770"><title>5. Gemcitabine-Specific Gene Interaction Modules</title><sec id="sec5dot1-genes-10-00770"><title>5.1. Gemcitabine-Specific Gene Deletion Enhancement</title><p>Gemcitabine-specific deletion enhancement indicates genes for which loss of function increases vulnerability to gemcitabine to a greater extent than cytarabine. Therefore, these genes provide insight into cytotoxic mechanisms that are unique between the two deoxycytidine analogs. Representative clusters were GO-enriched for intralumenal vesicle formation (1-0-10), peptidyl-tyrosine dephosphorylation (1-0-0), and the Set1C/COMPASS and HDA1 complexes (<xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>C, <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A&#x02013;C, <xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref>). GTA identified negative regulation of macroautophagy; protein urmylation; and the RAVE, GATOR (Iml1), and Elongator holoenzyme complexes (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A, <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). Pharmacogenomics integration is highlighted for clusters 2-0.2-1, 1-0-10, and 1-0-0 (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D; see also, <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8</xref>). Taken together, the results suggest that autophagy-related processes and perhaps others less well-characterized by GO buffer cytotoxicity of gemcitabine to a greater extent than cytarabine.</p><table-wrap id="genes-10-00770-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t004_Table 4</object-id><label>Table 4</label><caption><p>Yeast&#x02013;human homologs predicted to buffer or promote gemcitabine to greater degree than cytarabine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">yGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">hGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">H</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem_L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt_L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description_Human</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CLB5</td><td align="center" valign="middle" rowspan="1" colspan="1">CCNA1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">5.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B157-genes-10-00770" ref-type="bibr">157</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">cyclin A1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDA1</td><td align="center" valign="middle" rowspan="1" colspan="1">HDAC5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B158-genes-10-00770" ref-type="bibr">158</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">histone deacetylase 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDA1</td><td align="center" valign="middle" rowspan="1" colspan="1">HDAC6</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B99-genes-10-00770" ref-type="bibr">99</xref>,<xref rid="B159-genes-10-00770" ref-type="bibr">159</xref>,<xref rid="B160-genes-10-00770" ref-type="bibr">160</xref>,<xref rid="B161-genes-10-00770" ref-type="bibr">161</xref>,<xref rid="B162-genes-10-00770" ref-type="bibr">162</xref>,<xref rid="B163-genes-10-00770" ref-type="bibr">163</xref>,<xref rid="B164-genes-10-00770" ref-type="bibr">164</xref>,<xref rid="B165-genes-10-00770" ref-type="bibr">165</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">histone deacetylase 6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSE1</td><td align="center" valign="middle" rowspan="1" colspan="1">TOM1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">target of myb1 membrane trafficking protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSE1</td><td align="center" valign="middle" rowspan="1" colspan="1">TOM1L2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B151-genes-10-00770" ref-type="bibr">151</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">target of myb1 like 2 membrane trafficking protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NMA1</td><td align="center" valign="middle" rowspan="1" colspan="1">NMNAT1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B166-genes-10-00770" ref-type="bibr">166</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">nicotinamide nucleotide adenylyltransferase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NMA1</td><td align="center" valign="middle" rowspan="1" colspan="1">NMNAT2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B167-genes-10-00770" ref-type="bibr">167</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">nicotinamide nucleotide adenylyltransferase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NMA1</td><td align="center" valign="middle" rowspan="1" colspan="1">NMNAT2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B167-genes-10-00770" ref-type="bibr">167</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">nicotinamide nucleotide adenylyltransferase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NMA1</td><td align="center" valign="middle" rowspan="1" colspan="1">NMNAT3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">nicotinamide nucleotide adenylyltransferase 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD54</td><td align="center" valign="middle" rowspan="1" colspan="1">ATRX</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B168-genes-10-00770" ref-type="bibr">168</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ATRX, chromatin remodeler</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD54</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD54B</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD54 homolog B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD54</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD54L</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD54 like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SCS2</td><td align="center" valign="middle" rowspan="1" colspan="1">VAPB</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H, L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B100-genes-10-00770" ref-type="bibr">100</xref>,<xref rid="B169-genes-10-00770" ref-type="bibr">169</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">VAMP associated protein B and C</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS30</td><td align="center" valign="middle" rowspan="1" colspan="1">BECN1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B170-genes-10-00770" ref-type="bibr">170</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">beclin 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS30</td><td align="center" valign="middle" rowspan="1" colspan="1">BECN1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B170-genes-10-00770" ref-type="bibr">170</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">beclin 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DID4_2</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMP2A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B171-genes-10-00770" ref-type="bibr">171</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">charged multivesicular body protein 2A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DID4_2</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMP2B</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B172-genes-10-00770" ref-type="bibr">172</xref>,<xref rid="B173-genes-10-00770" ref-type="bibr">173</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">charged multivesicular body protein 2B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YPT32</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB2A</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B174-genes-10-00770" ref-type="bibr">174</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB2A, member RAS oncogene family</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YPT32</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB2B</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B175-genes-10-00770" ref-type="bibr">175</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB2B, member RAS oncogene family</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KEX2</td><td align="center" valign="middle" rowspan="1" colspan="1">PCSK1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B176-genes-10-00770" ref-type="bibr">176</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">proprotein convertase subtilisin/kexin type 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KEX2</td><td align="center" valign="middle" rowspan="1" colspan="1">PCSK2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">proprotein convertase subtilisin/kexin type 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KEX2</td><td align="center" valign="middle" rowspan="1" colspan="1">PCSK5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>,<xref rid="B178-genes-10-00770" ref-type="bibr">178</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">proprotein convertase subtilisin/kexin type 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KEX2</td><td align="center" valign="middle" rowspan="1" colspan="1">PCSK7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>,<xref rid="B179-genes-10-00770" ref-type="bibr">179</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">proprotein convertase subtilisin/kexin type 7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PEP12</td><td align="center" valign="middle" rowspan="1" colspan="1">STX12</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B180-genes-10-00770" ref-type="bibr">180</xref>,<xref rid="B181-genes-10-00770" ref-type="bibr">181</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">syntaxin 12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PEP12</td><td align="center" valign="middle" rowspan="1" colspan="1">STX12</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B180-genes-10-00770" ref-type="bibr">180</xref>,<xref rid="B181-genes-10-00770" ref-type="bibr">181</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">syntaxin 12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS27</td><td align="center" valign="middle" rowspan="1" colspan="1">WDFY1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">14.3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B149-genes-10-00770" ref-type="bibr">149</xref>,<xref rid="B150-genes-10-00770" ref-type="bibr">150</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">WD repeat and FYVE domain containing 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS41</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS41</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">14.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B148-genes-10-00770" ref-type="bibr">148</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS41, HOPS complex subunit</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS8</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS8</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.3</td><td align="center" valign="middle" rowspan="1" colspan="1">14.4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B152-genes-10-00770" ref-type="bibr">152</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS8, CORVET complex subunit</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VAM6_2</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS39</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">13.9</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B152-genes-10-00770" ref-type="bibr">152</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS39, HOPS complex subunit</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DID4_1</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMP2A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.3</td><td align="center" valign="middle" rowspan="1" colspan="1">14.5</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B171-genes-10-00770" ref-type="bibr">171</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">charged multivesicular body protein 2A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DID4_1</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMP2A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.3</td><td align="center" valign="middle" rowspan="1" colspan="1">14.5</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B171-genes-10-00770" ref-type="bibr">171</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">charged multivesicular body protein 2A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DID4_1</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMP2B</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.3</td><td align="center" valign="middle" rowspan="1" colspan="1">14.5</td><td align="center" valign="middle" rowspan="1" colspan="1">8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B172-genes-10-00770" ref-type="bibr">172</xref>,<xref rid="B173-genes-10-00770" ref-type="bibr">173</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">charged multivesicular body protein 2B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FKH2</td><td align="center" valign="middle" rowspan="1" colspan="1">FOXG1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B134-genes-10-00770" ref-type="bibr">134</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">forkhead box G1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FKH2</td><td align="center" valign="middle" rowspan="1" colspan="1">FOXH1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B137-genes-10-00770" ref-type="bibr">137</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">forkhead box H1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FKH2</td><td align="center" valign="middle" rowspan="1" colspan="1">FOXJ1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B133-genes-10-00770" ref-type="bibr">133</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">forkhead box J1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FKH2</td><td align="center" valign="middle" rowspan="1" colspan="1">FOXJ3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B135-genes-10-00770" ref-type="bibr">135</xref>,<xref rid="B136-genes-10-00770" ref-type="bibr">136</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">forkhead box J3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1</td><td align="center" valign="middle" rowspan="1" colspan="1">NME3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 nucleoside diphosphate kinase 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1</td><td align="center" valign="middle" rowspan="1" colspan="1">NME4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 nucleoside diphosphate kinase 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1</td><td align="center" valign="middle" rowspan="1" colspan="1">NME5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B182-genes-10-00770" ref-type="bibr">182</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 family member 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1</td><td align="center" valign="middle" rowspan="1" colspan="1">NME6</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 nucleoside diphosphate kinase 6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1</td><td align="center" valign="middle" rowspan="1" colspan="1">NME7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 family member 7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALD6</td><td align="center" valign="middle" rowspan="1" colspan="1">ALDH1A1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B183-genes-10-00770" ref-type="bibr">183</xref>,<xref rid="B184-genes-10-00770" ref-type="bibr">184</xref>,<xref rid="B185-genes-10-00770" ref-type="bibr">185</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">aldehyde dehydrogenase 1 family member A1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALD6</td><td align="center" valign="middle" rowspan="1" colspan="1">ALDH1A2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">aldehyde dehydrogenase 1 family member A2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALD6</td><td align="center" valign="middle" rowspan="1" colspan="1">ALDH1B1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B185-genes-10-00770" ref-type="bibr">185</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">aldehyde dehydrogenase 1 family member B1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALD6</td><td align="center" valign="middle" rowspan="1" colspan="1">ALDH7A1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B185-genes-10-00770" ref-type="bibr">185</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">aldehyde dehydrogenase 7 family member A1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKA2</td><td align="center" valign="middle" rowspan="1" colspan="1">CSNK2A1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B186-genes-10-00770" ref-type="bibr">186</xref>,<xref rid="B187-genes-10-00770" ref-type="bibr">187</xref>,<xref rid="B188-genes-10-00770" ref-type="bibr">188</xref>,<xref rid="B189-genes-10-00770" ref-type="bibr">189</xref>,<xref rid="B190-genes-10-00770" ref-type="bibr">190</xref>,<xref rid="B191-genes-10-00770" ref-type="bibr">191</xref>,<xref rid="B192-genes-10-00770" ref-type="bibr">192</xref>,<xref rid="B193-genes-10-00770" ref-type="bibr">193</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">casein kinase 2 &#x003b1; 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CKA2</td><td align="center" valign="middle" rowspan="1" colspan="1">CSNK2A2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B186-genes-10-00770" ref-type="bibr">186</xref>,<xref rid="B187-genes-10-00770" ref-type="bibr">187</xref>,<xref rid="B188-genes-10-00770" ref-type="bibr">188</xref>,<xref rid="B189-genes-10-00770" ref-type="bibr">189</xref>,<xref rid="B190-genes-10-00770" ref-type="bibr">190</xref>,<xref rid="B191-genes-10-00770" ref-type="bibr">191</xref>,<xref rid="B192-genes-10-00770" ref-type="bibr">192</xref>,<xref rid="B193-genes-10-00770" ref-type="bibr">193</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">casein kinase 2 &#x003b1; 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CLB2</td><td align="center" valign="middle" rowspan="1" colspan="1">CCNA2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B194-genes-10-00770" ref-type="bibr">194</xref>,<xref rid="B195-genes-10-00770" ref-type="bibr">195</xref>,<xref rid="B196-genes-10-00770" ref-type="bibr">196</xref>,<xref rid="B197-genes-10-00770" ref-type="bibr">197</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">cyclin A2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CLB2</td><td align="center" valign="middle" rowspan="1" colspan="1">CCNB1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B194-genes-10-00770" ref-type="bibr">194</xref>,<xref rid="B195-genes-10-00770" ref-type="bibr">195</xref>,<xref rid="B196-genes-10-00770" ref-type="bibr">196</xref>,<xref rid="B197-genes-10-00770" ref-type="bibr">197</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">cyclin B1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EFT2</td><td align="center" valign="middle" rowspan="1" colspan="1">EEF2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B198-genes-10-00770" ref-type="bibr">198</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">eukaryotic translation elongation factor 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EFT2</td><td align="center" valign="middle" rowspan="1" colspan="1">EFTUD2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B199-genes-10-00770" ref-type="bibr">199</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">elongation factor Tu GTP binding domain containing 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OLA1</td><td align="center" valign="middle" rowspan="1" colspan="1">OLA1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B200-genes-10-00770" ref-type="bibr">200</xref>,<xref rid="B201-genes-10-00770" ref-type="bibr">201</xref>,<xref rid="B202-genes-10-00770" ref-type="bibr">202</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Obg like ATPase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OLA1</td><td align="center" valign="middle" rowspan="1" colspan="1">OLA1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B200-genes-10-00770" ref-type="bibr">200</xref>,<xref rid="B201-genes-10-00770" ref-type="bibr">201</xref>,<xref rid="B202-genes-10-00770" ref-type="bibr">202</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Obg like ATPase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RPA49</td><td align="center" valign="middle" rowspan="1" colspan="1">POLR1E</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B203-genes-10-00770" ref-type="bibr">203</xref>,<xref rid="B204-genes-10-00770" ref-type="bibr">204</xref>,<xref rid="B205-genes-10-00770" ref-type="bibr">205</xref>,<xref rid="B206-genes-10-00770" ref-type="bibr">206</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RNA polymerase I subunit E</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SKY1</td><td align="center" valign="middle" rowspan="1" colspan="1">SRPK1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B207-genes-10-00770" ref-type="bibr">207</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">SRSF protein kinase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SNC2</td><td align="center" valign="middle" rowspan="1" colspan="1">VAMP8</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B208-genes-10-00770" ref-type="bibr">208</xref>,<xref rid="B209-genes-10-00770" ref-type="bibr">209</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">vesicle associated membrane protein 8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TOP1</td><td align="center" valign="middle" rowspan="1" colspan="1">TOP1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B210-genes-10-00770" ref-type="bibr">210</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA topoisomerase I</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TOP1</td><td align="center" valign="middle" rowspan="1" colspan="1">TOP1MT</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA topoisomerase I mitochondrial</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YPT6</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB34</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-7</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B211-genes-10-00770" ref-type="bibr">211</xref>,<xref rid="B212-genes-10-00770" ref-type="bibr">212</xref>,<xref rid="B213-genes-10-00770" ref-type="bibr">213</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">RAB34, member RAS oncogene family</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RPP2B</td><td align="center" valign="middle" rowspan="1" colspan="1">RPLP2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.8-0</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B214-genes-10-00770" ref-type="bibr">214</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">ribosomal protein lateral stalk subunit P2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YGR054W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EIF2A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-0.8-0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B215-genes-10-00770" ref-type="bibr">215</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eukaryotic translation initiation factor 2A</td></tr></tbody></table><table-wrap-foot><fn><p>Data headers are the same as described above for <xref rid="genes-10-00770-t003" ref-type="table">Table 3</xref>. The REMc clusters 1-0-0, 1-0-0, and 2-0.2-1 are deletion enhancing, while 1-0-7 and 2-0.8-0 are deletion suppressing (see <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D,E).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec5dot2-genes-10-00770"><title>5.2. Autophagy Related Processes</title><p>Autophagy-related processes and complexes consisted of intralumenal vesicle formation (1-0-0; BRO1, DOA4, DID4, VPS24, VPS4), the GATOR/SEACIT/Iml1 complex (NPR2, NPR3), autophagosome maturation (VAM3, CCZ1), negative regulation of macroautophagy (PHO85, PCL5, KSP1, SIC1, PHO80), and the RAVE complex (RAV1, RAV2) (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A). </p><p>Of the autophagy-related complexes, Npr2 and Npr3 form an evolutionarily conserved heterodimer involved in mediating induction of autophagy by inhibition of TORC1 signaling in response to amino acid starvation [<xref rid="B216-genes-10-00770" ref-type="bibr">216</xref>], also promoting non-nitrogen starvation-induced autophagy [<xref rid="B217-genes-10-00770" ref-type="bibr">217</xref>] (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A). The RAVE complex (<italic>RAV1/2</italic>) promotes assembly of the vacuolar ATPase [<xref rid="B218-genes-10-00770" ref-type="bibr">218</xref>,<xref rid="B219-genes-10-00770" ref-type="bibr">219</xref>], which is required for vacuolar acidification and efficient autophagy [<xref rid="B220-genes-10-00770" ref-type="bibr">220</xref>]. Gene deletion strains in the term negative regulation of macroautophagy (<italic>PHO85, PHO80,</italic> and <italic>SIC1</italic>) [<xref rid="B221-genes-10-00770" ref-type="bibr">221</xref>], which seemed from the automated assessment to suggest an opposing effect, were less compelling following detailed visualization of the data, due to the associated high shift and cytarabine deletion-enhancing interaction (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A). </p><p>Regarding the term intralumenal vesicle formation, Vps24 and Did4 are components of the ESCRT-III complex (see <xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>E and <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A), which functions at endosomes, and the ATPase Vps4 is required for disassembly of the complex [<xref rid="B222-genes-10-00770" ref-type="bibr">222</xref>]. Doa4 interacts with Vps20 of ESCRT-III to promote intralumenal vesicle formation, which also requires <italic>BRO1</italic> [<xref rid="B223-genes-10-00770" ref-type="bibr">223</xref>]. Pharmacogenomics correlation revealed UES in cancer cell lines for <italic>DID4/CHMP2A/CHMP2B (</italic><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D; 1-0-10). During autophagy, <italic>CHMP2A</italic> translocates to the phagophore to regulate separation of the inner and outer autophagosomal membranes to form double-membrane autophagosomes [<xref rid="B171-genes-10-00770" ref-type="bibr">171</xref>]. <italic>CHMP2B</italic> is a member of the ESCRT-III complex required for efficient autophagy and has reduced expression in melanoma [<xref rid="B172-genes-10-00770" ref-type="bibr">172</xref>,<xref rid="B173-genes-10-00770" ref-type="bibr">173</xref>], raising the hypothesis that gemcitabine could have efficacy in that context.</p><p>Other genes involved in autophagy-related processes that had human homologs UES in cancer cell lines included: (1) <italic>PEP12/STX12</italic> (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D; 1-0-10), a t-SNARE required for mitophagy [<xref rid="B180-genes-10-00770" ref-type="bibr">180</xref>], for which underexpression is associated with risk of recurrence [<xref rid="B181-genes-10-00770" ref-type="bibr">181</xref>]; and (2) <italic>VPS30/BECN1,</italic> knockdown of which enhances gemcitabine cytotoxicity in pancreatic cancer stem cells [<xref rid="B170-genes-10-00770" ref-type="bibr">170</xref>]. Furthermore, gemcitabine treatment has been found to upregulate autophagy in pancreatic or breast cancer, which buffers drug cytotoxicity as inferred by the combination of gemcitabine with autophagy inhibitors&#x02019; increased killing of cancer cells [<xref rid="B224-genes-10-00770" ref-type="bibr">224</xref>,<xref rid="B225-genes-10-00770" ref-type="bibr">225</xref>,<xref rid="B226-genes-10-00770" ref-type="bibr">226</xref>]. Thus, autophagy-related findings from the yeast model appear consistent with, and to build upon, previous cancer cell models.</p></sec><sec id="sec5dot3-genes-10-00770"><title>5.3. Histone Modification and Chromatin Remodeling</title><p>GTF/REMc identified the Hda1 and Set1C/COMPASS (1-0-0) complexes as gemcitabine-specific deletion enhancing, which was confirmed by term-specific heatmaps (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B). The Set1C complex has been characterized to have a role in cell cycle coordination [<xref rid="B227-genes-10-00770" ref-type="bibr">227</xref>], which may be reflected by greater deletion enhancing interaction for the K than for the L CPP. The Set1C/COMPASS complex catalyzes mono-, di-, and tri- methylation of histone H3K4, which can differentially influence gene transcription depending on the number of methyl groups added [<xref rid="B228-genes-10-00770" ref-type="bibr">228</xref>,<xref rid="B229-genes-10-00770" ref-type="bibr">229</xref>,<xref rid="B230-genes-10-00770" ref-type="bibr">230</xref>,<xref rid="B231-genes-10-00770" ref-type="bibr">231</xref>], and was implicated by <italic>BRE2</italic>, <italic>SWD1</italic>, <italic>SWD3</italic>, <italic>SDC1</italic>, <italic>SPP1,</italic> and <italic>SHG1</italic> (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B). The SWD1 ortholog, <italic>RBBP5</italic>, which was UES with gemcitabine in lung tissue (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File C</xref>; 1-0-4), is upregulated in self-renewing cancer stem cells in glioblastoma and necessary for their self-renewal, is involved in the epithelial-mesenchymal transition in prostate cancer cells via its role in H3K4 trimethylation, and is upregulated in hepatocellular carcinoma [<xref rid="B232-genes-10-00770" ref-type="bibr">232</xref>,<xref rid="B233-genes-10-00770" ref-type="bibr">233</xref>,<xref rid="B234-genes-10-00770" ref-type="bibr">234</xref>,<xref rid="B235-genes-10-00770" ref-type="bibr">235</xref>]. Furthermore, gemcitabine sensitivity of pancreatic cancer cell lines was enhanced by H3K4me3 inhibition with verticillin A [<xref rid="B233-genes-10-00770" ref-type="bibr">233</xref>]. </p><p>Histone deacetylases also influence cell cycle regulation [<xref rid="B236-genes-10-00770" ref-type="bibr">236</xref>], and the three genes that make up the yeast Hda1 deacetylase complex (homologous to mammalian class II Hda1-like proteins [<xref rid="B237-genes-10-00770" ref-type="bibr">237</xref>,<xref rid="B238-genes-10-00770" ref-type="bibr">238</xref>]) were gemcitabine deletion enhancers (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B). Similar effects in cancer cells include <italic>HDAC6</italic> knockdown in pediatric acute myeloid leukemia cells, which enhances cytarabine-induced apoptosis [<xref rid="B158-genes-10-00770" ref-type="bibr">158</xref>,<xref rid="B159-genes-10-00770" ref-type="bibr">159</xref>,<xref rid="B160-genes-10-00770" ref-type="bibr">160</xref>] and the use of histone deacetylase inhibitors in combination with gemcitabine, which augments killing of pancreatic cancer cell lines [<xref rid="B161-genes-10-00770" ref-type="bibr">161</xref>,<xref rid="B162-genes-10-00770" ref-type="bibr">162</xref>,<xref rid="B163-genes-10-00770" ref-type="bibr">163</xref>,<xref rid="B164-genes-10-00770" ref-type="bibr">164</xref>,<xref rid="B165-genes-10-00770" ref-type="bibr">165</xref>] and HeLa cells [<xref rid="B99-genes-10-00770" ref-type="bibr">99</xref>]. </p></sec><sec id="sec5dot4-genes-10-00770"><title>5.4. Peptidyl&#x02013;Tyrosine Dephosphorylation</title><p>REMc/GTF identified peptidyl-tyrosine dephosphorylation (1-0-0), for which the term-specific heatmap (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 7</xref>) revealed six genes previously characterized for their requirement in oxidant-induced cell cycle arrest and RNA virus replication [<xref rid="B239-genes-10-00770" ref-type="bibr">239</xref>,<xref rid="B240-genes-10-00770" ref-type="bibr">240</xref>], OCA1-6. Two additional tyrosine phosphatases, <italic>YMR1</italic> and <italic>PTP1</italic>, had similar interaction profiles (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>C). <italic>OCA1-3</italic> deletions enhance growth defects associated with reactive oxygen species or caffeine treatment [<xref rid="B239-genes-10-00770" ref-type="bibr">239</xref>,<xref rid="B240-genes-10-00770" ref-type="bibr">240</xref>], and <italic>OCA1-4</italic> and <italic>OCA6</italic> are deletion suppressors of the cdc13-1 mutation [<xref rid="B241-genes-10-00770" ref-type="bibr">241</xref>]. Although it does not have a tyrosine phosphatase motif, Oca5 deletion also displayed gemcitabine-specific enhancement, consistent with the other genes annotated to this module (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>C). However, due to the regulatory nature and limited evolutionary conservation of tyrosine phosphorylation, it is not obvious how to predict functionally homologous genetic modules in cancer cells.</p></sec><sec id="sec5dot5-genes-10-00770"><title>5.5. Elongator Holoenzyme Complex and Protein Urmylation</title><p>By GTA, K interactions revealed protein urmylation (<italic>NCS6</italic>, <italic>NCS2</italic>, <italic>UBA4</italic>, <italic>ELP6</italic>, <italic>ELP2</italic>, <italic>URM1</italic>, and <italic>URE2</italic>) and the elongator holoenzyme complex (<italic>IKI1, IKI3, ELP2, ELP3, ELP4</italic>, and <italic>ELP6</italic>) (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 2, Figure S4</xref>). Protein urmylation involves the covalent modification of lysine residues with the ubiquitin-related modifier, Urm1 [<xref rid="B242-genes-10-00770" ref-type="bibr">242</xref>]. The elongator holoenzyme complex has function in tRNA wobble position uridine thiolation (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 2, Figure S4</xref>), which occurs using Ure1 as a sulfur carrier [<xref rid="B243-genes-10-00770" ref-type="bibr">243</xref>,<xref rid="B244-genes-10-00770" ref-type="bibr">244</xref>,<xref rid="B245-genes-10-00770" ref-type="bibr">245</xref>]. The two processes share the <italic>ELP2</italic> and <italic>ELP6</italic> genes and may be distinct modules buffering gemcitabine cytotoxicity. However, several genes involved in tRNA wobble uridine modification have roles in cancer development and deficiency in this pathway enhances targeted therapy in melanoma [<xref rid="B246-genes-10-00770" ref-type="bibr">246</xref>,<xref rid="B247-genes-10-00770" ref-type="bibr">247</xref>], implicating this module as potentially important for personalized anticancer efficacy of gemcitabine.</p></sec><sec id="sec5dot6-genes-10-00770"><title>5.6. Gemcitabine-Buffering by Non-GO-Enriched Yeast-Human Homologs </title><p>Homologs with correlated gemcitabine-specific yeast gene deletion enhancement and cancer cell UES (clusters 2-0.2-1, 1-0-10, and 1-0-0) included the family of nucleoside diphosphate kinases (NDKs) (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D; <xref rid="genes-10-00770-t004" ref-type="table">Table 4</xref>). A single member of the NDK family, <italic>YNK1</italic>, exists in yeast, while the human genome encodes several paralogs (<italic>NME</italic> genes) (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File A</xref>). The NDKs transfer the &#x003b3; phosphate of ATP to nucleoside diphosphate as the final step of purine and pyrimidine nucleoside and deoxynucleoside triphosphate biosynthesis and salvage [<xref rid="B248-genes-10-00770" ref-type="bibr">248</xref>,<xref rid="B249-genes-10-00770" ref-type="bibr">249</xref>]. Thus, NDK appears to modulate gemcitabine toxicity by differential activity for endogenous substrates vs. nucleoside analog drugs. In yeast, deletion enhancement by YNK1 was selective for gemcitabine, however the effects in cancer cells are potentially more complex due to multiple NDK genes. In PharmacoDB, <italic>NME3</italic> and <italic>5</italic> were UES for gemcitabine, while <italic>NME4</italic>, <italic>6</italic>, and <italic>7</italic> were OES for cytarabine, implicating differential specificity of <italic>NME</italic> genes for natural and/or medicinal nucleosides as well as possible influences of other kinases, which have, for example, been shown to act on gemcitabine diphosphate [<xref rid="B250-genes-10-00770" ref-type="bibr">250</xref>]. <italic>NME5</italic> overexpression was previously associated with gemcitabine-resistant cancer, and its knockdown can increase gemcitabine efficacy [<xref rid="B182-genes-10-00770" ref-type="bibr">182</xref>]. Thus, the anticancer efficacy of gemcitabine could be influenced by differential expression and activity of NDK isoforms across tissues [<xref rid="B251-genes-10-00770" ref-type="bibr">251</xref>], such that NME gene expression could be predictive of response to nucleoside analogs, or perhaps targeted for synergistic antitumor activity. </p><p><italic>KEX2</italic> is the yeast member of the calcium-dependent proprotein convertase subtilisin/kexin type serine proteases, which functions in the secretory pathway. Four of the seven human homologs of KEX2 were UES in the pharmacogenomics analysis (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D; 1-0-10), including: (1) <italic>PCSK1</italic>, which can be downregulated by pancreatic cancer derived exosomes [<xref rid="B176-genes-10-00770" ref-type="bibr">176</xref>], (2) <italic>PCSK2</italic>, which has reduced expression in lung cancer [<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>], (3) <italic>PCSK5</italic>, which is also reduced in lung cancer and, furthermore, when reduced in triple negative breast cancer, leads to loss of the Gdf11 tumor suppressor [<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>,<xref rid="B178-genes-10-00770" ref-type="bibr">178</xref>], and (4) <italic>PCSK7</italic>, which has been reported both to have reduced expression in lung cancer and increased expression in gemcitabine-resistant cells [<xref rid="B177-genes-10-00770" ref-type="bibr">177</xref>,<xref rid="B179-genes-10-00770" ref-type="bibr">179</xref>]. Thus, loss of this gene family may create cancer-specific vulnerabilities to gemcitabine cytotoxicity.</p><p><italic>NMA1</italic> and its human homologs <italic>NMNAT1, NMNAT2,</italic> and <italic>NMNAT3</italic> are nicotinic acid mononucleotide adenylyltransferases involved in NAD biosynthesis and homeostasis, which were found to be UES for both gemcitabine and cytarabine (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0). Loss of function mutations and underexpression of <italic>NMNAT1</italic> are associated with increased rRNA expression and sensitivity to DNA damage in lung cancer cell lines [<xref rid="B166-genes-10-00770" ref-type="bibr">166</xref>], consistent with the hypothesis that they could have deletion-enhancing therapeutic benefit in cancers treated with gemcitabine or cytarabine.</p><p><italic>RAD54</italic> is a DNA-dependent ATPase that stimulates strand exchange in recombinational DNA repair, which is a known vulnerability of cancer [<xref rid="B252-genes-10-00770" ref-type="bibr">252</xref>]. The human homolog of <italic>RAD54</italic>, <italic>ATRX</italic>, was UES by PharmacoDB analysis (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0), and loss of <italic>ATRX</italic> has been associated with improved response to gemcitabine plus radiation therapy in glioma patients with <italic>IDH1</italic> mutations [<xref rid="B168-genes-10-00770" ref-type="bibr">168</xref>].</p><p><italic>SCS2/VAPB</italic> is an integral ER membrane protein that was deletion-enhancing and UES for gemcitabine (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0). <italic>VAPB</italic> regulates phospholipid metabolism and interacts with <italic>ACBD5</italic> (also described above) to promote ER-peroxisome tethering [<xref rid="B100-genes-10-00770" ref-type="bibr">100</xref>] and promotes proliferation in breast cancer via <italic>AKT1</italic> [<xref rid="B169-genes-10-00770" ref-type="bibr">169</xref>]. </p><p><italic>YPT32/RAB2A/RAB2B</italic> (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0) is a Rab family GTPase involved in the trans-Golgi exocytic pathway, which accumulates during replication stress in yeast [<xref rid="B155-genes-10-00770" ref-type="bibr">155</xref>]. <italic>RAB2A</italic> overexpression promotes breast cancer stem cell expansion and tumorigenesis [<xref rid="B174-genes-10-00770" ref-type="bibr">174</xref>], and downregulation of <italic>RAB2B</italic> by miR-448 promotes cell cycle arrest and apoptosis in pancreatic cancer cells [<xref rid="B175-genes-10-00770" ref-type="bibr">175</xref>]. </p><p><italic>CLB5</italic>, a B-type cyclin, is involved in initiation of DNA replication and G1-S progression, for which promoter hypermethylation of the human homolog, <italic>CCNA1</italic>, is associated with multiple cancers [<xref rid="B157-genes-10-00770" ref-type="bibr">157</xref>], and which was found to be UES with gemcitabine (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0). </p></sec><sec id="sec5dot7-genes-10-00770"><title>5.7. Gemcitabine-Specific Gene Deletion Suppression</title><p>Representing this class of gene interaction, pharmacogenomics integration is highlighted for clusters 2-0.8-0 and 1-0-7 (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>E). Although there was limited gene ontology enrichment, the term phosphatidylserine biosynthetic process (<italic>UME6</italic> and <italic>CHO1</italic>) and the GARP (<italic>VPS51</italic>-<italic>54</italic>) and Lem3p-Dnf1p complexes were identified (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>F, <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). Ume6 is involved in both positive and negative regulation of the phosphatidylserine synthase, Cho1 [<xref rid="B253-genes-10-00770" ref-type="bibr">253</xref>,<xref rid="B254-genes-10-00770" ref-type="bibr">254</xref>]. Phosphatidylserine exposure to the plasma membrane is a marker of yeast and mammalian apoptosis [<xref rid="B255-genes-10-00770" ref-type="bibr">255</xref>], the latter of which is induced by gemcitabine [<xref rid="B256-genes-10-00770" ref-type="bibr">256</xref>]. In pancreatic cancer cells, addition of the sphingolipid, sphingomyelin, enhances gemcitabine cytotoxicity through increased apoptosis [<xref rid="B256-genes-10-00770" ref-type="bibr">256</xref>,<xref rid="B257-genes-10-00770" ref-type="bibr">257</xref>]. Moreover, GARP complex deficiency leads to reduction of sphingomyelin [<xref rid="B258-genes-10-00770" ref-type="bibr">258</xref>] and accumulation of sphingolipid intermediates, consistent with the hypothesis that reduced sphingolipid metabolism alleviates gemcitabine-mediated apoptosis. Lem3 complexes with Dnf1 or Dnf2 to form phospholipid flippases at the plasma and early endosome/trans-Golgi network membranes and regulate phosphatidylethanolamine and phosphatidylserine membrane content [<xref rid="B259-genes-10-00770" ref-type="bibr">259</xref>,<xref rid="B260-genes-10-00770" ref-type="bibr">260</xref>], potentially further influencing the apoptotic response. The Lem3-Dnf1 and Lem3-Dnf2 flippases are regulated by the serine/threonine kinase Fpk1 [<xref rid="B261-genes-10-00770" ref-type="bibr">261</xref>], which is also a gemcitabine-specific deletion suppressor (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>F).</p></sec><sec id="sec5dot8-genes-10-00770"><title>5.8. Correlation of Gemcitabine-Specific Gene Deletion Suppression with OES in Cancer Cells</title><p>Although yeast genes associated with GO-enriched terms from gemcitabine-specific deletion suppression (2-0.8-0 and 1-0-7) did not have human homologs that were OES in GDSC, several homologs of &#x02018;non-GO-enriched&#x02019; genes were OES (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>E; <xref rid="genes-10-00770-t004" ref-type="table">Table 4</xref>). These included: (1) <italic>YGR054W/EIF2A</italic>, a eukaryotic initiation factor orthologous between yeast and human that has been implicated in translation of upstream ORFs as part of tumor initiation [<xref rid="B215-genes-10-00770" ref-type="bibr">215</xref>]. Thus, gemcitabine treatment in the context of EIF2A overexpression may increase efficacy. (2) <italic>EFT2/EEF2/EFTUD2</italic> (eukaryotic translation elongation factor 2), which further implicates translational regulation as a gemcitabine-targetable cancer driver. <italic>EEF2</italic> is overexpressed in numerous cancer types [<xref rid="B198-genes-10-00770" ref-type="bibr">198</xref>] and <italic>EFTUD2</italic> knockdown induces apoptosis in breast cancer cells [<xref rid="B199-genes-10-00770" ref-type="bibr">199</xref>]. (3) <italic>RPP2B/RPLP2</italic>, a component of the 60S ribosomal subunit stalk that is overexpressed in gynecologic cancer [<xref rid="B214-genes-10-00770" ref-type="bibr">214</xref>], again suggesting dysregulated translation promotes gemcitabine toxicity. (4) <italic>RPA49/POLR1E</italic>, a component of Pol1 [<xref rid="B203-genes-10-00770" ref-type="bibr">203</xref>,<xref rid="B204-genes-10-00770" ref-type="bibr">204</xref>,<xref rid="B205-genes-10-00770" ref-type="bibr">205</xref>] that has higher expression in bladder cancer and has been recently proposed as a novel target for anticancer therapy [<xref rid="B206-genes-10-00770" ref-type="bibr">206</xref>]. (5) <italic>OLA1/OLA1</italic> is a GTPase that is conserved from human to bacteria [<xref rid="B200-genes-10-00770" ref-type="bibr">200</xref>]. It is implicated in regulation of ribosomal translation [<xref rid="B201-genes-10-00770" ref-type="bibr">201</xref>] and has increased expression associated with poorer survival in lung cancer patients [<xref rid="B202-genes-10-00770" ref-type="bibr">202</xref>]. The interactions described above suggest gemcitabine may be more effective in the context of &#x0201c;oncogenic ribosomes&#x0201d; [<xref rid="B262-genes-10-00770" ref-type="bibr">262</xref>]. (6) <italic>CKA2</italic>, the &#x003b1; catalytic subunit of casein kinase 2, has two human homologs, <italic>CSNK2A1</italic> and CSNK2A2, which were OES with gemcitabine. They can be upregulated in cancer [<xref rid="B186-genes-10-00770" ref-type="bibr">186</xref>,<xref rid="B187-genes-10-00770" ref-type="bibr">187</xref>,<xref rid="B188-genes-10-00770" ref-type="bibr">188</xref>,<xref rid="B189-genes-10-00770" ref-type="bibr">189</xref>,<xref rid="B190-genes-10-00770" ref-type="bibr">190</xref>,<xref rid="B191-genes-10-00770" ref-type="bibr">191</xref>] and are considered targets for treatment [<xref rid="B193-genes-10-00770" ref-type="bibr">193</xref>]. (7) <italic>CLB2/CCNA2/CCNB1</italic>, a B-type cyclin involved in cell cycle progression, of which both <italic>CCNA2</italic> and <italic>CCNB1</italic> are overexpressed in breast and colorectal cancer [<xref rid="B194-genes-10-00770" ref-type="bibr">194</xref>,<xref rid="B195-genes-10-00770" ref-type="bibr">195</xref>,<xref rid="B196-genes-10-00770" ref-type="bibr">196</xref>,<xref rid="B197-genes-10-00770" ref-type="bibr">197</xref>]. Moreover, the observation that <italic>CLB2</italic> deletion (suppressing effect) opposes that of <italic>CLB5</italic> (deletion enhancing; see above <xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D, 1-0-0) has been previously described in the context of loss of the S-phase checkpoint [<xref rid="B263-genes-10-00770" ref-type="bibr">263</xref>]. (8) <italic>SKY1/SRPK1</italic> (serine&#x02013;arginine-rich serine&#x02013;threonine kinase), which is overexpressed in glioma and prostate, breast, and lung cancer [<xref rid="B207-genes-10-00770" ref-type="bibr">207</xref>]. (9) <italic>SNC2/VAMP8</italic>, which functions in fusion of Golgi-derived vesicles with the plasma membrane and is overexpressed in glioma and breast cancer [<xref rid="B208-genes-10-00770" ref-type="bibr">208</xref>,<xref rid="B209-genes-10-00770" ref-type="bibr">209</xref>]. (10) <italic>YPT6/RAB34</italic>, which functions in fusion of endosome-derived vesicles with the late Golgi and is overexpressed in glioma, breast cancer, and hepatocellular carcinoma [<xref rid="B211-genes-10-00770" ref-type="bibr">211</xref>,<xref rid="B212-genes-10-00770" ref-type="bibr">212</xref>,<xref rid="B213-genes-10-00770" ref-type="bibr">213</xref>]. (11) <italic>TOP1/TOP1/TOP1MT</italic>, Topoisomerase I, which has increased copy number in pancreatic and bile duct cancer [<xref rid="B210-genes-10-00770" ref-type="bibr">210</xref>]. (12) <italic>ALD6</italic>, which encodes cytosolic aldehyde dehydrogenase and was a deletion suppressor for both gemcitabine and cytarabine, having multiple homologs that were OES (<italic>ALDH1A1</italic>, <italic>ALDH1A2</italic>, <italic>ALDH1B1</italic>, and <italic>ALDH7A1. ALDH1B1</italic>). Overexpression of ALDH genes is observed in colorectal and pancreatic cancer [<xref rid="B183-genes-10-00770" ref-type="bibr">183</xref>,<xref rid="B184-genes-10-00770" ref-type="bibr">184</xref>] and is a prognostic marker of cancer stem cells [<xref rid="B185-genes-10-00770" ref-type="bibr">185</xref>]. </p></sec></sec><sec id="sec6-genes-10-00770"><title>6. Cytarabine-Specific Gene Interaction Modules</title><sec id="sec6dot1-genes-10-00770"><title>6.1. Cytarabine-Specific Gene Deletion Enhancement</title><p>Cytarabine-specific deletion enhancement suggests functions that buffer cytotoxic effects of cytarabine to a greater extent than gemcitabine, potentially informing on differential activities of the drugs. There was no notable GO enrichment by REMc/GTF, but four functions of potential relevance were revealed by GTA (<xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A, <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). Two of them, the HIR complex (<italic>HIR1-3,</italic> HPC2) and sphinganine kinase activity (<italic>LCB4, LCB5</italic>) were relatively weak, being deletion-enhancing only for the L CPP (<xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A). <italic>LCB4/5</italic> homologs that were UES in PharmacoDB included: (1) <italic>CERKL</italic> (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, Files B&#x02013;C</xref>; 1-0-6), a ceramide kinase-like gene that regulates autophagy by stabilizing <italic>SIRT1</italic> [<xref rid="B264-genes-10-00770" ref-type="bibr">264</xref>], a gene mentioned above for its inhibition being synergistic with cytarabine against acute lymphoblastic leukemia cells [<xref rid="B138-genes-10-00770" ref-type="bibr">138</xref>], and (2) <italic>AGK</italic>, which is overexpressed in hepatocellular carcinoma, glioma, breast, and cervical squamous cell cancers [<xref rid="B265-genes-10-00770" ref-type="bibr">265</xref>,<xref rid="B266-genes-10-00770" ref-type="bibr">266</xref>,<xref rid="B267-genes-10-00770" ref-type="bibr">267</xref>,<xref rid="B268-genes-10-00770" ref-type="bibr">268</xref>]. Two stronger interaction modules, evidenced by deletion enhancement for both the K and L CPPs, were protein localization to septin ring <italic>(HSL1</italic> and <italic>ELM1</italic>) and the <italic>Sec61</italic> translocon complex (<italic>SBH1, SBH2</italic>, and <italic>SEC61</italic>) (<xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A, <xref rid="genes-10-00770-t002" ref-type="table">Table 2</xref>). In yeast, Hsl1 and Elm1 are annotated as &#x0201c;bud sensors&#x0201d; to recruit Hsl7 to the septin ring at the bud site to degrade the mitotic inhibitor, Swe1 [<xref rid="B269-genes-10-00770" ref-type="bibr">269</xref>]. The <italic>HSL1</italic> homologs, <italic>BRSK1</italic> and <italic>BRSK2</italic>, were UES in the cancer data. <italic>BRSK1</italic> is mutated in gastric and colorectal carcinoma [<xref rid="B270-genes-10-00770" ref-type="bibr">270</xref>] and its decreased expression is associated with breast cancer [<xref rid="B271-genes-10-00770" ref-type="bibr">271</xref>], but <italic>BRSK2</italic> is overexpressed in pancreatic cancer, where it is AKT-activating [<xref rid="B272-genes-10-00770" ref-type="bibr">272</xref>]. PharmacoDB also identified the <italic>SEC61</italic> homolog, <italic>SEC61A1</italic>, which is upregulated in colon adenocarcinoma tissue [<xref rid="B273-genes-10-00770" ref-type="bibr">273</xref>]. </p><table-wrap id="genes-10-00770-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t005_Table 5</object-id><label>Table 5</label><caption><p>Yeast&#x02013;human homologs predicted to buffer cytarabine to greater degree than gemcitabine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">yGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">hGene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">H</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem_L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt_L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description_Human</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">CACNA1A</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">calcium voltage-gated channel subunit alpha1 A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">CACNA1B</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">calcium voltage-gated channel subunit alpha1 B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">CACNA1C</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, H, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">calcium voltage-gated channel subunit alpha1 C</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">CACNA1E</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">calcium voltage-gated channel subunit alpha1 E</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">CACNA1F</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">calcium voltage-gated channel subunit alpha1 F</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">NALCN</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">sodium leak channel, non-selective</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FAT1</td><td align="center" valign="middle" rowspan="1" colspan="1">SLC27A2</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B275-genes-10-00770" ref-type="bibr">275</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">solute carrier family 27 member 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FAT1</td><td align="center" valign="middle" rowspan="1" colspan="1">SLC27A3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B276-genes-10-00770" ref-type="bibr">276</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">solute carrier family 27 member 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FOL2</td><td align="center" valign="middle" rowspan="1" colspan="1">GCH1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">7.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B277-genes-10-00770" ref-type="bibr">277</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">GTP cyclohydrolase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSL1</td><td align="center" valign="middle" rowspan="1" colspan="1">BRSK1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B270-genes-10-00770" ref-type="bibr">270</xref>,<xref rid="B271-genes-10-00770" ref-type="bibr">271</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">BR serine/threonine kinase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HSL1</td><td align="center" valign="middle" rowspan="1" colspan="1">BRSK2</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B272-genes-10-00770" ref-type="bibr">272</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">BR serine/threonine kinase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IZH1</td><td align="center" valign="middle" rowspan="1" colspan="1">ADIPOR1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B278-genes-10-00770" ref-type="bibr">278</xref>,<xref rid="B279-genes-10-00770" ref-type="bibr">279</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">adiponectin receptor 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IZH1</td><td align="center" valign="middle" rowspan="1" colspan="1">PAQR4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">progestin and adipoQ receptor family member 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAP1</td><td align="center" valign="middle" rowspan="1" colspan="1">NAP1L3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">A, L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B280-genes-10-00770" ref-type="bibr">280</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">nucleosome assembly protein 1 like 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NAP1</td><td align="center" valign="middle" rowspan="1" colspan="1">NAP1L4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" rowspan="1" colspan="1">L</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">nucleosome assembly protein 1 like 4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMEM87B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-0-9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A, H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B281-genes-10-00770" ref-type="bibr">281</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">transmembrane protein 87B</td></tr></tbody></table><table-wrap-foot><fn><p>The data descriptions are the same as for <xref rid="genes-10-00770-t003" ref-type="table">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec6dot2-genes-10-00770"><title>6.2. Human Genes that have Deletion Enhancing Yeast Homologs and Confer Cytarabine UES </title><p>We identified human genes that were UES to cytarabine and homologous to yeast genes in REMc clusters (1-0-9 and 2-0.13-0) displaying a pattern of cytarabine-specific deletion enhancement (<xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>B; <xref rid="genes-10-00770-t005" ref-type="table">Table 5</xref>). Cancer-relevant examples include:<list list-type="simple"><list-item><label>(1)</label><p>Ptm1, which is a protein of unknown function that copurifies with late Golgi vesicles containing the v-SNARE, Tlg2p, but interestingly, its human homologs, <italic>TMEM87A</italic> and <italic>TMEM87B</italic>, were UES for cytarabine and identified in a study focused on cytarabine efficacy in acute myelogenous leukemia [<xref rid="B281-genes-10-00770" ref-type="bibr">281</xref>].</p></list-item><list-item><label>(2)</label><p><italic>NAP1/NAP1L3/NAP1L4</italic>, which is a nucleosome assembly protein involved in nuclear transport and exchange of histones H2A and H2B and also interacts with Clb2, is phosphorylated by CK2, and has protein abundance that increases in response to DNA replication stress [<xref rid="B155-genes-10-00770" ref-type="bibr">155</xref>]. <italic>NAP1L3</italic> is overexpressed in breast cancer [<xref rid="B280-genes-10-00770" ref-type="bibr">280</xref>].</p></list-item><list-item><label>(3)</label><p><italic>CCH1</italic>, which is a voltage-gated high-affinity calcium channel with several homologs that were UES, including: <italic>CACNA1A</italic>, underexpressed in breast, colorectal, esophageal, gastric, and brain cancers; <italic>CACNA1B</italic>, underexpressed in breast and brain cancers; <italic>CACNA1C</italic>, underexpressed in brain, bladder, lung, lymphoma, prostate, and renal cancers; <italic>CACNA1E</italic>, underexpressed in breast, brain, gastric, leukemia, lung, and prostate cancers; and <italic>CACNA1F</italic>, underexpressed in lymphoma [<xref rid="B274-genes-10-00770" ref-type="bibr">274</xref>].</p></list-item><list-item><label>(4)</label><p><italic>IZH1</italic>, a yeast membrane protein involved in zinc ion homeostasis, having a human homolog, <italic>PAQR1/ADIPOR1</italic> that encodes the adiponectin receptor protein 1, which is differentially regulated in breast cancers [<xref rid="B278-genes-10-00770" ref-type="bibr">278</xref>,<xref rid="B279-genes-10-00770" ref-type="bibr">279</xref>].</p></list-item><list-item><label>(5)</label><p><italic>FAT1</italic>, a yeast fatty acid transporter and very long-chain fatty acyl-CoA synthetase that corresponds to <italic>SLC27A2</italic> (very long-chain acyl Co-A synthetase), which is underexpressed in lung cancer [<xref rid="B275-genes-10-00770" ref-type="bibr">275</xref>], and <italic>SLC27A3</italic> (long-chain fatty acid transport), which is hypermethylated in melanoma [<xref rid="B276-genes-10-00770" ref-type="bibr">276</xref>].</p></list-item><list-item><label>(6)</label><p><italic>FOL2/GCH1</italic>, a GTP-cyclohydrolase that catalyzes the first step in folic acid biosynthesis. Downregulation of <italic>GCH1</italic> occurs in esophageal squamous cell carcinoma [<xref rid="B277-genes-10-00770" ref-type="bibr">277</xref>].</p></list-item></list></p></sec></sec><sec sec-type="discussion" id="sec7-genes-10-00770"><title>7. Discussion</title><p>Informative phenomic models have been developed for multiple human diseases, including cystic fibrosis, neurodegenerative disorders, and cancer [<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B282-genes-10-00770" ref-type="bibr">282</xref>,<xref rid="B283-genes-10-00770" ref-type="bibr">283</xref>,<xref rid="B284-genes-10-00770" ref-type="bibr">284</xref>]. Molecular models include mutations in conserved residues of yeast homologs of a disease gene and introduction of human alleles into yeast. Complementation of gene functions by human homologs, and vice versa, has demonstrated evolutionary conservation of gene functions [<xref rid="B285-genes-10-00770" ref-type="bibr">285</xref>,<xref rid="B286-genes-10-00770" ref-type="bibr">286</xref>,<xref rid="B287-genes-10-00770" ref-type="bibr">287</xref>]. Like their basic functions, gene interactions are conserved [<xref rid="B288-genes-10-00770" ref-type="bibr">288</xref>,<xref rid="B289-genes-10-00770" ref-type="bibr">289</xref>] and yeast is unique in its capability to address complex genetic interactions experimentally [<xref rid="B290-genes-10-00770" ref-type="bibr">290</xref>]. Here, we model how yeast phenomic assessment of gene&#x02013;drug interaction could be employed as part of a precision oncology paradigm to predict efficacy of cytotoxic chemotherapy based on the unique cancer genetic profiles of individual patients.</p><p>To model the networks that buffer deoxyribonucleoside analogs, we humanized yeast by introducing deoxycytidine kinase into the YKO/KD strain collection, as yeast do not encode dCK in their genomes, and thus cannot activate the unphosphorylated drugs. We hypothesized that gemcitabine and cytarabine would have different buffering profiles, despite their similar mechanisms of action, due to their distinct anticancer efficacies. Results of the unbiased yeast phenomic experiments confirmed this expectation, revealing distinct, though partially overlapping, gene interaction networks. Differential interaction predominated despite the similarity of the molecules, illustrating that distinct mechanisms for buffering anticancer cytotoxic drug responses can be inferred from yeast phenomics and thus applied to predict how an individual&#x02019;s cancer genome could influence responses to treatment [<xref rid="B3-genes-10-00770" ref-type="bibr">3</xref>,<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>].</p><p>Deletion enhancement of both gemcitabine and cytarabine suggested processes that function to buffer nucleoside analog cytotoxicity in common (<xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>), in contrast to buffering mechanisms that acted differentially in response to the drugs. Functionally enriched processes that buffered both drugs to a similar extent included the intra-S DNA damage checkpoint; positive regulation of DNA-dependent DNA replication initiation; vesicle fusion with vacuole; and the Mre11, checkpoint clamp, RecQ helicase-Topo III, CORVET, HOPS, ESCRT, GET, Ubp3-Bre5 deubiquitination complexes.</p><p>Among the drug-specific deletion enhancing interactions, autophagy, histone modification, chromatin remodeling, and peptidyl-tyrosine dephosphorylation buffered gemcitabine more so than cytarabine (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>). There were only a few cytarabine-specific deletion enhancing GO-enriched terms, but there were many individual genes with human homologs having cancer relevance that buffered cytarabine relatively specifically (<xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>). On the other hand, genes that preferentially promote cytotoxicity were observed primarily for gemcitabine, and enriched functions were related to apoptosis, including phosphatidylserine biosynthesis, and the GARP and Lem2/3 complexes (<xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>).</p><p>The model we constructed incorporates the powerful pharmacogenomics datasets and analysis tools from PharmacoDB, mining them by integration of yeast phenomic drug&#x02013;gene interaction experiments. We integrated yeast phenomic and PharmacoDB data to identify, across the respective datasets, correlations between deletion enhancement and underexpression sensitivity or deletion suppression and overexpression sensitivity. Deletion enhancement indicates genes that are biomarkers and synergistic targets to augment drug efficacy and expand the therapeutic window, whereas deletion suppression identifies genes that promote drug cytotoxicity, and thus confer sensitivity when hyper-functional and resistance when deficient. A particularly attractive class of drug&#x02013;gene interaction is overexpression sensitivity involving driver genes, however, anticancer efficacy could also be conferred by lethal drug&#x02013;gene interactions involving passenger genes, tumor suppressor genes, or components of genetic buffering networks that become altered due to genomic instability (<xref ref-type="fig" rid="genes-10-00770-f001">Figure 1</xref>A). The cancer literature revealed many deletion enhancing/UES and deletion suppressing/OES genes to have roles in cancer, suggesting that integration of yeast phenomic models and pharmacogenomics data could have clinical utility for choosing cytotoxic treatments based on gene expression profiles of individual cancers. While predictions sometimes involved GO-enriched processes, often the genes were identified individually. Assessment of conserved buffering genes (number of yeast deletion enhancers with human homologs exhibiting underexpression sensitivity) was estimated to be around 50% (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File A&#x02014;see &#x02018;Conservation_buffering_homologs&#x02019;</xref>). </p><p>We focused discussion of conserved homologs with cancer relevance based on the integration of yeast and human data, the extent of homology, the annotated functions, and the existing cancer literature. We note that although genes specifically buffering cytarabine were less well annotated and less conserved overall, they were equally relevant in the model, with about half of all buffering gene interactions in yeast evidenced in the PharmacoDB functional genomic data (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, File A.&#x02014;&#x02018;Conservation_buffering_homologs&#x02019; worksheet</xref>). Thus, the supplemental materials serve as a resource for future analyses of genes that remain to be annotated (<xref ref-type="app" rid="app1-genes-10-00770">Additional File 8, Files A&#x02013;D</xref>).</p><p>As shown by Birrell et al., differential gene expression is a poor predictor of which genes are required for response to a drug [<xref rid="B52-genes-10-00770" ref-type="bibr">52</xref>]. Thus, yeast phenomic models (i.e., Q-HTCP of the YKO/KD library) may help clarify the milieu of potentially causal associations between differential gene expression and drug sensitivity observed in cancer cells by individually testing in yeast the influences on cell proliferation of evolutionarily related protein products. As far as we know, this work represents the first application of this fundamental observation from yeast to systems level experimental data from human cells. Literature-based validations of the yeast phenomic model of nucleoside analogs in human cancer cell lines and other cancer models are exemplified in <xref rid="genes-10-00770-t006" ref-type="table">Table 6</xref>. These examples illustrate that integrative, systems level drug&#x02013;gene interaction modeling employing the experimental power of <italic>S. cerevisiae</italic> phenomics could be applicable to cancer genomic profiling for systems level, precision oncology. </p><p>In summary, the yeast phenomic model of nucleoside analog toxicity appears to serve as a valuable resource for interpreting cancer pharmacogenomics data regarding gene&#x02013;drug interaction that could be predictive of patient-specific chemotherapeutic efficacy. Since it&#x02019;s not possible to collect comparable phenomic information from human populations or cancerous tissue alone [<xref rid="B5-genes-10-00770" ref-type="bibr">5</xref>], systems-level yeast phenomic models can help expand and integrate relevant (i.e., evolutionarily conserved) aspects of the extensive cancer literature with regard to cancer-specific vulnerabilities to cytotoxic therapies. A deeper understanding of how genomic instability influences the genetic network that buffers chemotherapeutic agents like nucleoside analogs could guide future research to personalize anticancer therapies based on cancer genomic profiles unique to individual patients. Thus, a future direction for this work should include development of algorithms that prospectively predict chemotherapy response in individual patient cancer cells, which could be tested as part of a prognostic evaluation. In this initial study, we focused on expression data from PharmacoDB, rather than mutation data, because differential gene expression in cancer cells is more analogous to the quantitative changes in gene expression resulting from gene KO/KD than qualitative or indeterminate effects resulting from point mutations, for example. However, an interesting future direction could be to analyze mutation data in conjunction with gene expression and yeast phenomic data, for example to identify eQTLs associated with UES or OES genes [<xref rid="B291-genes-10-00770" ref-type="bibr">291</xref>]. With regard to the number of interactions observed in the yeast model, we note this depends on the inclusiveness of homology. <italic>S. cerevisiae</italic>, as a single cell organism and evolutionarily distant relative of humans, is informative about gene interactions across many different human cell types. Thus, yeast genetic interactions are merely hypothesis-generating and require appropriate future testing of human homologs and in human cell types. While yeast phenomic models of human disease are powerful engines of discovery, findings can only be truly prioritized and focused at this time in models more directly relevant to the human conditions of interest. </p></sec><sec sec-type="conclusions" id="sec8-genes-10-00770"><title>8. Conclusions</title><p>A humanized yeast phenomic model of deoxycytidine kinase was developed to map drug&#x02013;gene interactions modulating antiproliferative effects of nucleoside analogs in a eukaryotic cell and to investigate the relevance of the resulting networks for precision oncology by integration with cancer pharmacogenomics-derived associations between gene expression and cancer cell line drug sensitivity. The yeast phenomic model revealed gene&#x02013;drug interaction for the two deoxycytidine analogs, gemcitabine and cytarabine, to be largely different, consistent with the distinct types of cancer for which they are used clinically. The model overall suggested evolutionary conservation of drug&#x02013;gene interaction that could be used as a resource to predict anticancer therapeutic efficacy based on genetic information specific to individual patients&#x02019; tumors. Yeast phenomics affords a scalable, high-resolution approach to model, at a systems level, the genetic requirements for sensitivity and resistance to cytotoxic agents and, thus, the potential to resolve complex influences of genetic variation on drug response more accurately. Global and quantitative models of the distinct genetic buffering networks required to maintain cellular homeostasis after exposure to chemotherapeutic agents could aid precision oncology paradigms aimed at identifying composite genomic derangements that create enhanced cancer cell-specific vulnerabilities to particular anticancer drugs. Further in this regard, cytotoxic chemotherapeutic agents are used in combination, so another direction for yeast phenomic analysis of anticancer agents would be to characterize clinically relevant drug combinations.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the following funding agencies for their support: American Cancer Society (RSG-10-066-01-TBE), Howard Hughes Medical Institute (P/S ECA 57005927), NIH/NHLBI (R01 HL136414), NIH/NIA (R01 AG043076), and Cystic Fibrosis Foundation (HARTMA16G0). The authors also thank Amanda Stisher for assistance with constructing MIY16 and Bo Xu and William Parker for providing the deoxycytidine kinase cDNA cloned into a plasmid. </p></ack><app-group><app id="app1-genes-10-00770"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2073-4425/10/10/770/s1">https://www.mdpi.com/2073-4425/10/10/770/s1</uri>, Additional File 1: Supplemental tables: Tables S1&#x02013;S6. Table S1: Primers used in construction of the synthetic genetic array (SGA) &#x02018;query&#x02019; strain (MIY16) for doxycycline-inducible deoxycytidine kinase expression (see Figure S1), Table S2: Drug&#x02013;gene interaction data from genome-wide experiments for gemcitabine YKO/KD strains, Table S3: Drug&#x02013;gene interaction data from genome-wide experiments for gemcitabine reference strains, Table S4: Drug&#x02013;gene interaction data from genome-wide experiments for cytarabine YKO/KD strains. Table S5: Drug&#x02013;gene interaction data from genome-wide experiments for cytarabine reference strains, Table S6: Summary statistics of interaction z-scores for the YKO/YKD and reference cultures from the phenomic analyses of gemcitabine and cytarabine drug&#x02013;gene interaction, including the ranges, averages, standard deviations, and representative interaction z-scores in the tails of the distributions. Additional File 2: Supplemental figures. Figure S1: Construction of tet-inducible dCK allele, Figure S2: Reference strain distributions for rate (r) and area under curve (AUC) with gemcitabine or cytarabine treatment, Figure S3: Gene deletion suppression modules exhibiting high shift or variable interaction, Figure S4: Elongator holoenzyme complex, protein urmylation, and tRNA wobble position uridine thiolation gene modules exhibit variable shift and deletion enhancing interaction profiles. Additional File 3: Gene&#x02013;gemcitabine interaction plots for (A) YKO, (B) KD, and (C) reference strains. Additional File 4: Gene&#x02013;cytarabine interaction plots for (A) YKO, (B) KD, and (C) reference strains. The first two pages in Additional Files 3 and 4 display the reference distributions used to calculate gene&#x02013;drug interactions. Summary data comparing them are in Additional File 1, Table S6. Additional File 5: REMc results: File A is a table providing REMc results and associated gene interaction and shift data. File B is the heatmap representation of each REMc cluster after incorporating shift values and hierarchical clustering. Gene label colors for YKO and YKD are black and red, respectively. File C contains tables of GTF results from the process, function, and component ontologies for each REMc cluster. Additional File 6. Gene ontology term averaging (GTA) results and interactive plots. File A contains all GTA values, cross-referenced with REMc-enriched terms. Files B and C display GTA values associated with above-threshold GTA scores plotted for gemcitabine vs. cytarabine for L and K, respectively. They should be opened in an Internet web browser so that embedded information from Additional File 6A can be viewed by scrolling over points on the graphs. Subsets in each of the plots can be toggled off and on by clicking on the respective legend label. In the embedded information, X1 represents gemcitabine and X2 represents cytarabine information. Additional File 7: GO term-specific heatmaps for REMc/GTF-enriched modules, generated as described in methods and <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>. Child terms are presented in subsequent pages of the parent file name. GO terms having more than 100 children, with two or fewer genes annotated to the term, or a file size over 400 KB are not represented. All heatmaps are generated with the same layout (see <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>). Additional File 8: Integration of yeast phenomic drug&#x02013;gene interaction data with cancer cell line pharmacogenomic data (gene expression and drug sensitivity correlations) to predict differential gene expression in cancer cells that is causally associated with enhanced gemcitabine or cytarabine cytotoxicity. File A contains three tables of all UES and OES human genes from the GDSC (gemcitabine and cytarabine) and gCSI (gemcitabine only) databases, also indicating whether deletion-enhancing or deletion-suppressing gene&#x02013;drug interactions from phenomic analysis of yeast homologs predicted causal associations. Homology relationships and other associated data are coassembled. Files B&#x02013;D consist of heatmaps and corresponding tables of yeast drug&#x02013;gene interaction sets that predict causality for UES or OES human genes identified (File B) across all tissue, (File C) in lung, or (File D) in hematopoietic and lymphoid tissue. See <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref> for explanation of colors for gene labels and homology type. Note: the teal color, which represents cytarabine-specific UES/OES in the heatmaps in the main manuscript figures corresponds to darker blue in the supplemental heatmaps, while gold, representing gemcitabine-specific UES/OES in the main manuscript corresponds to bright yellow. Black corresponds to UES or OES for both drugs).</p><supplementary-material content-type="local-data" id="genes-10-00770-s001"><media xlink:href="genes-10-00770-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.L.H.; methodology and software, B.A.M., J.G., J.L.H., and S.M.S.; formal analysis, J.L.H. and S.M.S.; investigation, D.W., I.P., and M.I.; resources, J.L.H. and M.N.; data curation, J.R.; writing&#x02014;original draft preparation, J.L.H. and S.M.S.; writing&#x02014;review and editing, J.L.H. and S.M.S.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>J.L.H. has ownership in Spectrum PhenomX, LLC, a company that was formed to commercialize Q-HTCP technology. The authors declare no other competing interests.</p></notes><glossary><title>List of Abbreviations and Glossary of Terms</title><p>AraC&#x02014;cytarabine; cytosine arabinoside. CPPs&#x02014;cell proliferation parameters: parameters of the logistic growth equation used to fit cell proliferation data obtained by Q-HTCP. The CPPs used to assess gene interaction in this study were K (carrying capacity) and L (time required to reach half of carrying capacity) [<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>,<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>,<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. DAmP&#x02014;decreased abundance of mRNA. Production: refers to a method of making YKD alleles, where the 3&#x02032; UTR of essential genes is disrupted, reducing mRNA stability and gene dosage [<xref rid="B292-genes-10-00770" ref-type="bibr">292</xref>]. dCK&#x02014;deoxycytidine kinase. dCMP&#x02014;deoxycytidine monophosphate. DE&#x02014;deletion enhancer: gene loss of function (knockout or knockdown) that results in enhancement/increase of drug sensitivity [<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>]. dFdC&#x02014;2&#x02032;,2&#x02032;-difluoro 2&#x02032;-deoxycytidine, gemcitabine. dNTP&#x02014;deoxyribonucleotide triphosphate. DS&#x02014;deletion suppressor: gene loss of function (knockout or knockdown) that results in suppression / reduction of drug sensitivity [<xref rid="B9-genes-10-00770" ref-type="bibr">9</xref>]. ESCRT&#x02014;endosomal sorting complex required for transport. GARP complex&#x02014;Golgi-associated retrograde protein complex. gCSI&#x02014;the Genentech cell line screening initiative: one of two pharmacogenomics datasets used in this study (<uri xlink:href="https://pharmacodb.pmgenomics.ca/datasets/4">https://pharmacodb.pmgenomics.ca/datasets/4</uri>). GDSC1000&#x02013;Genomics of Drug Sensitivity in Cancer: One of two pharmacogenomics datasets used in this study (<uri xlink:href="https://pharmacodb.pmgenomics.ca/datasets/5">https://pharmacodb.pmgenomics.ca/datasets/5</uri>). GO&#x02014;gene ontology. GTF&#x02014;gene ontology term finder: an algorithm to assess GO term enrichment amongst a list of genes; applied to REMc (clustering) results [<xref rid="B41-genes-10-00770" ref-type="bibr">41</xref>]. GTA&#x02014;gene ontology term averaging: an assessment of GO term function obtained by averaging the gene interaction values for all genes of a GO term. GTA value&#x02014;gene ontology term average value. gtaSD&#x02014;standard deviation of GTA value. GTA score&#x02014;(GTA value &#x02013; gtaSD). HaL&#x02014;hematopoietic and lymphoid tissue. HDAC&#x02014;histone deacetylase complex. HLD&#x02014;human-like media with dextrose [<xref rid="B8-genes-10-00770" ref-type="bibr">8</xref>]: the yeast media used in this study. INT&#x02014;interaction score. NDK&#x02014;nucleoside diphosphate kinase. OES&#x02014;overexpression sensitivity: refers to association of increased gene expression with drug sensitivity in pharmacogenomics data [<xref rid="B32-genes-10-00770" ref-type="bibr">32</xref>]. PharmacoDB&#x02014;the resource used for cancer pharmacogenomics analysis [<xref rid="B32-genes-10-00770" ref-type="bibr">32</xref>]. PPOD&#x02014;Princeton protein orthology database. Q-HTCP&#x02014;quantitative high-throughput cell array phenotyping: a method of imaging, image analysis, and growth curve fitting to obtain cell proliferation parameters [<xref rid="B7-genes-10-00770" ref-type="bibr">7</xref>,<xref rid="B37-genes-10-00770" ref-type="bibr">37</xref>]. Ref&#x02014;reference: the genetic background from which the YKO/KD library was derived. REMc&#x02014;recursive expectation maximization clustering: a probabilistic clustering algorithm that determines a discrete number of clusters from a data matrix [<xref rid="B40-genes-10-00770" ref-type="bibr">40</xref>]. RNR&#x02014;ribonucleotide reductase. SD&#x02014;standard deviation. SGA&#x02014;synthetic genetic array. SGD&#x02014;saccharomyces genome database. UES&#x02014;underexpression sensitivity: refers to association of reduced gene expression with drug sensitivity in pharmacogenomics data [<xref rid="B32-genes-10-00770" ref-type="bibr">32</xref>]. YKO&#x02014;yeast knockout. YKD&#x02014;yeast knockdown: DAmP alleles. YKO/KD&#x02014;yeast knockout or knockdown.</p></glossary><ref-list><title>References</title><ref id="B1-genes-10-00770"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torti</surname><given-names>D.</given-names></name><name><surname>Trusolino</surname><given-names>L.</given-names></name></person-group><article-title>Oncogene addiction as a foundational rationale for targeted anticancer therapy: Promises and perils</article-title><source>EMBO Mol. Med.</source><year>2011</year><volume>3</volume><fpage>623</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1002/emmm.201100176</pub-id><?supplied-pmid 21953712?><pub-id pub-id-type="pmid">21953712</pub-id></element-citation></ref><ref id="B2-genes-10-00770"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masui</surname><given-names>K.</given-names></name><name><surname>Gini</surname><given-names>B.</given-names></name><name><surname>Wykosky</surname><given-names>J.</given-names></name><name><surname>Zanca</surname><given-names>C.</given-names></name><name><surname>Mischel</surname><given-names>P.S.</given-names></name><name><surname>Furnari</surname><given-names>F.B.</given-names></name><name><surname>Cavenee</surname><given-names>W.K.</given-names></name></person-group><article-title>A tale of two approaches: Complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments</article-title><source>Carcinogenesis</source><year>2013</year><volume>34</volume><fpage>725</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt086</pub-id><pub-id pub-id-type="pmid">23455378</pub-id></element-citation></ref><ref id="B3-genes-10-00770"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwell</surname><given-names>L.H.</given-names></name><name><surname>Szankasi</surname><given-names>P.</given-names></name><name><surname>Roberts</surname><given-names>C.J.</given-names></name><name><surname>Murray</surname><given-names>A.W.</given-names></name><name><surname>Friend</surname><given-names>S.H.</given-names></name></person-group><article-title>Integrating genetic approaches into the discovery of anticancer drugs</article-title><source>Science</source><year>1997</year><volume>278</volume><fpage>1064</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1126/science.278.5340.1064</pub-id><?supplied-pmid 9353181?><pub-id pub-id-type="pmid">9353181</pub-id></element-citation></ref><ref id="B4-genes-10-00770"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivas</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>J.P.</given-names></name><name><surname>Yang</surname><given-names>C.C.</given-names></name><name><surname>Sun</surname><given-names>S.M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Gross</surname><given-names>A.M.</given-names></name><name><surname>Jensen</surname><given-names>J.</given-names></name><name><surname>Licon</surname><given-names>K.</given-names></name><name><surname>Bojorquez-Gomez</surname><given-names>A.</given-names></name><name><surname>Klepper</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy</article-title><source>Mol. Cell</source><year>2016</year><volume>63</volume><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.022</pub-id><?supplied-pmid 27453043?><pub-id pub-id-type="pmid">27453043</pub-id></element-citation></ref><ref id="B5-genes-10-00770"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name><name><surname>Garvik</surname><given-names>B.</given-names></name><name><surname>Hartwell</surname><given-names>L.</given-names></name></person-group><article-title>Principles for the buffering of genetic variation</article-title><source>Science</source><year>2001</year><volume>291</volume><fpage>1001</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1126/science.291.5506.1001</pub-id><?supplied-pmid 11232561?><pub-id pub-id-type="pmid">11232561</pub-id></element-citation></ref><ref id="B6-genes-10-00770"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name><name><surname>Tippery</surname><given-names>N.P.</given-names></name></person-group><article-title>Systematic quantification of gene interactions by phenotypic array analysis</article-title><source>Genome Biol.</source><year>2004</year><volume>5</volume><fpage>R49</fpage><pub-id pub-id-type="doi">10.1186/gb-2004-5-7-r49</pub-id><pub-id pub-id-type="pmid">15239834</pub-id></element-citation></ref><ref id="B7-genes-10-00770"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>N.A.</given-names></name><name><surname>Laws</surname><given-names>R.J.</given-names></name><name><surname>Wardman</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>L.P.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>Accurate, precise modeling of cell proliferation kinetics from time-lapse imaging and automated image analysis of agar yeast culture arrays</article-title><source>BMC Syst. Biol.</source><year>2007</year><volume>1</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1186/1752-0509-1-3</pub-id><?supplied-pmid 17408510?><pub-id pub-id-type="pmid">17408510</pub-id></element-citation></ref><ref id="B8-genes-10-00770"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name><name><surname>Stisher</surname><given-names>C.</given-names></name><name><surname>Outlaw</surname><given-names>D.A.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Shah</surname><given-names>N.A.</given-names></name><name><surname>Tian</surname><given-names>D.</given-names></name><name><surname>Santos</surname><given-names>S.M.</given-names></name><name><surname>Rodgers</surname><given-names>J.W.</given-names></name><name><surname>White</surname><given-names>R.A.</given-names></name></person-group><article-title>Yeast Phenomics: An Experimental Approach for Modeling Gene Interaction Networks that Buffer Disease</article-title><source>Genes</source><year>2015</year><volume>6</volume><fpage>24</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3390/genes6010024</pub-id><pub-id pub-id-type="pmid">25668739</pub-id></element-citation></ref><ref id="B9-genes-10-00770"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louie</surname><given-names>R.J.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Rodgers</surname><given-names>J.W.</given-names></name><name><surname>White</surname><given-names>R.</given-names></name><name><surname>Shah</surname><given-names>N.</given-names></name><name><surname>Pagant</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>P.</given-names></name><name><surname>Livstone</surname><given-names>M.</given-names></name><name><surname>Dolinski</surname><given-names>K.</given-names></name><name><surname>McKinney</surname><given-names>B.A.</given-names></name><etal/></person-group><article-title>A yeast phenomic model for the gene interaction network modulating CFTR-&#x02206;F508 protein biogenesis</article-title><source>Genome Med.</source><year>2012</year><volume>4</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/gm404</pub-id><?supplied-pmid 23270647?><pub-id pub-id-type="pmid">23270647</pub-id></element-citation></ref><ref id="B10-genes-10-00770"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galmarini</surname><given-names>C.M.</given-names></name><name><surname>Mackey</surname><given-names>J.R.</given-names></name><name><surname>Dumontet</surname><given-names>C.</given-names></name></person-group><article-title>Nucleoside analogues and nucleobases in cancer treatment</article-title><source>Lancet Oncol.</source><year>2002</year><volume>3</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(02)00788-X</pub-id><pub-id pub-id-type="pmid">12142171</pub-id></element-citation></ref><ref id="B11-genes-10-00770"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>W.B.</given-names></name></person-group><article-title>Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer</article-title><source>Chem. Rev.</source><year>2009</year><volume>109</volume><fpage>2880</fpage><lpage>2893</lpage><pub-id pub-id-type="doi">10.1021/cr900028p</pub-id><?supplied-pmid 19476376?><pub-id pub-id-type="pmid">19476376</pub-id></element-citation></ref><ref id="B12-genes-10-00770"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Sousa Cavalcante</surname><given-names>L.</given-names></name><name><surname>Monteiro</surname><given-names>G.</given-names></name></person-group><article-title>Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer</article-title><source>Eur. J. Pharmacol.</source><year>2014</year><volume>741</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.07.041</pub-id><?supplied-pmid 25084222?><pub-id pub-id-type="pmid">25084222</pub-id></element-citation></ref><ref id="B13-genes-10-00770"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Kurata</surname><given-names>T.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name></person-group><article-title>Gemcitabine: Efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer</article-title><source>Clin. Med. Insights Oncol.</source><year>2011</year><volume>5</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.4137/CMO.S6252</pub-id><?supplied-pmid 21695043?><pub-id pub-id-type="pmid">21695043</pub-id></element-citation></ref><ref id="B14-genes-10-00770"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>F.A.</given-names></name><name><surname>Counsell</surname><given-names>N.</given-names></name><name><surname>Colombo</surname><given-names>N.</given-names></name><name><surname>Pfisterer</surname><given-names>J.</given-names></name><name><surname>du Bois</surname><given-names>A.</given-names></name><name><surname>Parmar</surname><given-names>M.K.</given-names></name><name><surname>Vergote</surname><given-names>I.B.</given-names></name><name><surname>Gonzalez-Martin</surname><given-names>A.</given-names></name><name><surname>Alberts</surname><given-names>D.S.</given-names></name><name><surname>Plante</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis using individual patient data</article-title><source>Ann. Oncol.</source><year>2013</year><volume>24</volume><fpage>3028</fpage><lpage>3034</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt406</pub-id><?supplied-pmid 24190964?><pub-id pub-id-type="pmid">24190964</pub-id></element-citation></ref><ref id="B15-genes-10-00770"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alli</surname><given-names>E.</given-names></name><name><surname>Sharma</surname><given-names>V.B.</given-names></name><name><surname>Hartman</surname><given-names>A.R.</given-names></name><name><surname>Lin</surname><given-names>P.S.</given-names></name><name><surname>McPherson</surname><given-names>L.</given-names></name><name><surname>Ford</surname><given-names>J.M.</given-names></name></person-group><article-title>Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells</article-title><source>BMC Pharmacol.</source><year>2011</year><volume>11</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2210-11-7</pub-id><pub-id pub-id-type="pmid">21771338</pub-id></element-citation></ref><ref id="B16-genes-10-00770"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>N.D.</given-names></name><name><surname>Schiller</surname><given-names>G.J.</given-names></name></person-group><article-title>High-dose cytarabine (HD araC) in the treatment of leukemias: A review</article-title><source>Curr. Hematol. Malig. Rep.</source><year>2013</year><volume>8</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1007/s11899-013-0156-3</pub-id><?supplied-pmid 23666364?><pub-id pub-id-type="pmid">23666364</pub-id></element-citation></ref><ref id="B17-genes-10-00770"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannetti</surname><given-names>E.</given-names></name><name><surname>Del Tacca</surname><given-names>M.</given-names></name><name><surname>Mey</surname><given-names>V.</given-names></name><name><surname>Funel</surname><given-names>N.</given-names></name><name><surname>Nannizzi</surname><given-names>S.</given-names></name><name><surname>Ricci</surname><given-names>S.</given-names></name><name><surname>Orlandini</surname><given-names>C.</given-names></name><name><surname>Boggi</surname><given-names>U.</given-names></name><name><surname>Campani</surname><given-names>D.</given-names></name><name><surname>Del Chiaro</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>3928</fpage><lpage>3935</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4203</pub-id><pub-id pub-id-type="pmid">16585222</pub-id></element-citation></ref><ref id="B18-genes-10-00770"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skrypek</surname><given-names>N.</given-names></name><name><surname>Duchene</surname><given-names>B.</given-names></name><name><surname>Hebbar</surname><given-names>M.</given-names></name><name><surname>Leteurtre</surname><given-names>E.</given-names></name><name><surname>van Seuningen</surname><given-names>I.</given-names></name><name><surname>Jonckheere</surname><given-names>N.</given-names></name></person-group><article-title>The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>1714</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.179</pub-id><pub-id pub-id-type="pmid">22580602</pub-id></element-citation></ref><ref id="B19-genes-10-00770"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Kweon</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>T.H.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>T.S.</given-names></name></person-group><article-title>Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells</article-title><source>Int. J. Oncol.</source><year>2009</year><volume>34</volume><fpage>1165</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">19287976</pub-id></element-citation></ref><ref id="B20-genes-10-00770"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duxbury</surname><given-names>M.S.</given-names></name><name><surname>Ito</surname><given-names>H.</given-names></name><name><surname>Zinner</surname><given-names>M.J.</given-names></name><name><surname>Ashley</surname><given-names>S.W.</given-names></name><name><surname>Whang</surname><given-names>E.E.</given-names></name></person-group><article-title>RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207272</pub-id><pub-id pub-id-type="pmid">14661056</pub-id></element-citation></ref><ref id="B21-genes-10-00770"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J.D.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Flagella</surname><given-names>M.</given-names></name><name><surname>Geeganage</surname><given-names>S.</given-names></name><name><surname>Gelbert</surname><given-names>L.M.</given-names></name><name><surname>Slapak</surname><given-names>C.A.</given-names></name></person-group><article-title>An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>3761</fpage><lpage>3766</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3363</pub-id><?supplied-pmid 15172981?><pub-id pub-id-type="pmid">15172981</pub-id></element-citation></ref><ref id="B22-genes-10-00770"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Fridley</surname><given-names>B.L.</given-names></name><name><surname>Kalari</surname><given-names>K.</given-names></name><name><surname>Jenkins</surname><given-names>G.</given-names></name><name><surname>Batzler</surname><given-names>A.</given-names></name><name><surname>Weinshilboum</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Gemcitabine and arabinosylcytosin pharmacogenomics: Genome-wide association and drug response biomarkers</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7765</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007765</pub-id><?supplied-pmid 19898621?><pub-id pub-id-type="pmid">19898621</pub-id></element-citation></ref><ref id="B23-genes-10-00770"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innocenti</surname><given-names>F.</given-names></name><name><surname>Owzar</surname><given-names>K.</given-names></name><name><surname>Cox</surname><given-names>N.L.</given-names></name><name><surname>Evans</surname><given-names>P.</given-names></name><name><surname>Kubo</surname><given-names>M.</given-names></name><name><surname>Zembutsu</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Hollis</surname><given-names>D.</given-names></name><name><surname>Mushiroda</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1387</pub-id><?supplied-pmid 22142827?><pub-id pub-id-type="pmid">22142827</pub-id></element-citation></ref><ref id="B24-genes-10-00770"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>H.Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.P.</given-names></name></person-group><article-title>Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>407</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.027</pub-id><pub-id pub-id-type="pmid">21316338</pub-id></element-citation></ref><ref id="B25-genes-10-00770"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bargal</surname><given-names>S.A.</given-names></name><name><surname>Rafiee</surname><given-names>R.</given-names></name><name><surname>Crews</surname><given-names>K.R.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Rubnitz</surname><given-names>J.E.</given-names></name><name><surname>Ribeiro</surname><given-names>R.C.</given-names></name><name><surname>Downing</surname><given-names>J.R.</given-names></name><name><surname>Pounds</surname><given-names>S.B.</given-names></name><name><surname>Lamba</surname><given-names>J.K.</given-names></name></person-group><article-title>Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>34859</fpage><lpage>34875</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26163</pub-id><?supplied-pmid 30405880?><pub-id pub-id-type="pmid">30405880</pub-id></element-citation></ref><ref id="B26-genes-10-00770"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamazon</surname><given-names>E.R.</given-names></name><name><surname>Lamba</surname><given-names>J.K.</given-names></name><name><surname>Pounds</surname><given-names>S.</given-names></name><name><surname>Stark</surname><given-names>A.L.</given-names></name><name><surname>Wheeler</surname><given-names>H.E.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Im</surname><given-names>H.K.</given-names></name><name><surname>Mitra</surname><given-names>A.K.</given-names></name><name><surname>Rubnitz</surname><given-names>J.E.</given-names></name><name><surname>Ribeiro</surname><given-names>R.C.</given-names></name><etal/></person-group><article-title>Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4366</fpage><lpage>4376</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-10-464149</pub-id><pub-id pub-id-type="pmid">23538338</pub-id></element-citation></ref><ref id="B27-genes-10-00770"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giaever</surname><given-names>G.</given-names></name><name><surname>Chu</surname><given-names>A.M.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><name><surname>Connelly</surname><given-names>C.</given-names></name><name><surname>Riles</surname><given-names>L.</given-names></name><name><surname>Veronneau</surname><given-names>S.</given-names></name><name><surname>Dow</surname><given-names>S.</given-names></name><name><surname>Lucau-Danila</surname><given-names>A.</given-names></name><name><surname>Anderson</surname><given-names>K.</given-names></name><name><surname>Andre</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Functional profiling of the Saccharomyces cerevisiae genome</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/nature00935</pub-id><pub-id pub-id-type="pmid">12140549</pub-id></element-citation></ref><ref id="B28-genes-10-00770"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>A.H.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name></person-group><article-title>Synthetic genetic array analysis in Saccharomyces cerevisiae</article-title><source>Methods Mol. Biol.</source><year>2006</year><volume>313</volume><fpage>171</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">16118434</pub-id></element-citation></ref><ref id="B29-genes-10-00770"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Pass</surname><given-names>R.</given-names></name><name><surname>Togay</surname><given-names>S.O.</given-names></name><name><surname>Rodgers</surname><given-names>J.W.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>Stringent Mating-Type-Regulated Auxotrophy Increases the Accuracy of Systematic Genetic Interaction Screens with Saccharomyces cerevisiae Mutant Arrays</article-title><source>Genetics</source><year>2009</year><volume>181</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1534/genetics.108.092981</pub-id><pub-id pub-id-type="pmid">18957706</pub-id></element-citation></ref><ref id="B30-genes-10-00770"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Soares</surname><given-names>J.</given-names></name><name><surname>Greninger</surname><given-names>P.</given-names></name><name><surname>Edelman</surname><given-names>E.J.</given-names></name><name><surname>Lightfoot</surname><given-names>H.</given-names></name><name><surname>Forbes</surname><given-names>S.</given-names></name><name><surname>Bindal</surname><given-names>N.</given-names></name><name><surname>Beare</surname><given-names>D.</given-names></name><name><surname>Smith</surname><given-names>J.A.</given-names></name><name><surname>Thompson</surname><given-names>I.R.</given-names></name><etal/></person-group><article-title>Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><fpage>D955</fpage><lpage>D961</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id><pub-id pub-id-type="pmid">23180760</pub-id></element-citation></ref><ref id="B31-genes-10-00770"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klijn</surname><given-names>C.</given-names></name><name><surname>Durinck</surname><given-names>S.</given-names></name><name><surname>Stawiski</surname><given-names>E.W.</given-names></name><name><surname>Haverty</surname><given-names>P.M.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Degenhardt</surname><given-names>J.</given-names></name><name><surname>Mayba</surname><given-names>O.</given-names></name><name><surname>Gnad</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A comprehensive transcriptional portrait of human cancer cell lines</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>306</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/nbt.3080</pub-id><?supplied-pmid 25485619?><pub-id pub-id-type="pmid">25485619</pub-id></element-citation></ref><ref id="B32-genes-10-00770"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnov</surname><given-names>P.</given-names></name><name><surname>Kofia</surname><given-names>V.</given-names></name><name><surname>Maru</surname><given-names>A.</given-names></name><name><surname>Freeman</surname><given-names>M.</given-names></name><name><surname>Ho</surname><given-names>C.</given-names></name><name><surname>El-Hachem</surname><given-names>N.</given-names></name><name><surname>Adam</surname><given-names>G.A.</given-names></name><name><surname>Ba-Alawi</surname><given-names>W.</given-names></name><name><surname>Safikhani</surname><given-names>Z.</given-names></name><name><surname>Haibe-Kains</surname><given-names>B.</given-names></name></person-group><article-title>PharmacoDB: An integrative database for mining in vitro anticancer drug screening studies</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D994</fpage><lpage>D1002</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx911</pub-id><?supplied-pmid 30053271?><pub-id pub-id-type="pmid">30053271</pub-id></element-citation></ref><ref id="B33-genes-10-00770"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>Buffering of deoxyribonucleotide pool homeostasis by threonine metabolism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>11700</fpage><lpage>11705</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705212104</pub-id><?supplied-pmid 17606896?><pub-id pub-id-type="pmid">17606896</pub-id></element-citation></ref><ref id="B34-genes-10-00770"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belli</surname><given-names>G.</given-names></name><name><surname>Gari</surname><given-names>E.</given-names></name><name><surname>Piedrafita</surname><given-names>L.</given-names></name><name><surname>Aldea</surname><given-names>M.</given-names></name><name><surname>Herrero</surname><given-names>E.</given-names></name></person-group><article-title>An activator/repressor dual system allows tight tetracycline-regulated gene expression in budding yeast</article-title><source>Nucleic Acids Res.</source><year>1998</year><volume>26</volume><fpage>942</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.1093/nar/26.4.942</pub-id><?supplied-pmid 9461451?><pub-id pub-id-type="pmid">9461451</pub-id></element-citation></ref><ref id="B35-genes-10-00770"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>William</surname><given-names>D.</given-names></name></person-group><source>Charakterisierung der C Terminalen Dom&#x000e4;ne von Mycobacterium Tuberculosis Protein A</source><publisher-name>Friedrich-Alexander-Universit&#x000e4;t Erlangen-N&#x000fc;rnberg</publisher-name><publisher-loc>Erlangen, Germany</publisher-loc><year>2012</year></element-citation></ref><ref id="B36-genes-10-00770"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>A.L.</given-names></name><name><surname>McCusker</surname><given-names>J.H.</given-names></name></person-group><article-title>Three new dominant drug resistance cassettes for gene disruption in Saccharomyces cerevisiae</article-title><source>Yeast</source><year>1999</year><volume>15</volume><fpage>1541</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0061(199910)15:14&#x0003c;1541::AID-YEA476&#x0003e;3.0.CO;2-K</pub-id><pub-id pub-id-type="pmid">10514571</pub-id></element-citation></ref><ref id="B37-genes-10-00770"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>Phenomic assessment of genetic buffering by kinetic analysis of cell arrays</article-title><source>Methods Mol. Biol.</source><year>2014</year><volume>1205</volume><fpage>187</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-1363-3_12</pub-id><?supplied-pmid 25213246?><pub-id pub-id-type="pmid">25213246</pub-id></element-citation></ref><ref id="B38-genes-10-00770"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>R.</given-names></name><name><surname>St Onge</surname><given-names>R.P.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name><name><surname>Giaever</surname><given-names>G.</given-names></name><name><surname>Roth</surname><given-names>F.P.</given-names></name></person-group><article-title>Defining genetic interaction</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>3461</fpage><lpage>3466</lpage><pub-id pub-id-type="doi">10.1073/pnas.0712255105</pub-id><?supplied-pmid 18305163?><pub-id pub-id-type="pmid">18305163</pub-id></element-citation></ref><ref id="B39-genes-10-00770"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>S.M.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin</article-title><source>bioRxiv</source><year>2019</year><fpage>517490</fpage><pub-id pub-id-type="doi">10.1101/517490</pub-id></element-citation></ref><ref id="B40-genes-10-00770"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>D.</given-names></name><name><surname>McKinney</surname><given-names>B.A.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name></person-group><article-title>Recursive expectation-maximization clustering: A method for identifying buffering mechanisms composed of phenomic modules</article-title><source>Chaos</source><year>2010</year><volume>20</volume><fpage>026103</fpage><pub-id pub-id-type="doi">10.1063/1.3455188</pub-id><pub-id pub-id-type="pmid">20590332</pub-id></element-citation></ref><ref id="B41-genes-10-00770"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>E.I.</given-names></name><name><surname>Weng</surname><given-names>S.</given-names></name><name><surname>Gollub</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Botstein</surname><given-names>D.</given-names></name><name><surname>Cherry</surname><given-names>J.M.</given-names></name><name><surname>Sherlock</surname><given-names>G.</given-names></name></person-group><article-title>GO::TermFinder&#x02014;Open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes</article-title><source>Bioinformatics</source><year>2004</year><volume>20</volume><fpage>3710</fpage><lpage>3715</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth456</pub-id><?supplied-pmid 15297299?><pub-id pub-id-type="pmid">15297299</pub-id></element-citation></ref><ref id="B42-genes-10-00770"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherry</surname><given-names>J.M.</given-names></name><name><surname>Hong</surname><given-names>E.L.</given-names></name><name><surname>Amundsen</surname><given-names>C.</given-names></name><name><surname>Balakrishnan</surname><given-names>R.</given-names></name><name><surname>Binkley</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>E.T.</given-names></name><name><surname>Christie</surname><given-names>K.R.</given-names></name><name><surname>Costanzo</surname><given-names>M.C.</given-names></name><name><surname>Dwight</surname><given-names>S.S.</given-names></name><name><surname>Engel</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Saccharomyces Genome Database: The genomics resource of budding yeast</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>D700</fpage><lpage>D705</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr1029</pub-id><?supplied-pmid 22110037?><pub-id pub-id-type="pmid">22110037</pub-id></element-citation></ref><ref id="B43-genes-10-00770"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnov</surname><given-names>P.</given-names></name><name><surname>Safikhani</surname><given-names>Z.</given-names></name><name><surname>El-Hachem</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>She</surname><given-names>A.</given-names></name><name><surname>Olsen</surname><given-names>C.</given-names></name><name><surname>Freeman</surname><given-names>M.</given-names></name><name><surname>Selby</surname><given-names>H.</given-names></name><name><surname>Gendoo</surname><given-names>D.M.</given-names></name><name><surname>Grossmann</surname><given-names>P.</given-names></name><etal/></person-group><article-title>PharmacoGx: An R package for analysis of large pharmacogenomic datasets</article-title><source>Bioinformatics</source><year>2016</year><volume>32</volume><fpage>1244</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv723</pub-id><?supplied-pmid 26656004?><pub-id pub-id-type="pmid">26656004</pub-id></element-citation></ref><ref id="B44-genes-10-00770"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S.</given-names></name><name><surname>Moreau</surname><given-names>Y.</given-names></name><name><surname>Kasprzyk</surname><given-names>A.</given-names></name><name><surname>Davis</surname><given-names>S.</given-names></name><name><surname>De Moor</surname><given-names>B.</given-names></name><name><surname>Brazma</surname><given-names>A.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name></person-group><article-title>BioMart and Bioconductor: A powerful link between biological databases and microarray data analysis</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti525</pub-id><?supplied-pmid 16082012?><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="B45-genes-10-00770"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S.</given-names></name><name><surname>Spellman</surname><given-names>P.T.</given-names></name><name><surname>Birney</surname><given-names>E.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name></person-group><article-title>Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt</article-title><source>Nat. Protoc.</source><year>2009</year><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.97</pub-id><?supplied-pmid 19617889?><pub-id pub-id-type="pmid">19617889</pub-id></element-citation></ref><ref id="B46-genes-10-00770"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerbino</surname><given-names>D.R.</given-names></name><name><surname>Achuthan</surname><given-names>P.</given-names></name><name><surname>Akanni</surname><given-names>W.</given-names></name><name><surname>Amode</surname><given-names>M.R.</given-names></name><name><surname>Barrell</surname><given-names>D.</given-names></name><name><surname>Bhai</surname><given-names>J.</given-names></name><name><surname>Billis</surname><given-names>K.</given-names></name><name><surname>Cummins</surname><given-names>C.</given-names></name><name><surname>Gall</surname><given-names>A.</given-names></name><name><surname>Giron</surname><given-names>C.G.</given-names></name><etal/></person-group><article-title>Ensembl 2018</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D754</fpage><lpage>D761</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1098</pub-id><pub-id pub-id-type="pmid">29155950</pub-id></element-citation></ref><ref id="B47-genes-10-00770"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinicke</surname><given-names>S.</given-names></name><name><surname>Livstone</surname><given-names>M.S.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Oughtred</surname><given-names>R.</given-names></name><name><surname>Kang</surname><given-names>F.</given-names></name><name><surname>Angiuoli</surname><given-names>S.V.</given-names></name><name><surname>White</surname><given-names>O.</given-names></name><name><surname>Botstein</surname><given-names>D.</given-names></name><name><surname>Dolinski</surname><given-names>K.</given-names></name></person-group><article-title>The Princeton Protein Orthology Database (P-POD): A comparative genomics analysis tool for biologists</article-title><source>PLoS ONE</source><year>2007</year><volume>2</volume><elocation-id>e766</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000766</pub-id><pub-id pub-id-type="pmid">17712414</pub-id></element-citation></ref><ref id="B48-genes-10-00770"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>A.H.</given-names></name><name><surname>Evangelista</surname><given-names>M.</given-names></name><name><surname>Parsons</surname><given-names>A.B.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Bader</surname><given-names>G.D.</given-names></name><name><surname>Page</surname><given-names>N.</given-names></name><name><surname>Robinson</surname><given-names>M.</given-names></name><name><surname>Raghibizadeh</surname><given-names>S.</given-names></name><name><surname>Hogue</surname><given-names>C.W.</given-names></name><name><surname>Bussey</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Systematic genetic analysis with ordered arrays of yeast deletion mutants</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>2364</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1126/science.1065810</pub-id><pub-id pub-id-type="pmid">11743205</pub-id></element-citation></ref><ref id="B49-genes-10-00770"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnett</surname><given-names>M.J.</given-names></name><name><surname>Edelman</surname><given-names>E.J.</given-names></name><name><surname>Heidorn</surname><given-names>S.J.</given-names></name><name><surname>Greenman</surname><given-names>C.D.</given-names></name><name><surname>Dastur</surname><given-names>A.</given-names></name><name><surname>Lau</surname><given-names>K.W.</given-names></name><name><surname>Greninger</surname><given-names>P.</given-names></name><name><surname>Thompson</surname><given-names>I.R.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Soares</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Systematic identification of genomic markers of drug sensitivity in cancer cells</article-title><source>Nature</source><year>2012</year><volume>483</volume><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/nature11005</pub-id><pub-id pub-id-type="pmid">22460902</pub-id></element-citation></ref><ref id="B50-genes-10-00770"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haverty</surname><given-names>P.M.</given-names></name><name><surname>Lin</surname><given-names>E.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Lam</surname><given-names>B.</given-names></name><name><surname>Lianoglou</surname><given-names>S.</given-names></name><name><surname>Neve</surname><given-names>R.M.</given-names></name><name><surname>Martin</surname><given-names>S.</given-names></name><name><surname>Settleman</surname><given-names>J.</given-names></name><name><surname>Yauch</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>Reproducible pharmacogenomic profiling of cancer cell line panels</article-title><source>Nature</source><year>2016</year><volume>533</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature17987</pub-id><pub-id pub-id-type="pmid">27193678</pub-id></element-citation></ref><ref id="B51-genes-10-00770"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwell</surname><given-names>L.H.</given-names></name><name><surname>Hopfield</surname><given-names>J.J.</given-names></name><name><surname>Leibler</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>A.W.</given-names></name></person-group><article-title>From molecular to modular cell biology</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>C47</fpage><lpage>C52</lpage><pub-id pub-id-type="doi">10.1038/35011540</pub-id><pub-id pub-id-type="pmid">10591225</pub-id></element-citation></ref><ref id="B52-genes-10-00770"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birrell</surname><given-names>G.W.</given-names></name><name><surname>Brown</surname><given-names>J.A.</given-names></name><name><surname>Wu</surname><given-names>H.I.</given-names></name><name><surname>Giaever</surname><given-names>G.</given-names></name><name><surname>Chu</surname><given-names>A.M.</given-names></name><name><surname>Davis</surname><given-names>R.W.</given-names></name><name><surname>Brown</surname><given-names>J.M.</given-names></name></person-group><article-title>Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>8778</fpage><lpage>8783</lpage><pub-id pub-id-type="doi">10.1073/pnas.132275199</pub-id><?supplied-pmid 12077312?><pub-id pub-id-type="pmid">12077312</pub-id></element-citation></ref><ref id="B53-genes-10-00770"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neil</surname><given-names>N.J.</given-names></name><name><surname>Bailey</surname><given-names>M.L.</given-names></name><name><surname>Hieter</surname><given-names>P.</given-names></name></person-group><article-title>Synthetic lethality and cancer</article-title><source>Nat. Rev. Genet.</source><year>2017</year><volume>18</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/nrg.2017.47</pub-id><?supplied-pmid 28649135?><pub-id pub-id-type="pmid">28649135</pub-id></element-citation></ref><ref id="B54-genes-10-00770"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGary</surname><given-names>K.L.</given-names></name><name><surname>Park</surname><given-names>T.J.</given-names></name><name><surname>Woods</surname><given-names>J.O.</given-names></name><name><surname>Cha</surname><given-names>H.J.</given-names></name><name><surname>Wallingford</surname><given-names>J.B.</given-names></name><name><surname>Marcotte</surname><given-names>E.M.</given-names></name></person-group><article-title>Systematic discovery of nonobvious human disease models through orthologous phenotypes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>6544</fpage><lpage>6549</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910200107</pub-id><?supplied-pmid 20308572?><pub-id pub-id-type="pmid">20308572</pub-id></element-citation></ref><ref id="B55-genes-10-00770"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J.P.</given-names></name><name><surname>Ideker</surname><given-names>T.</given-names></name></person-group><article-title>Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls</article-title><source>J. Mol. Biol.</source><year>2018</year><volume>430</volume><fpage>2900</fpage><lpage>2912</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2018.06.026</pub-id><?supplied-pmid 29932943?><pub-id pub-id-type="pmid">29932943</pub-id></element-citation></ref><ref id="B56-genes-10-00770"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>M.</given-names></name><name><surname>Allen</surname><given-names>C.</given-names></name><name><surname>Nickoloff</surname><given-names>J.A.</given-names></name><name><surname>Hromas</surname><given-names>R.</given-names></name></person-group><article-title>Synthetic lethality: Exploiting the addiction of cancer to DNA repair</article-title><source>Blood</source><year>2011</year><volume>117</volume><fpage>6074</fpage><lpage>6082</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-01-313734</pub-id><?supplied-pmid 21441464?><pub-id pub-id-type="pmid">21441464</pub-id></element-citation></ref><ref id="B57-genes-10-00770"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S.H.</given-names></name><name><surname>Bode</surname><given-names>A.M.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name></person-group><article-title>Precision medicine: The foundation of future cancer therapeutics</article-title><source>NPJ Precis. Oncol.</source><year>2017</year><volume>1</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1038/s41698-017-0016-z</pub-id><pub-id pub-id-type="pmid">29872700</pub-id></element-citation></ref><ref id="B58-genes-10-00770"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimomura</surname><given-names>I.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name><name><surname>Ochiya</surname><given-names>T.</given-names></name></person-group><article-title>Synthetic Lethality in Lung Cancer-From the Perspective of Cancer Genomics</article-title><source>Medicines</source><year>2019</year><volume>6</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.3390/medicines6010038</pub-id></element-citation></ref><ref id="B59-genes-10-00770"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Bellaoui</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Desai</surname><given-names>R.</given-names></name><name><surname>Morozov</surname><given-names>P.</given-names></name><name><surname>Delgado-Cruzata</surname><given-names>L.</given-names></name><name><surname>Rothstein</surname><given-names>R.</given-names></name><name><surname>Freyer</surname><given-names>G.A.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name><name><surname>Brown</surname><given-names>G.W.</given-names></name></person-group><article-title>RMI1/NCE4, a suppressor of genome instability, encodes a member of the RecQ helicase/Topo III complex</article-title><source>EMBO J.</source><year>2005</year><volume>24</volume><fpage>2024</fpage><lpage>2033</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600684</pub-id><?supplied-pmid 15889139?><pub-id pub-id-type="pmid">15889139</pub-id></element-citation></ref><ref id="B60-genes-10-00770"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejka</surname><given-names>P.</given-names></name><name><surname>Plank</surname><given-names>J.L.</given-names></name><name><surname>Dombrowski</surname><given-names>C.C.</given-names></name><name><surname>Kowalczykowski</surname><given-names>S.C.</given-names></name></person-group><article-title>Decatenation of DNA by the S. cerevisiae Sgs1-Top3-Rmi1 and RPA complex: A mechanism for disentangling chromosomes</article-title><source>Mol. Cell</source><year>2012</year><volume>47</volume><fpage>886</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.06.032</pub-id><pub-id pub-id-type="pmid">22885009</pub-id></element-citation></ref><ref id="B61-genes-10-00770"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saponaro</surname><given-names>M.</given-names></name><name><surname>Kantidakis</surname><given-names>T.</given-names></name><name><surname>Mitter</surname><given-names>R.</given-names></name><name><surname>Kelly</surname><given-names>G.P.</given-names></name><name><surname>Heron</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>H.</given-names></name><name><surname>Soding</surname><given-names>J.</given-names></name><name><surname>Stewart</surname><given-names>A.</given-names></name><name><surname>Svejstrup</surname><given-names>J.Q.</given-names></name></person-group><article-title>RECQL5 controls transcript elongation and suppresses genome instability associated with transcription stress</article-title><source>Cell</source><year>2014</year><volume>157</volume><fpage>1037</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.03.048</pub-id><pub-id pub-id-type="pmid">24836610</pub-id></element-citation></ref><ref id="B62-genes-10-00770"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Raynard</surname><given-names>S.</given-names></name><name><surname>Sehorn</surname><given-names>M.G.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Bussen</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Stark</surname><given-names>J.M.</given-names></name><name><surname>Barnes</surname><given-names>E.L.</given-names></name><name><surname>Chi</surname><given-names>P.</given-names></name><name><surname>Janscak</surname><given-names>P.</given-names></name><etal/></person-group><article-title>RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments</article-title><source>Genes Dev.</source><year>2007</year><volume>21</volume><fpage>3073</fpage><lpage>3084</lpage><pub-id pub-id-type="doi">10.1101/gad.1609107</pub-id><?supplied-pmid 18003859?><pub-id pub-id-type="pmid">18003859</pub-id></element-citation></ref><ref id="B63-genes-10-00770"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C.A.</given-names></name><name><surname>Sarlos</surname><given-names>K.</given-names></name><name><surname>Logan</surname><given-names>C.V.</given-names></name><name><surname>Thakur</surname><given-names>R.S.</given-names></name><name><surname>Parry</surname><given-names>D.A.</given-names></name><name><surname>Bizard</surname><given-names>A.H.</given-names></name><name><surname>Leitch</surname><given-names>A.</given-names></name><name><surname>Cleal</surname><given-names>L.</given-names></name><name><surname>Ali</surname><given-names>N.S.</given-names></name><name><surname>Al-Owain</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Mutations in TOP3A Cause a Bloom Syndrome-like Disorder</article-title><source>Am. J. Hum. Genet.</source><year>2018</year><volume>103</volume><fpage>221</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2018.07.001</pub-id><?supplied-pmid 30057030?><pub-id pub-id-type="pmid">30057030</pub-id></element-citation></ref><ref id="B64-genes-10-00770"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.D.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group><article-title>Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer</article-title><source>J. Ovarian Res.</source><year>2016</year><volume>9</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13048-016-0244-9</pub-id><?supplied-pmid 27315793?><pub-id pub-id-type="pmid">27315793</pub-id></element-citation></ref><ref id="B65-genes-10-00770"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broberg</surname><given-names>K.</given-names></name><name><surname>Huynh</surname><given-names>E.</given-names></name><name><surname>Schlawicke Engstrom</surname><given-names>K.</given-names></name><name><surname>Bjork</surname><given-names>J.</given-names></name><name><surname>Albin</surname><given-names>M.</given-names></name><name><surname>Ingvar</surname><given-names>C.</given-names></name><name><surname>Olsson</surname><given-names>H.</given-names></name><name><surname>Hoglund</surname><given-names>M.</given-names></name></person-group><article-title>Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><elocation-id>140</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-9-140</pub-id><?supplied-pmid 19432957?><pub-id pub-id-type="pmid">19432957</pub-id></element-citation></ref><ref id="B66-genes-10-00770"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>H.</given-names></name><name><surname>Yabe</surname><given-names>A.</given-names></name><name><surname>Mine</surname><given-names>N.</given-names></name><name><surname>Mikami</surname><given-names>I.</given-names></name><name><surname>Fujiwara</surname><given-names>H.</given-names></name><name><surname>Terada</surname><given-names>Y.</given-names></name><name><surname>Hirano</surname><given-names>A.</given-names></name><name><surname>Tsuneizumi</surname><given-names>M.</given-names></name><name><surname>Yokota</surname><given-names>T.</given-names></name><name><surname>Emi</surname><given-names>M.</given-names></name></person-group><article-title>Down-regulation in human cancers of DRHC, a novel helicase-like gene from 17q25.1 that inhibits cell growth</article-title><source>Cancer Lett.</source><year>2003</year><volume>193</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S0304383502006882</pub-id><?supplied-pmid 12691822?><pub-id pub-id-type="pmid">12691822</pub-id></element-citation></ref><ref id="B67-genes-10-00770"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamamoto</surname><given-names>R.</given-names></name><name><surname>Furukawa</surname><given-names>Y.</given-names></name><name><surname>Morita</surname><given-names>M.</given-names></name><name><surname>Iimura</surname><given-names>Y.</given-names></name><name><surname>Silva</surname><given-names>F.P.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Yagyu</surname><given-names>R.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name></person-group><article-title>SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells</article-title><source>Nat. Cell Biol.</source><year>2004</year><volume>6</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/ncb1151</pub-id><pub-id pub-id-type="pmid">15235609</pub-id></element-citation></ref><ref id="B68-genes-10-00770"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasgall</surname><given-names>P.A.</given-names></name><name><surname>Hoogewijs</surname><given-names>D.</given-names></name><name><surname>Faza</surname><given-names>M.B.</given-names></name><name><surname>Panse</surname><given-names>V.G.</given-names></name><name><surname>Wenger</surname><given-names>R.H.</given-names></name><name><surname>Camenisch</surname><given-names>G.</given-names></name></person-group><article-title>The putative RNA helicase HELZ promotes cell proliferation, translation initiation and ribosomal protein S6 phosphorylation</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e22107</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022107</pub-id><pub-id pub-id-type="pmid">21765940</pub-id></element-citation></ref><ref id="B69-genes-10-00770"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepeler</surname><given-names>T.</given-names></name><name><surname>Holm</surname><given-names>A.</given-names></name><name><surname>Halvey</surname><given-names>P.</given-names></name><name><surname>Nordentoft</surname><given-names>I.</given-names></name><name><surname>Lamy</surname><given-names>P.</given-names></name><name><surname>Riising</surname><given-names>E.M.</given-names></name><name><surname>Christensen</surname><given-names>L.L.</given-names></name><name><surname>Thorsen</surname><given-names>K.</given-names></name><name><surname>Liebler</surname><given-names>D.C.</given-names></name><name><surname>Helin</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Attenuation of the &#x003b2;-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>2750</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.453</pub-id><pub-id pub-id-type="pmid">21963845</pub-id></element-citation></ref><ref id="B70-genes-10-00770"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Miao</surname><given-names>B.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Fei</surname><given-names>S.</given-names></name></person-group><article-title>The Human RNA Surveillance Factor UPF1 Modulates Gastric Cancer Progression by Targeting Long Non-Coding RNA MALAT1</article-title><source>Cell. Physiol. Biochem.</source><year>2017</year><volume>42</volume><fpage>2194</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1159/000479994</pub-id><pub-id pub-id-type="pmid">28942451</pub-id></element-citation></ref><ref id="B71-genes-10-00770"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2016</year><volume>35</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0286-2</pub-id><pub-id pub-id-type="pmid">26759305</pub-id></element-citation></ref><ref id="B72-genes-10-00770"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Karam</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>F.</given-names></name><name><surname>Ji</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>596</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/nm.3548</pub-id><?supplied-pmid 24859531?><pub-id pub-id-type="pmid">24859531</pub-id></element-citation></ref><ref id="B73-genes-10-00770"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.B.</given-names></name><name><surname>Liu</surname><given-names>Y.Y.</given-names></name><name><surname>Cheng</surname><given-names>L.B.</given-names></name><name><surname>Lu</surname><given-names>J.W.</given-names></name><name><surname>Zeng</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>P.H.</given-names></name></person-group><article-title>AMPKalpha phosphatase Ppm1E upregulation in human gastric cancer is required for cell proliferation</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>31288</fpage><lpage>31296</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16126</pub-id><?supplied-pmid 28423719?><pub-id pub-id-type="pmid">28423719</pub-id></element-citation></ref><ref id="B74-genes-10-00770"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thean</surname><given-names>L.F.</given-names></name><name><surname>Loi</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>K.S.</given-names></name><name><surname>Koh</surname><given-names>P.K.</given-names></name><name><surname>Eu</surname><given-names>K.W.</given-names></name><name><surname>Cheah</surname><given-names>P.Y.</given-names></name></person-group><article-title>Genome-wide scan identifies a copy number variable region at 3q26 that regulates PPM1L in APC mutation-negative familial colorectal cancer patients</article-title><source>Genes Chromosomes Cancer</source><year>2010</year><volume>49</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1002/gcc.20724</pub-id><?supplied-pmid 19847890?><pub-id pub-id-type="pmid">19847890</pub-id></element-citation></ref><ref id="B75-genes-10-00770"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Sugimoto</surname><given-names>K.</given-names></name></person-group><article-title>Role of a complex containing Rad17, Mec3, and Ddc1 in the yeast DNA damage checkpoint pathway</article-title><source>Mol. Cell. Biol.</source><year>1999</year><volume>19</volume><fpage>1136</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.2.1136</pub-id><?supplied-pmid 9891048?><pub-id pub-id-type="pmid">9891048</pub-id></element-citation></ref><ref id="B76-genes-10-00770"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paciotti</surname><given-names>V.</given-names></name><name><surname>Lucchini</surname><given-names>G.</given-names></name><name><surname>Plevani</surname><given-names>P.</given-names></name><name><surname>Longhese</surname><given-names>M.P.</given-names></name></person-group><article-title>Mec1p is essential for phosphorylation of the yeast DNA damage checkpoint protein Ddc1p, which physically interacts with Mec3p</article-title><source>EMBO J.</source><year>1998</year><volume>17</volume><fpage>4199</fpage><lpage>4209</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.14.4199</pub-id><?supplied-pmid 9670034?><pub-id pub-id-type="pmid">9670034</pub-id></element-citation></ref><ref id="B77-genes-10-00770"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majka</surname><given-names>J.</given-names></name><name><surname>Burgers</surname><given-names>P.M.</given-names></name></person-group><article-title>Yeast Rad17/Mec3/Ddc1: A sliding clamp for the DNA damage checkpoint</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1073/pnas.0437148100</pub-id><?supplied-pmid 12604797?><pub-id pub-id-type="pmid">12604797</pub-id></element-citation></ref><ref id="B78-genes-10-00770"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navadgi-Patil</surname><given-names>V.M.</given-names></name><name><surname>Burgers</surname><given-names>P.M.</given-names></name></person-group><article-title>The unstructured C-terminal tail of the 9-1-1 clamp subunit Ddc1 activates Mec1/ATR via two distinct mechanisms</article-title><source>Mol. Cell</source><year>2009</year><volume>36</volume><fpage>743</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.10.014</pub-id><?supplied-pmid 20005839?><pub-id pub-id-type="pmid">20005839</pub-id></element-citation></ref><ref id="B79-genes-10-00770"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredebohm</surname><given-names>J.</given-names></name><name><surname>Wolf</surname><given-names>J.</given-names></name><name><surname>Hoheisel</surname><given-names>J.D.</given-names></name><name><surname>Boettcher</surname><given-names>M.</given-names></name></person-group><article-title>Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine</article-title><source>J. Cell Sci.</source><year>2013</year><volume>126</volume><fpage>3380</fpage><lpage>3389</lpage><pub-id pub-id-type="doi">10.1242/jcs.124768</pub-id><pub-id pub-id-type="pmid">23687379</pub-id></element-citation></ref><ref id="B80-genes-10-00770"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Bachran</surname><given-names>C.</given-names></name><name><surname>Gupta</surname><given-names>P.</given-names></name><name><surname>Miller-Randolph</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Crown</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wein</surname><given-names>A.N.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Fattah</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Diphthamide modification on eukaryotic elongation factor 2 is needed to assure fidelity of mRNA translation and mouse development</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>13817</fpage><lpage>13822</lpage><pub-id pub-id-type="doi">10.1073/pnas.1206933109</pub-id><?supplied-pmid 22869748?><pub-id pub-id-type="pmid">22869748</pub-id></element-citation></ref><ref id="B81-genes-10-00770"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villahermosa</surname><given-names>D.</given-names></name><name><surname>Fleck</surname><given-names>O.</given-names></name></person-group><article-title>Elp3 and Dph3 of Schizosaccharomyces pombe mediate cellular stress responses through tRNA(Lys)UUU modifications</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>7225</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-07647-1</pub-id><pub-id pub-id-type="pmid">28775286</pub-id></element-citation></ref><ref id="B82-genes-10-00770"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denisova</surname><given-names>E.</given-names></name><name><surname>Heidenreich</surname><given-names>B.</given-names></name><name><surname>Nagore</surname><given-names>E.</given-names></name><name><surname>Rachakonda</surname><given-names>P.S.</given-names></name><name><surname>Hosen</surname><given-names>I.</given-names></name><name><surname>Akrap</surname><given-names>I.</given-names></name><name><surname>Traves</surname><given-names>V.</given-names></name><name><surname>Garcia-Casado</surname><given-names>Z.</given-names></name><name><surname>Lopez-Guerrero</surname><given-names>J.A.</given-names></name><name><surname>Requena</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Frequent DPH3 promoter mutations in skin cancers</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>35922</fpage><lpage>35930</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5771</pub-id><?supplied-pmid 26416425?><pub-id pub-id-type="pmid">26416425</pub-id></element-citation></ref><ref id="B83-genes-10-00770"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abiatari</surname><given-names>I.</given-names></name><name><surname>Gillen</surname><given-names>S.</given-names></name><name><surname>DeOliveira</surname><given-names>T.</given-names></name><name><surname>Klose</surname><given-names>T.</given-names></name><name><surname>Bo</surname><given-names>K.</given-names></name><name><surname>Giese</surname><given-names>N.A.</given-names></name><name><surname>Friess</surname><given-names>H.</given-names></name><name><surname>Kleeff</surname><given-names>J.</given-names></name></person-group><article-title>The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells</article-title><source>Int. J. Oncol.</source><year>2009</year><volume>35</volume><fpage>1111</fpage><lpage>1116</lpage><?supplied-pmid 19787265?><pub-id pub-id-type="pmid">19787265</pub-id></element-citation></ref><ref id="B84-genes-10-00770"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.R.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>An</surname><given-names>C.H.</given-names></name><name><surname>Kim</surname><given-names>S.S.</given-names></name><name><surname>Yoo</surname><given-names>N.J.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name></person-group><article-title>Frameshift mutation of MAPRE3, a microtubule-related gene, in gastric and colorectal cancers with microsatellite instability</article-title><source>Pathology</source><year>2010</year><volume>42</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3109/00313025.2010.494285</pub-id><?supplied-pmid 20632835?><pub-id pub-id-type="pmid">20632835</pub-id></element-citation></ref><ref id="B85-genes-10-00770"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>M.A.</given-names></name><name><surname>Denton</surname><given-names>E.L.</given-names></name><name><surname>Arrowsmith</surname><given-names>C.H.</given-names></name><name><surname>Lupien</surname><given-names>M.</given-names></name><name><surname>Schapira</surname><given-names>M.</given-names></name></person-group><article-title>A global assessment of cancer genomic alterations in epigenetic mechanisms</article-title><source>Epigenet. Chromatin</source><year>2014</year><volume>7</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1756-8935-7-29</pub-id><?supplied-pmid 25484917?><pub-id pub-id-type="pmid">25484917</pub-id></element-citation></ref><ref id="B86-genes-10-00770"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harsay</surname><given-names>E.</given-names></name><name><surname>Schekman</surname><given-names>R.</given-names></name></person-group><article-title>Avl9p, a member of a novel protein superfamily, functions in the late secretory pathway</article-title><source>Mol. Biol. Cell</source><year>2007</year><volume>18</volume><fpage>1203</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1091/mbc.e06-11-1035</pub-id><?supplied-pmid 17229886?><pub-id pub-id-type="pmid">17229886</pub-id></element-citation></ref><ref id="B87-genes-10-00770"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Kipreos</surname><given-names>E.T.</given-names></name><name><surname>Dalton</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name></person-group><article-title>Cancer driver candidate genes AVL9, DENND5A and NUPL1 contribute to MDCK cystogenesis</article-title><source>Oncoscience</source><year>2014</year><volume>1</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.18632/oncoscience.107</pub-id><pub-id pub-id-type="pmid">25621300</pub-id></element-citation></ref><ref id="B88-genes-10-00770"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Chai</surname><given-names>R.</given-names></name><name><surname>Zhong</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Cao</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name></person-group><article-title>Hypoxia-regulated lncRNA CRPAT4 promotes cell migration via regulating AVL9 in clear cell renal cell carcinomas</article-title><source>Onco Targets Ther.</source><year>2018</year><volume>11</volume><fpage>4537</fpage><lpage>4545</lpage><pub-id pub-id-type="doi">10.2147/OTT.S169155</pub-id><pub-id pub-id-type="pmid">30122945</pub-id></element-citation></ref><ref id="B89-genes-10-00770"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name></person-group><article-title>Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma</article-title><source>Clin. Proteom.</source><year>2017</year><volume>14</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s12014-017-9150-4</pub-id></element-citation></ref><ref id="B90-genes-10-00770"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdanov</surname><given-names>A.</given-names></name><name><surname>Moiseenko</surname><given-names>F.</given-names></name><name><surname>Dubina</surname><given-names>M.</given-names></name></person-group><article-title>Abnormal expression of ATP1A1 and ATP1A2 in breast cancer</article-title><source>F1000Res.</source><year>2017</year><volume>6</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.12688/f1000research.10481.1</pub-id><pub-id pub-id-type="pmid">28529692</pub-id></element-citation></ref><ref id="B91-genes-10-00770"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cialfi</surname><given-names>S.</given-names></name><name><surname>Le Pera</surname><given-names>L.</given-names></name><name><surname>De Blasio</surname><given-names>C.</given-names></name><name><surname>Mariano</surname><given-names>G.</given-names></name><name><surname>Palermo</surname><given-names>R.</given-names></name><name><surname>Zonfrilli</surname><given-names>A.</given-names></name><name><surname>Uccelletti</surname><given-names>D.</given-names></name><name><surname>Palleschi</surname><given-names>C.</given-names></name><name><surname>Biolcati</surname><given-names>G.</given-names></name><name><surname>Barbieri</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey-Hailey disease</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>31567</fpage><pub-id pub-id-type="doi">10.1038/srep31567</pub-id><pub-id pub-id-type="pmid">27528123</pub-id></element-citation></ref><ref id="B92-genes-10-00770"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okunade</surname><given-names>G.W.</given-names></name><name><surname>Miller</surname><given-names>M.L.</given-names></name><name><surname>Azhar</surname><given-names>M.</given-names></name><name><surname>Andringa</surname><given-names>A.</given-names></name><name><surname>Sanford</surname><given-names>L.P.</given-names></name><name><surname>Doetschman</surname><given-names>T.</given-names></name><name><surname>Prasad</surname><given-names>V.</given-names></name><name><surname>Shull</surname><given-names>G.E.</given-names></name></person-group><article-title>Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>26517</fpage><lpage>26527</lpage><pub-id pub-id-type="doi">10.1074/jbc.M703029200</pub-id><?supplied-pmid 17597066?><pub-id pub-id-type="pmid">17597066</pub-id></element-citation></ref><ref id="B93-genes-10-00770"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Ji</surname><given-names>B.</given-names></name></person-group><article-title>Knockdown of Rab21 inhibits proliferation and induces apoptosis in human glioma cells</article-title><source>Cell. Mol. Biol. Lett.</source><year>2017</year><volume>22</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s11658-017-0062-0</pub-id><pub-id pub-id-type="pmid">29270202</pub-id></element-citation></ref><ref id="B94-genes-10-00770"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>S.</given-names></name><name><surname>Gaggioli</surname><given-names>C.</given-names></name><name><surname>Sahai</surname><given-names>E.</given-names></name></person-group><article-title>A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605469</pub-id><?supplied-pmid 19953096?><pub-id pub-id-type="pmid">19953096</pub-id></element-citation></ref><ref id="B95-genes-10-00770"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.H.</given-names></name><name><surname>Nan</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>J.L.</given-names></name><name><surname>Chen</surname><given-names>Z.N.</given-names></name></person-group><article-title>Rab22a enhances CD147 recycling and is required for lung cancer cell migration and invasion</article-title><source>Exp. Cell Res.</source><year>2017</year><volume>357</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2017.04.020</pub-id><pub-id pub-id-type="pmid">28433697</pub-id></element-citation></ref><ref id="B96-genes-10-00770"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Gilkes</surname><given-names>D.M.</given-names></name><name><surname>Takano</surname><given-names>N.</given-names></name><name><surname>Xiang</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Bishop</surname><given-names>C.J.</given-names></name><name><surname>Chaturvedi</surname><given-names>P.</given-names></name><name><surname>Green</surname><given-names>J.J.</given-names></name><name><surname>Semenza</surname><given-names>G.L.</given-names></name></person-group><article-title>Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E3234</fpage><lpage>E3242</lpage><pub-id pub-id-type="doi">10.1073/pnas.1410041111</pub-id><pub-id pub-id-type="pmid">24938788</pub-id></element-citation></ref><ref id="B97-genes-10-00770"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>F.J.</given-names></name><name><surname>Chen</surname><given-names>L.L.</given-names></name><name><surname>Wang</surname><given-names>L.Q.</given-names></name><name><surname>Nephew</surname><given-names>K.P.</given-names></name><name><surname>Wu</surname><given-names>Y.L.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>12291</fpage><lpage>12303</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2577</pub-id><?supplied-pmid 25460499?><pub-id pub-id-type="pmid">25460499</pub-id></element-citation></ref><ref id="B98-genes-10-00770"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>J.L.</given-names></name><name><surname>Castro</surname><given-names>I.G.</given-names></name><name><surname>Schrader</surname><given-names>T.A.</given-names></name><name><surname>Islinger</surname><given-names>M.</given-names></name><name><surname>Schrader</surname><given-names>M.</given-names></name></person-group><article-title>Peroxisomal ACBD4 interacts with VAPB and promotes ER-peroxisome associations</article-title><source>Cell Cycle</source><year>2017</year><volume>16</volume><fpage>1039</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1080/15384101.2017.1314422</pub-id><?supplied-pmid 28463579?><pub-id pub-id-type="pmid">28463579</pub-id></element-citation></ref><ref id="B99-genes-10-00770"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez-Blanco</surname><given-names>A.</given-names></name><name><surname>Perez-Plasencia</surname><given-names>C.</given-names></name><name><surname>Perez-Cardenas</surname><given-names>E.</given-names></name><name><surname>Carrasco-Legleu</surname><given-names>C.</given-names></name><name><surname>Rangel-Lopez</surname><given-names>E.</given-names></name><name><surname>Segura-Pacheco</surname><given-names>B.</given-names></name><name><surname>Taja-Chayeb</surname><given-names>L.</given-names></name><name><surname>Trejo-Becerril</surname><given-names>C.</given-names></name><name><surname>Gonzalez-Fierro</surname><given-names>A.</given-names></name><name><surname>Candelaria</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines</article-title><source>Cancer Cell Int.</source><year>2006</year><volume>6</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1475-2867-6-2</pub-id><pub-id pub-id-type="pmid">16448574</pub-id></element-citation></ref><ref id="B100-genes-10-00770"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>R.</given-names></name><name><surname>Cheng</surname><given-names>D.</given-names></name><name><surname>Coyaud</surname><given-names>E.</given-names></name><name><surname>Freeman</surname><given-names>S.</given-names></name><name><surname>Di Pietro</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Vissa</surname><given-names>A.</given-names></name><name><surname>Yip</surname><given-names>C.M.</given-names></name><name><surname>Fairn</surname><given-names>G.D.</given-names></name><name><surname>Braverman</surname><given-names>N.</given-names></name><etal/></person-group><article-title>VAPs and ACBD5 tether peroxisomes to the ER for peroxisome maintenance and lipid homeostasis</article-title><source>J. Cell Biol.</source><year>2017</year><volume>216</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1083/jcb.201608128</pub-id><pub-id pub-id-type="pmid">28108526</pub-id></element-citation></ref><ref id="B101-genes-10-00770"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>K.</given-names></name><name><surname>Rice</surname><given-names>S.D.</given-names></name><name><surname>Gingrich</surname><given-names>D.A.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Mi</surname><given-names>Z.</given-names></name><name><surname>Tian</surname><given-names>C.</given-names></name><name><surname>Ding</surname><given-names>Z.</given-names></name><name><surname>Brower</surname><given-names>S.L.</given-names></name><name><surname>Ervin</surname><given-names>P.R.</given-names><suffix>Jr.</suffix></name><name><surname>Gabrin</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e40900</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0040900</pub-id><pub-id pub-id-type="pmid">22815861</pub-id></element-citation></ref><ref id="B102-genes-10-00770"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>I.</given-names></name><name><surname>Zeneroli</surname><given-names>M.L.</given-names></name><name><surname>Corsi</surname><given-names>L.</given-names></name><name><surname>Avallone</surname><given-names>R.</given-names></name><name><surname>Farina</surname><given-names>F.</given-names></name><name><surname>Alho</surname><given-names>H.</given-names></name><name><surname>Baraldi</surname><given-names>C.</given-names></name><name><surname>Ferrarese</surname><given-names>C.</given-names></name><name><surname>Pecora</surname><given-names>N.</given-names></name><name><surname>Frigo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma</article-title><source>Life Sci.</source><year>1998</year><volume>63</volume><fpage>1269</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(98)00388-9</pub-id><pub-id pub-id-type="pmid">9771915</pub-id></element-citation></ref><ref id="B103-genes-10-00770"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>F.T.</given-names></name><name><surname>Rahman</surname><given-names>S.M.</given-names></name><name><surname>Hassanein</surname><given-names>M.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Hoeksema</surname><given-names>M.D.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Eisenberg</surname><given-names>R.</given-names></name><name><surname>Chaurand</surname><given-names>P.</given-names></name><name><surname>Caprioli</surname><given-names>R.M.</given-names></name><name><surname>Shiota</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acyl-coenzyme A-binding protein regulates &#x003b2;-oxidation required for growth and survival of non-small cell lung cancer</article-title><source>Cancer Prev. Res. (Phila.)</source><year>2014</year><volume>7</volume><fpage>748</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-14-0057</pub-id><?supplied-pmid 24819876?><pub-id pub-id-type="pmid">24819876</pub-id></element-citation></ref><ref id="B104-genes-10-00770"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Qiao</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2007</year><volume>361</volume><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.07.085</pub-id><?supplied-pmid 17678621?><pub-id pub-id-type="pmid">17678621</pub-id></element-citation></ref><ref id="B105-genes-10-00770"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Y.J.</given-names></name><name><surname>He</surname><given-names>Q.Y.</given-names></name><name><surname>Ma</surname><given-names>Y.F.</given-names></name><name><surname>Du</surname><given-names>Y.W.</given-names></name><name><surname>Liu</surname><given-names>G.C.</given-names></name><name><surname>Li</surname><given-names>Y.J.</given-names></name><name><surname>Tsao</surname><given-names>G.S.</given-names></name><name><surname>Ngai</surname><given-names>S.M.</given-names></name><name><surname>Chiu</surname><given-names>J.F.</given-names></name></person-group><article-title>Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma</article-title><source>J. Cell. Biochem.</source><year>2008</year><volume>104</volume><fpage>1625</fpage><lpage>1635</lpage><pub-id pub-id-type="doi">10.1002/jcb.21727</pub-id><?supplied-pmid 18320592?><pub-id pub-id-type="pmid">18320592</pub-id></element-citation></ref><ref id="B106-genes-10-00770"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhai</surname><given-names>Q.</given-names></name><name><surname>Bharadwaj</surname><given-names>U.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Fisher</surname><given-names>W.E.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name></person-group><article-title>Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>2284</fpage><lpage>2294</lpage><pub-id pub-id-type="doi">10.1002/cncr.21862</pub-id><pub-id pub-id-type="pmid">16604531</pub-id></element-citation></ref><ref id="B107-genes-10-00770"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Nishiumi</surname><given-names>S.</given-names></name><name><surname>Kono</surname><given-names>S.</given-names></name><name><surname>Takao</surname><given-names>S.</given-names></name><name><surname>Azuma</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name></person-group><article-title>Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>589</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3554-4</pub-id><?supplied-pmid 28851309?><pub-id pub-id-type="pmid">28851309</pub-id></element-citation></ref><ref id="B108-genes-10-00770"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mika</surname><given-names>A.</given-names></name><name><surname>Kobiela</surname><given-names>J.</given-names></name><name><surname>Czumaj</surname><given-names>A.</given-names></name><name><surname>Chmielewski</surname><given-names>M.</given-names></name><name><surname>Stepnowski</surname><given-names>P.</given-names></name><name><surname>Sledzinski</surname><given-names>T.</given-names></name></person-group><article-title>Hyper-Elongation in Colorectal Cancer Tissue&#x02014;Cerotic Acid is a Potential Novel Serum Metabolic Marker of Colorectal Malignancies</article-title><source>Cell. Physiol. Biochem.</source><year>2017</year><volume>41</volume><fpage>722</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1159/000458431</pub-id><pub-id pub-id-type="pmid">28214830</pub-id></element-citation></ref><ref id="B109-genes-10-00770"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zekri</surname><given-names>A.R.</given-names></name><name><surname>Hassan</surname><given-names>Z.K.</given-names></name><name><surname>Bahnassy</surname><given-names>A.A.</given-names></name><name><surname>Sherif</surname><given-names>G.M.</given-names></name><name><surname>ELdahshan</surname><given-names>D.</given-names></name><name><surname>Abouelhoda</surname><given-names>M.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Hafez</surname><given-names>M.M.</given-names></name></person-group><article-title>Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2012</year><volume>13</volume><fpage>5433</fpage><lpage>5438</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2012.13.11.5433</pub-id><pub-id pub-id-type="pmid">23317196</pub-id></element-citation></ref><ref id="B110-genes-10-00770"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.C.</given-names></name><name><surname>Feng</surname><given-names>Y.H.</given-names></name><name><surname>Wu</surname><given-names>H.T.</given-names></name><name><surname>Huang</surname><given-names>Y.S.</given-names></name><name><surname>Tung</surname><given-names>C.L.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Chang</surname><given-names>C.J.</given-names></name><name><surname>Shiau</surname><given-names>A.L.</given-names></name><name><surname>Wu</surname><given-names>C.L.</given-names></name></person-group><article-title>Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>6586</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-24633-3</pub-id><pub-id pub-id-type="pmid">29700319</pub-id></element-citation></ref><ref id="B111-genes-10-00770"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.H.</given-names></name><name><surname>Chen</surname><given-names>W.Y.</given-names></name><name><surname>Kuo</surname><given-names>Y.H.</given-names></name><name><surname>Tung</surname><given-names>C.L.</given-names></name><name><surname>Tsao</surname><given-names>C.J.</given-names></name><name><surname>Shiau</surname><given-names>A.L.</given-names></name><name><surname>Wu</surname><given-names>C.L.</given-names></name></person-group><article-title>Elovl6 is a poor prognostic predictor in breast cancer</article-title><source>Oncol. Lett.</source><year>2016</year><volume>12</volume><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4587</pub-id><pub-id pub-id-type="pmid">27347126</pub-id></element-citation></ref><ref id="B112-genes-10-00770"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H.F.</given-names></name><name><surname>Zhang</surname><given-names>X.Z.</given-names></name><name><surname>Liu</surname><given-names>B.G.</given-names></name><name><surname>Jia</surname><given-names>G.T.</given-names></name><name><surname>Li</surname><given-names>W.L.</given-names></name></person-group><article-title>Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271</article-title><source>Am. J. Cancer Res.</source><year>2017</year><volume>7</volume><fpage>1566</fpage><lpage>1576</lpage><?supplied-pmid 28744405?><pub-id pub-id-type="pmid">28744405</pub-id></element-citation></ref><ref id="B113-genes-10-00770"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagou</surname><given-names>M.E.</given-names></name><name><surname>Ganesh</surname><given-names>A.</given-names></name><name><surname>Phear</surname><given-names>G.</given-names></name><name><surname>Robinson</surname><given-names>D.</given-names></name><name><surname>Petermann</surname><given-names>E.</given-names></name><name><surname>Cox</surname><given-names>A.</given-names></name><name><surname>Meuth</surname><given-names>M.</given-names></name></person-group><article-title>Human PIF1 helicase supports DNA replication and cell growth under oncogenic-stress</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>11381</fpage><lpage>11398</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2501</pub-id><?supplied-pmid 25359767?><pub-id pub-id-type="pmid">25359767</pub-id></element-citation></ref><ref id="B114-genes-10-00770"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Choi</surname><given-names>S.I.</given-names></name><name><surname>Park</surname><given-names>E.S.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Ryu</surname><given-names>K.</given-names></name><name><surname>Park</surname><given-names>Y.K.</given-names></name><name><surname>Kwon</surname><given-names>S.Y.</given-names></name><name><surname>Yang</surname><given-names>S.I.</given-names></name><name><surname>Lee</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-kappaB signaling via its novel chaperoning function</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e22258</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022258</pub-id><?supplied-pmid 21857917?><pub-id pub-id-type="pmid">21857917</pub-id></element-citation></ref><ref id="B115-genes-10-00770"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slizhikova</surname><given-names>D.K.</given-names></name><name><surname>Vinogradova</surname><given-names>T.V.</given-names></name><name><surname>Sverdlov</surname><given-names>E.D.</given-names></name></person-group><article-title>The NOLA2 and RPS3A genes as highly informative markers for human squamous cell lung cancer</article-title><source>Bioorg. Khim.</source><year>2005</year><volume>31</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">15889794</pub-id></element-citation></ref><ref id="B116-genes-10-00770"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The Effect of MCM3AP-AS1/miR-211/KLF5/AGGF1 Axis Regulating Glioblastoma Angiogenesis</article-title><source>Front. Mol. Neurosci.</source><year>2017</year><volume>10</volume><fpage>437</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2017.00437</pub-id><?supplied-pmid 29375300?><pub-id pub-id-type="pmid">29375300</pub-id></element-citation></ref><ref id="B117-genes-10-00770"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name></person-group><article-title>Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy</article-title><source>Cancer Manag. Res.</source><year>2018</year><volume>10</volume><fpage>3533</fpage><lpage>3549</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S171661</pub-id><pub-id pub-id-type="pmid">30271202</pub-id></element-citation></ref><ref id="B118-genes-10-00770"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>M.E.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>G.H.</given-names></name><name><surname>Park</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name><name><surname>Oh</surname><given-names>S.O.</given-names></name></person-group><article-title>SAC3D1: A novel prognostic marker in hepatocellular carcinoma</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>15608</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-34129-9</pub-id><pub-id pub-id-type="pmid">30353105</pub-id></element-citation></ref><ref id="B119-genes-10-00770"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker</article-title><source>Clin. Transl. Oncol.</source><year>2016</year><volume>18</volume><fpage>776</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1007/s12094-015-1430-8</pub-id><pub-id pub-id-type="pmid">26527032</pub-id></element-citation></ref><ref id="B120-genes-10-00770"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalashnikova</surname><given-names>E.V.</given-names></name><name><surname>Revenko</surname><given-names>A.S.</given-names></name><name><surname>Gemo</surname><given-names>A.T.</given-names></name><name><surname>Andrews</surname><given-names>N.P.</given-names></name><name><surname>Tepper</surname><given-names>C.G.</given-names></name><name><surname>Zou</surname><given-names>J.X.</given-names></name><name><surname>Cardiff</surname><given-names>R.D.</given-names></name><name><surname>Borowsky</surname><given-names>A.D.</given-names></name><name><surname>Chen</surname><given-names>H.W.</given-names></name></person-group><article-title>ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>9402</fpage><lpage>9412</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1199</pub-id><pub-id pub-id-type="pmid">20864510</pub-id></element-citation></ref><ref id="B121-genes-10-00770"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group><article-title>ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma</article-title><source>Ann. Surg. Oncol.</source><year>2013</year><volume>20</volume><fpage>S577</fpage><lpage>S582</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3027-1</pub-id><pub-id pub-id-type="pmid">23775406</pub-id></element-citation></ref><ref id="B122-genes-10-00770"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>G.Y.</given-names></name><name><surname>Qin</surname><given-names>S.L.</given-names></name><name><surname>Yu</surname><given-names>M.H.</given-names></name><name><surname>Mu</surname><given-names>Y.F.</given-names></name><name><surname>Zhong</surname><given-names>M.</given-names></name></person-group><article-title>ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells</article-title><source>Gastroenterol. Res. Pract.</source><year>2015</year><volume>2015</volume><fpage>936564</fpage><pub-id pub-id-type="doi">10.1155/2015/936564</pub-id><?supplied-pmid 26697062?><pub-id pub-id-type="pmid">26697062</pub-id></element-citation></ref><ref id="B123-genes-10-00770"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>ATAD2 overexpression is associated with progression and prognosis in colorectal cancer</article-title><source>Jpn. J. Clin. Oncol.</source><year>2016</year><volume>46</volume><fpage>222</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyv195</pub-id><?supplied-pmid 26819280?><pub-id pub-id-type="pmid">26819280</pub-id></element-citation></ref><ref id="B124-genes-10-00770"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Dou</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>K.</given-names></name></person-group><article-title>Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer</article-title><source>Oncol. Rep.</source><year>2015</year><volume>33</volume><fpage>2337</fpage><lpage>2344</lpage><pub-id pub-id-type="doi">10.3892/or.2015.3867</pub-id><pub-id pub-id-type="pmid">25813398</pub-id></element-citation></ref><ref id="B125-genes-10-00770"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>H.W.</given-names></name><name><surname>Ha</surname><given-names>S.Y.</given-names></name><name><surname>Bang</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>C.K.</given-names></name></person-group><article-title>ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection</article-title><source>Cancer Res. Treat.</source><year>2015</year><volume>47</volume><fpage>853</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.4143/crt.2014.177</pub-id><?supplied-pmid 25687855?><pub-id pub-id-type="pmid">25687855</pub-id></element-citation></ref><ref id="B126-genes-10-00770"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usui</surname><given-names>T.</given-names></name><name><surname>Ohta</surname><given-names>T.</given-names></name><name><surname>Oshiumi</surname><given-names>H.</given-names></name><name><surname>Tomizawa</surname><given-names>J.</given-names></name><name><surname>Ogawa</surname><given-names>H.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name></person-group><article-title>Complex formation and functional versatility of Mre11 of budding yeast in recombination</article-title><source>Cell</source><year>1998</year><volume>95</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81640-2</pub-id><pub-id pub-id-type="pmid">9845372</pub-id></element-citation></ref><ref id="B127-genes-10-00770"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewald</surname><given-names>B.</given-names></name><name><surname>Sampath</surname><given-names>D.</given-names></name><name><surname>Plunkett</surname><given-names>W.</given-names></name></person-group><article-title>ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>7947</fpage><lpage>7955</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0971</pub-id><?supplied-pmid 18829552?><pub-id pub-id-type="pmid">18829552</pub-id></element-citation></ref><ref id="B128-genes-10-00770"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karnitz</surname><given-names>L.M.</given-names></name><name><surname>Flatten</surname><given-names>K.S.</given-names></name><name><surname>Wagner</surname><given-names>J.M.</given-names></name><name><surname>Loegering</surname><given-names>D.</given-names></name><name><surname>Hackbarth</surname><given-names>J.S.</given-names></name><name><surname>Arlander</surname><given-names>S.J.</given-names></name><name><surname>Vroman</surname><given-names>B.T.</given-names></name><name><surname>Thomas</surname><given-names>M.B.</given-names></name><name><surname>Baek</surname><given-names>Y.U.</given-names></name><name><surname>Hopkins</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival</article-title><source>Mol. Pharmacol.</source><year>2005</year><volume>68</volume><fpage>1636</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1124/mol.105.012716</pub-id><pub-id pub-id-type="pmid">16126823</pub-id></element-citation></ref><ref id="B129-genes-10-00770"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>T.</given-names></name><name><surname>Jiao</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>D.B.</given-names></name><name><surname>Abbruzzese</surname><given-names>J.L.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>2042</fpage><lpage>2048</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1520</pub-id><pub-id pub-id-type="pmid">18381943</pub-id></element-citation></ref><ref id="B130-genes-10-00770"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irlbacher</surname><given-names>H.</given-names></name><name><surname>Franke</surname><given-names>J.</given-names></name><name><surname>Manke</surname><given-names>T.</given-names></name><name><surname>Vingron</surname><given-names>M.</given-names></name><name><surname>Ehrenhofer-Murray</surname><given-names>A.E.</given-names></name></person-group><article-title>Control of replication initiation and heterochromatin formation in Saccharomyces cerevisiae by a regulator of meiotic gene expression</article-title><source>Genes Dev.</source><year>2005</year><volume>19</volume><fpage>1811</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1101/gad.334805</pub-id><pub-id pub-id-type="pmid">16077008</pub-id></element-citation></ref><ref id="B131-genes-10-00770"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>J.M.</given-names></name><name><surname>Irlbacher</surname><given-names>H.</given-names></name><name><surname>Ehrenhofer-Murray</surname><given-names>A.E.</given-names></name></person-group><article-title>Control of replication initiation by the Sum1/Rfm1/Hst1 histone deacetylase</article-title><source>BMC Mol. Biol.</source><year>2008</year><volume>9</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2199-9-100</pub-id><pub-id pub-id-type="pmid">18990212</pub-id></element-citation></ref><ref id="B132-genes-10-00770"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>S.R.</given-names></name><name><surname>Peace</surname><given-names>J.M.</given-names></name><name><surname>Ostrow</surname><given-names>A.Z.</given-names></name><name><surname>Gan</surname><given-names>Y.</given-names></name><name><surname>Rex</surname><given-names>A.E.</given-names></name><name><surname>Viggiani</surname><given-names>C.J.</given-names></name><name><surname>Tavare</surname><given-names>S.</given-names></name><name><surname>Aparicio</surname><given-names>O.M.</given-names></name></person-group><article-title>Forkhead transcription factors establish origin timing and long-range clustering in S. cerevisiae</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.12.012</pub-id><?supplied-pmid 22265405?><pub-id pub-id-type="pmid">22265405</pub-id></element-citation></ref><ref id="B133-genes-10-00770"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Xin</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Shang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Decreased expression of FOXJ1 is a potential prognostic predictor for progression and poor survival of gastric cancer</article-title><source>Ann. Surg. Oncol.</source><year>2015</year><volume>22</volume><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1245/s10434-014-3742-2</pub-id><?supplied-pmid 24809300?><pub-id pub-id-type="pmid">24809300</pub-id></element-citation></ref><ref id="B134-genes-10-00770"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.V.</given-names></name><name><surname>Chien</surname><given-names>C.D.</given-names></name><name><surname>Garee</surname><given-names>J.P.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wellstein</surname><given-names>A.</given-names></name><name><surname>Riegel</surname><given-names>A.T.</given-names></name></person-group><article-title>Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells</article-title><source>Mol. Endocrinol.</source><year>2013</year><volume>27</volume><fpage>1113</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1210/me.2012-1353</pub-id><?supplied-pmid 23660594?><pub-id pub-id-type="pmid">23660594</pub-id></element-citation></ref><ref id="B135-genes-10-00770"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Zu</surname><given-names>L.</given-names></name><name><surname>You</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>MiR-517a-3p accelerates lung cancer cell proliferation and invasion through inhibiting FOXJ3 expression</article-title><source>Life Sci.</source><year>2014</year><volume>108</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2014.05.006</pub-id><?supplied-pmid 24846831?><pub-id pub-id-type="pmid">24846831</pub-id></element-citation></ref><ref id="B136-genes-10-00770"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Q.I.</given-names></name></person-group><article-title>miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer</article-title><source>Oncol. Lett.</source><year>2016</year><volume>11</volume><fpage>2583</fpage><lpage>2589</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4269</pub-id><pub-id pub-id-type="pmid">27073521</pub-id></element-citation></ref><ref id="B137-genes-10-00770"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Benzyl isothiocyanate inhibits breast cancer cell tumorigenesis via repression of the FoxH1-Mediated Wnt/&#x003b2;-catenin pathway</article-title><source>Int. J. Clin. Exp. Med.</source><year>2015</year><volume>8</volume><fpage>17601</fpage><lpage>17611</lpage><?supplied-pmid 26770350?><pub-id pub-id-type="pmid">26770350</pub-id></element-citation></ref><ref id="B138-genes-10-00770"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>B.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name></person-group><article-title>Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-015-1282-1</pub-id><pub-id pub-id-type="pmid">25884180</pub-id></element-citation></ref><ref id="B139-genes-10-00770"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>D.J.</given-names></name><name><surname>Zhang</surname><given-names>J.M.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Zhuang</surname><given-names>B.</given-names></name><name><surname>Guo</surname><given-names>Q.Q.</given-names></name></person-group><article-title>Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma</article-title><source>Clin. Interv. Aging</source><year>2013</year><volume>8</volume><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.2147/CIA.S45064</pub-id><pub-id pub-id-type="pmid">23898224</pub-id></element-citation></ref><ref id="B140-genes-10-00770"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balderhaar</surname><given-names>H.J.</given-names></name><name><surname>Ungermann</surname><given-names>C.</given-names></name></person-group><article-title>CORVET and HOPS tethering complexes&#x02014;Coordinators of endosome and lysosome fusion</article-title><source>J. Cell Sci.</source><year>2013</year><volume>126</volume><fpage>1307</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1242/jcs.107805</pub-id><pub-id pub-id-type="pmid">23645161</pub-id></element-citation></ref><ref id="B141-genes-10-00770"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solinger</surname><given-names>J.A.</given-names></name><name><surname>Spang</surname><given-names>A.</given-names></name></person-group><article-title>Tethering complexes in the endocytic pathway: CORVET and HOPS</article-title><source>FEBS J.</source><year>2013</year><volume>280</volume><fpage>2743</fpage><lpage>2757</lpage><pub-id pub-id-type="doi">10.1111/febs.12151</pub-id><pub-id pub-id-type="pmid">23351085</pub-id></element-citation></ref><ref id="B142-genes-10-00770"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laidlaw</surname><given-names>K.M.E.</given-names></name><name><surname>MacDonald</surname><given-names>C.</given-names></name></person-group><article-title>Endosomal trafficking of yeast membrane proteins</article-title><source>Biochem. Soc. Trans.</source><year>2018</year><volume>46</volume><fpage>1551</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1042/BST20180258</pub-id><?supplied-pmid 30381337?><pub-id pub-id-type="pmid">30381337</pub-id></element-citation></ref><ref id="B143-genes-10-00770"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henne</surname><given-names>W.M.</given-names></name><name><surname>Buchkovich</surname><given-names>N.J.</given-names></name><name><surname>Emr</surname><given-names>S.D.</given-names></name></person-group><article-title>The ESCRT pathway</article-title><source>Dev. Cell</source><year>2011</year><volume>21</volume><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2011.05.015</pub-id><?supplied-pmid 21763610?><pub-id pub-id-type="pmid">21763610</pub-id></element-citation></ref><ref id="B144-genes-10-00770"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>M.</given-names></name><name><surname>Stutz</surname><given-names>F.</given-names></name><name><surname>Belgareh</surname><given-names>N.</given-names></name><name><surname>Haguenauer-Tsapis</surname><given-names>R.</given-names></name><name><surname>Dargemont</surname><given-names>C.</given-names></name></person-group><article-title>Ubp3 requires a cofactor, Bre5, to specifically de-ubiquitinate the COPII protein, Sec23</article-title><source>Nat. Cell Biol.</source><year>2003</year><volume>5</volume><fpage>661</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1038/ncb1003</pub-id><?supplied-pmid 12778054?><pub-id pub-id-type="pmid">12778054</pub-id></element-citation></ref><ref id="B145-genes-10-00770"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuldiner</surname><given-names>M.</given-names></name><name><surname>Collins</surname><given-names>S.R.</given-names></name><name><surname>Thompson</surname><given-names>N.J.</given-names></name><name><surname>Denic</surname><given-names>V.</given-names></name><name><surname>Bhamidipati</surname><given-names>A.</given-names></name><name><surname>Punna</surname><given-names>T.</given-names></name><name><surname>Ihmels</surname><given-names>J.</given-names></name><name><surname>Andrews</surname><given-names>B.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name><name><surname>Greenblatt</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>507</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.031</pub-id><?supplied-pmid 16269340?><pub-id pub-id-type="pmid">16269340</pub-id></element-citation></ref><ref id="B146-genes-10-00770"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuldiner</surname><given-names>M.</given-names></name><name><surname>Metz</surname><given-names>J.</given-names></name><name><surname>Schmid</surname><given-names>V.</given-names></name><name><surname>Denic</surname><given-names>V.</given-names></name><name><surname>Rakwalska</surname><given-names>M.</given-names></name><name><surname>Schmitt</surname><given-names>H.D.</given-names></name><name><surname>Schwappach</surname><given-names>B.</given-names></name><name><surname>Weissman</surname><given-names>J.S.</given-names></name></person-group><article-title>The GET complex mediates insertion of tail-anchored proteins into the ER membrane</article-title><source>Cell</source><year>2008</year><volume>134</volume><fpage>634</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.06.025</pub-id><pub-id pub-id-type="pmid">18724936</pub-id></element-citation></ref><ref id="B147-genes-10-00770"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beilharz</surname><given-names>T.</given-names></name><name><surname>Egan</surname><given-names>B.</given-names></name><name><surname>Silver</surname><given-names>P.A.</given-names></name><name><surname>Hofmann</surname><given-names>K.</given-names></name><name><surname>Lithgow</surname><given-names>T.</given-names></name></person-group><article-title>Bipartite signals mediate subcellular targeting of tail-anchored membrane proteins in Saccharomyces cerevisiae</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>8219</fpage><lpage>8223</lpage><pub-id pub-id-type="doi">10.1074/jbc.M212725200</pub-id><pub-id pub-id-type="pmid">12514182</pub-id></element-citation></ref><ref id="B148-genes-10-00770"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarrola-Villava</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Nagore</surname><given-names>E.</given-names></name><name><surname>Benfodda</surname><given-names>M.</given-names></name><name><surname>Guedj</surname><given-names>M.</given-names></name><name><surname>Gazal</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>H.H.</given-names></name><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Rachkonda</surname><given-names>P.S.</given-names></name><name><surname>Descamps</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition</article-title><source>Int. J. Cancer</source><year>2015</year><volume>136</volume><fpage>2109</fpage><lpage>2119</lpage><pub-id pub-id-type="doi">10.1002/ijc.29257</pub-id><pub-id pub-id-type="pmid">25303718</pub-id></element-citation></ref><ref id="B149-genes-10-00770"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name><name><surname>Polavaram</surname><given-names>N.S.</given-names></name><name><surname>Baretton</surname><given-names>G.B.</given-names></name><name><surname>Muders</surname><given-names>M.H.</given-names></name><name><surname>Batra</surname><given-names>S.</given-names></name><name><surname>Datta</surname><given-names>K.</given-names></name></person-group><article-title>NRP2 transcriptionally regulates its downstream effector WDFY1</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>23588</fpage><pub-id pub-id-type="doi">10.1038/srep23588</pub-id><pub-id pub-id-type="pmid">27026195</pub-id></element-citation></ref><ref id="B150-genes-10-00770"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>S.</given-names></name><name><surname>Polavaram</surname><given-names>N.S.</given-names></name><name><surname>Stanton</surname><given-names>M.J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Bhola</surname><given-names>T.</given-names></name><name><surname>Honscheid</surname><given-names>P.</given-names></name><name><surname>Donohue</surname><given-names>T.M.</given-names><suffix>Jr.</suffix></name><name><surname>Band</surname><given-names>H.</given-names></name><name><surname>Batra</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>418</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1488</pub-id><pub-id pub-id-type="pmid">26560516</pub-id></element-citation></ref><ref id="B151-genes-10-00770"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girirajan</surname><given-names>S.</given-names></name><name><surname>Hauck</surname><given-names>P.M.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Vlangos</surname><given-names>C.N.</given-names></name><name><surname>Szomju</surname><given-names>B.B.</given-names></name><name><surname>Solaymani-Kohal</surname><given-names>S.</given-names></name><name><surname>Mosier</surname><given-names>P.D.</given-names></name><name><surname>White</surname><given-names>K.L.</given-names><suffix>Jr.</suffix></name><name><surname>McCoy</surname><given-names>K.</given-names></name><name><surname>Elsea</surname><given-names>S.H.</given-names></name></person-group><article-title>Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response</article-title><source>Mamm. Genome</source><year>2008</year><volume>19</volume><fpage>246</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s00335-008-9100-6</pub-id><pub-id pub-id-type="pmid">18343975</pub-id></element-citation></ref><ref id="B152-genes-10-00770"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachmann</surname><given-names>J.</given-names></name><name><surname>Glaubke</surname><given-names>E.</given-names></name><name><surname>Moore</surname><given-names>P.S.</given-names></name><name><surname>Ungermann</surname><given-names>C.</given-names></name></person-group><article-title>The Vps39-like TRAP1 is an effector of Rab5 and likely the missing Vps3 subunit of human CORVET</article-title><source>Cell. Logist.</source><year>2014</year><volume>4</volume><fpage>e970840</fpage><pub-id pub-id-type="doi">10.4161/21592780.2014.970840</pub-id><?supplied-pmid 25750764?><pub-id pub-id-type="pmid">25750764</pub-id></element-citation></ref><ref id="B153-genes-10-00770"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chabes</surname><given-names>A.</given-names></name><name><surname>Georgieva</surname><given-names>B.</given-names></name><name><surname>Domkin</surname><given-names>V.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Rothstein</surname><given-names>R.</given-names></name><name><surname>Thelander</surname><given-names>L.</given-names></name></person-group><article-title>Survival of DNA damage in yeast directly depends on increased dNTP levels allowed by relaxed feedback inhibition of ribonucleotide reductase</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00075-8</pub-id><pub-id pub-id-type="pmid">12581528</pub-id></element-citation></ref><ref id="B154-genes-10-00770"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Bjorkholm</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name></person-group><article-title>ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells</article-title><source>Cell Death Dis.</source><year>2019</year><volume>10</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1038/s41419-019-1357-z</pub-id><?supplied-pmid 30692519?><pub-id pub-id-type="pmid">30692519</pub-id></element-citation></ref><ref id="B155-genes-10-00770"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkach</surname><given-names>J.M.</given-names></name><name><surname>Yimit</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>A.Y.</given-names></name><name><surname>Riffle</surname><given-names>M.</given-names></name><name><surname>Costanzo</surname><given-names>M.</given-names></name><name><surname>Jaschob</surname><given-names>D.</given-names></name><name><surname>Hendry</surname><given-names>J.A.</given-names></name><name><surname>Ou</surname><given-names>J.</given-names></name><name><surname>Moffat</surname><given-names>J.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stress</article-title><source>Nat. Cell Biol.</source><year>2012</year><volume>14</volume><fpage>966</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/ncb2549</pub-id><?supplied-pmid 22842922?><pub-id pub-id-type="pmid">22842922</pub-id></element-citation></ref><ref id="B156-genes-10-00770"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>P.S.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Cheong</surname><given-names>L.L.</given-names></name><name><surname>Liu</surname><given-names>S.C.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>T.</given-names></name><name><surname>Sze</surname><given-names>S.K.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Chng</surname><given-names>W.J.</given-names></name></person-group><article-title>LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>3043</fpage><lpage>3053</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2321</pub-id><?supplied-pmid 24686170?><pub-id pub-id-type="pmid">24686170</pub-id></element-citation></ref><ref id="B157-genes-10-00770"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Miao</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.N.</given-names></name><name><surname>Sun</surname><given-names>H.B.</given-names></name><name><surname>Xu</surname><given-names>Z.N.</given-names></name><name><surname>Han</surname><given-names>C.S.</given-names></name></person-group><article-title>Correlation of CCNA1 promoter methylation with malignant tumors: A meta-analysis introduction</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>134027</fpage><pub-id pub-id-type="doi">10.1155/2015/134027</pub-id><?supplied-pmid 25654082?><pub-id pub-id-type="pmid">25654082</pub-id></element-citation></ref><ref id="B158-genes-10-00770"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrick</surname><given-names>E.</given-names></name><name><surname>Peixoto</surname><given-names>P.</given-names></name><name><surname>Blomme</surname><given-names>A.</given-names></name><name><surname>Polese</surname><given-names>C.</given-names></name><name><surname>Matheus</surname><given-names>N.</given-names></name><name><surname>Cimino</surname><given-names>J.</given-names></name><name><surname>Frere</surname><given-names>A.</given-names></name><name><surname>Mouithys-Mickalad</surname><given-names>A.</given-names></name><name><surname>Serteyn</surname><given-names>D.</given-names></name><name><surname>Bettendorff</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>4859</fpage><lpage>4874</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.103</pub-id><?supplied-pmid 28414307?><pub-id pub-id-type="pmid">28414307</pub-id></element-citation></ref><ref id="B159-genes-10-00770"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.X.</given-names></name><name><surname>Wan</surname><given-names>R.Z.</given-names></name><name><surname>Liu</surname><given-names>Z.P.</given-names></name></person-group><article-title>Recent advances in the discovery of potent and selective HDAC6 inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>143</volume><fpage>1406</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.10.040</pub-id><pub-id pub-id-type="pmid">29133060</pub-id></element-citation></ref><ref id="B160-genes-10-00770"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Edwards</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Buck</surname><given-names>S.A.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name></person-group><article-title>Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17138</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017138</pub-id><?supplied-pmid 21359182?><pub-id pub-id-type="pmid">21359182</pub-id></element-citation></ref><ref id="B161-genes-10-00770"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwahashi</surname><given-names>S.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name><name><surname>Utsunomiya</surname><given-names>T.</given-names></name><name><surname>Morine</surname><given-names>Y.</given-names></name><name><surname>Imura</surname><given-names>S.</given-names></name><name><surname>Ikemoto</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name><name><surname>Hanaoka</surname><given-names>J.</given-names></name><name><surname>Sugimoto</surname><given-names>K.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name></person-group><article-title>Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-&#x003b1; on pancreatic cancer cells</article-title><source>Int. J. Clin. Oncol.</source><year>2011</year><volume>16</volume><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1007/s10147-011-0246-y</pub-id><pub-id pub-id-type="pmid">21556798</pub-id></element-citation></ref><ref id="B162-genes-10-00770"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>N.B.</given-names></name><name><surname>Arkus</surname><given-names>N.</given-names></name><name><surname>Gunn</surname><given-names>J.</given-names></name><name><surname>Korc</surname><given-names>M.</given-names></name></person-group><article-title>The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>18</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0914</pub-id><pub-id pub-id-type="pmid">17200334</pub-id></element-citation></ref><ref id="B163-genes-10-00770"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>M.H.</given-names></name><name><surname>Xu</surname><given-names>X.G.</given-names></name><name><surname>Yan</surname><given-names>S.L.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Ying</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>B.K.</given-names></name><name><surname>Tu</surname><given-names>Y.X.</given-names></name></person-group><article-title>Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>1621</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-20004-0</pub-id><pub-id pub-id-type="pmid">29374219</pub-id></element-citation></ref><ref id="B164-genes-10-00770"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>V.</given-names></name><name><surname>Richard</surname><given-names>N.</given-names></name><name><surname>Brady</surname><given-names>H.</given-names></name><name><surname>Maier</surname><given-names>A.</given-names></name><name><surname>Kelter</surname><given-names>G.</given-names></name><name><surname>Heise</surname><given-names>C.</given-names></name></person-group><article-title>Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells</article-title><source>Cancer Sci.</source><year>2011</year><volume>102</volume><fpage>1201</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.01921.x</pub-id><?supplied-pmid 21375679?><pub-id pub-id-type="pmid">21375679</pub-id></element-citation></ref><ref id="B165-genes-10-00770"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer</article-title><source>Am. J. Cancer Res.</source><year>2018</year><volume>8</volume><fpage>2402</fpage><lpage>2418</lpage><?supplied-pmid 30662800?><pub-id pub-id-type="pmid">30662800</pub-id></element-citation></ref><ref id="B166-genes-10-00770"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Kabra</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Koomen</surname><given-names>J.</given-names></name><name><surname>Haura</surname><given-names>E.B.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>20908</fpage><lpage>20917</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.470302</pub-id><pub-id pub-id-type="pmid">23737528</pub-id></element-citation></ref><ref id="B167-genes-10-00770"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>T.</given-names></name></person-group><article-title>SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2</article-title><source>Int. J. Oncol.</source><year>2013</year><volume>43</volume><fpage>1420</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.3892/ijo.2013.2103</pub-id><pub-id pub-id-type="pmid">24042441</pub-id></element-citation></ref><ref id="B168-genes-10-00770"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.M.</given-names></name><name><surname>Camelo-Piragua</surname><given-names>S.</given-names></name><name><surname>Schipper</surname><given-names>M.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Normolle</surname><given-names>D.</given-names></name><name><surname>Junck</surname><given-names>L.</given-names></name><name><surname>Mammoser</surname><given-names>A.</given-names></name><name><surname>Betz</surname><given-names>B.L.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2016</year><volume>94</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.10.032</pub-id><?supplied-pmid 26853339?><pub-id pub-id-type="pmid">26853339</pub-id></element-citation></ref><ref id="B169-genes-10-00770"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>A.</given-names></name><name><surname>Shyr</surname><given-names>Y.</given-names></name><name><surname>Lev</surname><given-names>S.</given-names></name><name><surname>Greenstein</surname><given-names>D.</given-names></name><name><surname>Brantley-Sieders</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e46281</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046281</pub-id><?supplied-pmid 23049696?><pub-id pub-id-type="pmid">23049696</pub-id></element-citation></ref><ref id="B170-genes-10-00770"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M.C.</given-names></name><name><surname>Wang</surname><given-names>H.C.</given-names></name><name><surname>Hou</surname><given-names>Y.C.</given-names></name><name><surname>Tung</surname><given-names>H.L.</given-names></name><name><surname>Chiu</surname><given-names>T.J.</given-names></name><name><surname>Shan</surname><given-names>Y.S.</given-names></name></person-group><article-title>Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine</article-title><source>Mol. Cancer</source><year>2015</year><volume>14</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.1186/s12943-015-0449-3</pub-id><pub-id pub-id-type="pmid">26458814</pub-id></element-citation></ref><ref id="B171-genes-10-00770"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Young</surname><given-names>M.M.</given-names></name><name><surname>Serfass</surname><given-names>J.M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gebru</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group><article-title>An autophagy assay reveals the ESCRT-III component CHMP2A as a regulator of phagophore closure</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2855</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05254-w</pub-id><pub-id pub-id-type="pmid">30030437</pub-id></element-citation></ref><ref id="B172-genes-10-00770"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Arcangelo</surname><given-names>D.</given-names></name><name><surname>Giampietri</surname><given-names>C.</given-names></name><name><surname>Muscio</surname><given-names>M.</given-names></name><name><surname>Scatozza</surname><given-names>F.</given-names></name><name><surname>Facchiano</surname><given-names>F.</given-names></name><name><surname>Facchiano</surname><given-names>A.</given-names></name></person-group><article-title>WIPI1, BAG1, and PEX3 Autophagy-Related Genes Are Relevant Melanoma Markers</article-title><source>Oxid. Med. Cell. Longev.</source><year>2018</year><volume>2018</volume><fpage>1471682</fpage><pub-id pub-id-type="doi">10.1155/2018/1471682</pub-id><?supplied-pmid 30622661?><pub-id pub-id-type="pmid">30622661</pub-id></element-citation></ref><ref id="B173-genes-10-00770"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filimonenko</surname><given-names>M.</given-names></name><name><surname>Stuffers</surname><given-names>S.</given-names></name><name><surname>Raiborg</surname><given-names>C.</given-names></name><name><surname>Yamamoto</surname><given-names>A.</given-names></name><name><surname>Malerod</surname><given-names>L.</given-names></name><name><surname>Fisher</surname><given-names>E.M.</given-names></name><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Brech</surname><given-names>A.</given-names></name><name><surname>Stenmark</surname><given-names>H.</given-names></name><name><surname>Simonsen</surname><given-names>A.</given-names></name></person-group><article-title>Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease</article-title><source>J. Cell Biol.</source><year>2007</year><volume>179</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1083/jcb.200702115</pub-id><?supplied-pmid 17984323?><pub-id pub-id-type="pmid">17984323</pub-id></element-citation></ref><ref id="B174-genes-10-00770"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M.L.</given-names></name><name><surname>Gong</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Wulf</surname><given-names>G.</given-names></name><name><surname>Lieberman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation</article-title><source>Cell Rep.</source><year>2015</year><volume>11</volume><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.002</pub-id><?supplied-pmid 25818297?><pub-id pub-id-type="pmid">25818297</pub-id></element-citation></ref><ref id="B175-genes-10-00770"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>miR448 targets Rab2B and is pivotal in the suppression of pancreatic cancer</article-title><source>Oncol. Rep.</source><year>2018</year><volume>40</volume><fpage>1379</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6562</pub-id><?supplied-pmid 30015954?><pub-id pub-id-type="pmid">30015954</pub-id></element-citation></ref><ref id="B176-genes-10-00770"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1cells in vitro by down-regulating the PCSK1/3</article-title><source>Cancer Lett.</source><year>2018</year><volume>431</volume><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.05.027</pub-id><?supplied-pmid 29800682?><pub-id pub-id-type="pmid">29800682</pub-id></element-citation></ref><ref id="B177-genes-10-00770"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demidyuk</surname><given-names>I.V.</given-names></name><name><surname>Shubin</surname><given-names>A.V.</given-names></name><name><surname>Gasanov</surname><given-names>E.V.</given-names></name><name><surname>Kurinov</surname><given-names>A.M.</given-names></name><name><surname>Demkin</surname><given-names>V.V.</given-names></name><name><surname>Vinogradova</surname><given-names>T.V.</given-names></name><name><surname>Zinovyeva</surname><given-names>M.V.</given-names></name><name><surname>Sass</surname><given-names>A.V.</given-names></name><name><surname>Zborovskaya</surname><given-names>I.B.</given-names></name><name><surname>Kostrov</surname><given-names>S.V.</given-names></name></person-group><article-title>Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e55752</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0055752</pub-id><?supplied-pmid 23409034?><pub-id pub-id-type="pmid">23409034</pub-id></element-citation></ref><ref id="B178-genes-10-00770"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajikar</surname><given-names>S.S.</given-names></name><name><surname>Wang</surname><given-names>C.C.</given-names></name><name><surname>Borten</surname><given-names>M.A.</given-names></name><name><surname>Pereira</surname><given-names>E.J.</given-names></name><name><surname>Atkins</surname><given-names>K.A.</given-names></name><name><surname>Janes</surname><given-names>K.A.</given-names></name></person-group><article-title>Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer</article-title><source>Dev. Cell</source><year>2017</year><volume>43</volume><fpage>418</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.10.027</pub-id><?supplied-pmid 29161592?><pub-id pub-id-type="pmid">29161592</pub-id></element-citation></ref><ref id="B179-genes-10-00770"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akada</surname><given-names>M.</given-names></name><name><surname>Crnogorac-Jurcevic</surname><given-names>T.</given-names></name><name><surname>Lattimore</surname><given-names>S.</given-names></name><name><surname>Mahon</surname><given-names>P.</given-names></name><name><surname>Lopes</surname><given-names>R.</given-names></name><name><surname>Sunamura</surname><given-names>M.</given-names></name><name><surname>Matsuno</surname><given-names>S.</given-names></name><name><surname>Lemoine</surname><given-names>N.R.</given-names></name></person-group><article-title>Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>3094</fpage><lpage>3101</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1785</pub-id><pub-id pub-id-type="pmid">15837765</pub-id></element-citation></ref><ref id="B180-genes-10-00770"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanki</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Baba</surname><given-names>M.</given-names></name><name><surname>Bartholomew</surname><given-names>C.R.</given-names></name><name><surname>Lynch-Day</surname><given-names>M.A.</given-names></name><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Mao</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Yen</surname><given-names>W.L.</given-names></name><etal/></person-group><article-title>A genomic screen for yeast mutants defective in selective mitochondria autophagy</article-title><source>Mol. Biol. Cell</source><year>2009</year><volume>20</volume><fpage>4730</fpage><lpage>4738</lpage><pub-id pub-id-type="doi">10.1091/mbc.e09-03-0225</pub-id><pub-id pub-id-type="pmid">19793921</pub-id></element-citation></ref><ref id="B181-genes-10-00770"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>I.R.</given-names></name><name><surname>Parkinson-Lawrence</surname><given-names>E.J.</given-names></name><name><surname>Keegan</surname><given-names>H.</given-names></name><name><surname>Spillane</surname><given-names>C.D.</given-names></name><name><surname>Barry-O&#x02019;Crowley</surname><given-names>J.</given-names></name><name><surname>Watson</surname><given-names>W.R.</given-names></name><name><surname>Selemidis</surname><given-names>S.</given-names></name><name><surname>Butler</surname><given-names>L.M.</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>J.J.</given-names></name><name><surname>Brooks</surname><given-names>D.A.</given-names></name></person-group><article-title>Endosomal gene expression: A new indicator for prostate cancer patient prognosis?</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>37919</fpage><lpage>37929</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6114</pub-id><?supplied-pmid 26473288?><pub-id pub-id-type="pmid">26473288</pub-id></element-citation></ref><ref id="B182-genes-10-00770"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Ouyang</surname><given-names>K.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><fpage>1261</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08521.x</pub-id><?supplied-pmid 22325559?><pub-id pub-id-type="pmid">22325559</pub-id></element-citation></ref><ref id="B183-genes-10-00770"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>A.</given-names></name><name><surname>Arcaroli</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Gasparetto</surname><given-names>M.</given-names></name><name><surname>Neumeister</surname><given-names>V.</given-names></name><name><surname>Thompson</surname><given-names>D.C.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Messersmith</surname><given-names>W.</given-names></name><name><surname>Vasiliou</surname><given-names>V.</given-names></name></person-group><article-title>Aldehyde dehydrogenase 1B1: A novel immunohistological marker for colorectal cancer</article-title><source>Br. J. Cancer</source><year>2017</year><volume>117</volume><fpage>1537</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.304</pub-id><?supplied-pmid 28881356?><pub-id pub-id-type="pmid">28881356</pub-id></element-citation></ref><ref id="B184-genes-10-00770"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Arcaroli</surname><given-names>J.J.</given-names></name><name><surname>Orlicky</surname><given-names>D.J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Messersmith</surname><given-names>W.A.</given-names></name><name><surname>Bagby</surname><given-names>S.</given-names></name><name><surname>Purkey</surname><given-names>A.</given-names></name><name><surname>Quackenbush</surname><given-names>K.S.</given-names></name><name><surname>Thompson</surname><given-names>D.C.</given-names></name><name><surname>Vasiliou</surname><given-names>V.</given-names></name></person-group><article-title>Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma</article-title><source>Pancreas</source><year>2016</year><volume>45</volume><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000000542</pub-id><pub-id pub-id-type="pmid">26566217</pub-id></element-citation></ref><ref id="B185-genes-10-00770"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chai</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>Aldehyde dehydrogenases and cancer stem cells</article-title><source>Cancer Lett.</source><year>2015</year><volume>369</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2015.08.018</pub-id><?supplied-pmid 26319899?><pub-id pub-id-type="pmid">26319899</pub-id></element-citation></ref><ref id="B186-genes-10-00770"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>J.S.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Jamiyandorj</surname><given-names>U.</given-names></name><name><surname>Kim</surname><given-names>K.M.</given-names></name><name><surname>Noh</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>J.R.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Kwon</surname><given-names>K.S.</given-names></name><name><surname>Jung</surname><given-names>S.H.</given-names></name><name><surname>Park</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>CK2alpha/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients</article-title><source>Am. J. Pathol.</source><year>2016</year><volume>186</volume><fpage>3297</fpage><lpage>3315</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2016.08.007</pub-id><pub-id pub-id-type="pmid">27746184</pub-id></element-citation></ref><ref id="B187-genes-10-00770"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Z.C.</given-names></name><name><surname>Tang</surname><given-names>R.X.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>Q.N.</given-names></name><name><surname>Lin</surname><given-names>J.Y.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Z.Y.</given-names></name></person-group><article-title>A meta-analysis and bioinformatics exploration of the diagnostic value and molecular mechanism of miR-193a-5p in lung cancer</article-title><source>Oncol. Lett.</source><year>2018</year><volume>16</volume><fpage>4114</fpage><lpage>4128</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.9174</pub-id><?supplied-pmid 30250529?><pub-id pub-id-type="pmid">30250529</pub-id></element-citation></ref><ref id="B188-genes-10-00770"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laramas</surname><given-names>M.</given-names></name><name><surname>Pasquier</surname><given-names>D.</given-names></name><name><surname>Filhol</surname><given-names>O.</given-names></name><name><surname>Ringeisen</surname><given-names>F.</given-names></name><name><surname>Descotes</surname><given-names>J.L.</given-names></name><name><surname>Cochet</surname><given-names>C.</given-names></name></person-group><article-title>Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer</article-title><source>Eur. J. Cancer</source><year>2007</year><volume>43</volume><fpage>928</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.11.021</pub-id><pub-id pub-id-type="pmid">17267203</pub-id></element-citation></ref><ref id="B189-genes-10-00770"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Protein kinase CK2alpha is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes</article-title><source>J. Transl. Med.</source><year>2011</year><volume>9</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-9-97</pub-id><pub-id pub-id-type="pmid">21702981</pub-id></element-citation></ref><ref id="B190-genes-10-00770"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>J.S.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Kim</surname><given-names>K.M.</given-names></name><name><surname>Kwon</surname><given-names>K.S.</given-names></name><name><surname>Kim</surname><given-names>C.Y.</given-names></name><name><surname>Lee</surname><given-names>H.K.</given-names></name><name><surname>Park</surname><given-names>B.H.</given-names></name><name><surname>Park</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Moon</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>CK2alpha phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients</article-title><source>Int. J. Cancer</source><year>2015</year><volume>136</volume><fpage>797</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1002/ijc.29043</pub-id><pub-id pub-id-type="pmid">24962073</pub-id></element-citation></ref><ref id="B191-genes-10-00770"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trembley</surname><given-names>J.H.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Unger</surname><given-names>G.</given-names></name><name><surname>Slaton</surname><given-names>J.</given-names></name><name><surname>Ahmed</surname><given-names>K.</given-names></name></person-group><article-title>Protein kinase CK2 in health and disease: CK2: A key player in cancer biology</article-title><source>Cell. Mol. Life Sci.</source><year>2009</year><volume>66</volume><fpage>1858</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-9154-y</pub-id><pub-id pub-id-type="pmid">19387548</pub-id></element-citation></ref><ref id="B192-genes-10-00770"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Chang</surname><given-names>J.T.</given-names></name><name><surname>Kao</surname><given-names>C.J.</given-names></name><name><surname>Huang</surname><given-names>R.S.</given-names></name></person-group><article-title>High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro</article-title><source>Mol. Cancer Ther.</source><year>2016</year><volume>15</volume><fpage>1123</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0943</pub-id><?supplied-pmid 26873729?><pub-id pub-id-type="pmid">26873729</pub-id></element-citation></ref><ref id="B193-genes-10-00770"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanif</surname><given-names>I.M.</given-names></name><name><surname>Hanif</surname><given-names>I.M.</given-names></name><name><surname>Shazib</surname><given-names>M.A.</given-names></name><name><surname>Ahmad</surname><given-names>K.A.</given-names></name><name><surname>Pervaiz</surname><given-names>S.</given-names></name></person-group><article-title>Casein Kinase II: An attractive target for anticancer drug design</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2010</year><volume>42</volume><fpage>1602</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2010.06.010</pub-id><?supplied-pmid 20558317?><pub-id pub-id-type="pmid">20558317</pub-id></element-citation></ref><ref id="B194-genes-10-00770"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Shu</surname><given-names>G.</given-names></name><name><surname>Yin</surname><given-names>G.</given-names></name></person-group><article-title>CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer</article-title><source>Cancer Manag. Res.</source><year>2018</year><volume>10</volume><fpage>5113</fpage><lpage>5124</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S176833</pub-id><?supplied-pmid 30464611?><pub-id pub-id-type="pmid">30464611</pub-id></element-citation></ref><ref id="B195-genes-10-00770"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Ao</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Ji</surname><given-names>J.</given-names></name></person-group><article-title>CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e91771</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0091771</pub-id><?supplied-pmid 24622579?><pub-id pub-id-type="pmid">24622579</pub-id></element-citation></ref><ref id="B196-genes-10-00770"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>CCNB1 is a prognostic biomarker for ER+ breast cancer</article-title><source>Med. Hypotheses</source><year>2014</year><volume>83</volume><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2014.06.013</pub-id><?supplied-pmid 25044212?><pub-id pub-id-type="pmid">25044212</pub-id></element-citation></ref><ref id="B197-genes-10-00770"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name></person-group><article-title>Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer</article-title><source>Cancer Biol. Ther.</source><year>2014</year><volume>15</volume><fpage>1268</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.4161/cbt.29691</pub-id><?supplied-pmid 24971465?><pub-id pub-id-type="pmid">24971465</pub-id></element-citation></ref><ref id="B198-genes-10-00770"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oji</surname><given-names>Y.</given-names></name><name><surname>Tatsumi</surname><given-names>N.</given-names></name><name><surname>Fukuda</surname><given-names>M.</given-names></name><name><surname>Nakatsuka</surname><given-names>S.</given-names></name><name><surname>Aoyagi</surname><given-names>S.</given-names></name><name><surname>Hirata</surname><given-names>E.</given-names></name><name><surname>Nanchi</surname><given-names>I.</given-names></name><name><surname>Fujiki</surname><given-names>F.</given-names></name><name><surname>Nakajima</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The translation elongation factor eEF2 is a novel tumorassociated antigen overexpressed in various types of cancers</article-title><source>Int. J. Oncol.</source><year>2014</year><volume>44</volume><fpage>1461</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2318</pub-id><pub-id pub-id-type="pmid">24589652</pub-id></element-citation></ref><ref id="B199-genes-10-00770"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N.</given-names></name><name><surname>Maeda</surname><given-names>M.</given-names></name><name><surname>Sugiyama</surname><given-names>M.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Hyodo</surname><given-names>T.</given-names></name><name><surname>Masuda</surname><given-names>A.</given-names></name><name><surname>Tsunoda</surname><given-names>N.</given-names></name><name><surname>Kokuryo</surname><given-names>T.</given-names></name><name><surname>Hamaguchi</surname><given-names>M.</given-names></name><name><surname>Nagino</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inhibition of SNW1 association with spliceosomal proteins promotes apoptosis in breast cancer cells</article-title><source>Cancer Med.</source><year>2015</year><volume>4</volume><fpage>268</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1002/cam4.366</pub-id><?supplied-pmid 25450007?><pub-id pub-id-type="pmid">25450007</pub-id></element-citation></ref><ref id="B200-genes-10-00770"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koller-Eichhorn</surname><given-names>R.</given-names></name><name><surname>Marquardt</surname><given-names>T.</given-names></name><name><surname>Gail</surname><given-names>R.</given-names></name><name><surname>Wittinghofer</surname><given-names>A.</given-names></name><name><surname>Kostrewa</surname><given-names>D.</given-names></name><name><surname>Kutay</surname><given-names>U.</given-names></name><name><surname>Kambach</surname><given-names>C.</given-names></name></person-group><article-title>Human OLA1 defines an ATPase subfamily in the Obg family of GTP-binding proteins</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>19928</fpage><lpage>19937</lpage><pub-id pub-id-type="doi">10.1074/jbc.M700541200</pub-id><?supplied-pmid 17430889?><pub-id pub-id-type="pmid">17430889</pub-id></element-citation></ref><ref id="B201-genes-10-00770"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>M.</given-names></name><name><surname>Gzyl</surname><given-names>K.E.</given-names></name><name><surname>Altamirano</surname><given-names>A.M.</given-names></name><name><surname>Vuong</surname><given-names>A.</given-names></name><name><surname>Urban</surname><given-names>K.</given-names></name><name><surname>Wieden</surname><given-names>H.J.</given-names></name></person-group><article-title>The 70S ribosome modulates the ATPase activity of Escherichia coli YchF</article-title><source>RNA Biol.</source><year>2012</year><volume>9</volume><fpage>1288</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.4161/rna.22131</pub-id><pub-id pub-id-type="pmid">22995830</pub-id></element-citation></ref><ref id="B202-genes-10-00770"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Liao</surname><given-names>C.</given-names></name><name><surname>Jeyabal</surname><given-names>P.V.</given-names></name><name><surname>Rubio</surname><given-names>V.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>Z.Z.</given-names></name></person-group><article-title>OLA1 contributes to epithelial-mesenchymal transition in lung cancer by modulating the GSK3beta/snail/E-cadherin signaling</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>10402</fpage><lpage>10413</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7224</pub-id><?supplied-pmid 26863455?><pub-id pub-id-type="pmid">26863455</pub-id></element-citation></ref><ref id="B203-genes-10-00770"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelison</surname><given-names>R.</given-names></name><name><surname>Dobbin</surname><given-names>Z.C.</given-names></name><name><surname>Katre</surname><given-names>A.A.</given-names></name><name><surname>Jeong</surname><given-names>D.H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Petrova</surname><given-names>Y.</given-names></name><name><surname>Llaneza</surname><given-names>D.C.</given-names></name><name><surname>Steg</surname><given-names>A.D.</given-names></name><name><surname>Parsons</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>6529</fpage><lpage>6540</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0282</pub-id><?supplied-pmid 28778862?><pub-id pub-id-type="pmid">28778862</pub-id></element-citation></ref><ref id="B204-genes-10-00770"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Baladandayuthapani</surname><given-names>V.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Jones</surname><given-names>R.J.</given-names></name><name><surname>Kuiatse</surname><given-names>I.</given-names></name><name><surname>Gu</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><etal/></person-group><article-title>RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>177</volume><fpage>80</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/bjh.14525</pub-id><?supplied-pmid 28369725?><pub-id pub-id-type="pmid">28369725</pub-id></element-citation></ref><ref id="B205-genes-10-00770"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossetti</surname><given-names>S.</given-names></name><name><surname>Wierzbicki</surname><given-names>A.J.</given-names></name><name><surname>Sacchi</surname><given-names>N.</given-names></name></person-group><article-title>Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: An offbeat approach to target MYC-driven cancer</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>5016</fpage><lpage>5031</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23579</pub-id><?supplied-pmid 29435159?><pub-id pub-id-type="pmid">29435159</pub-id></element-citation></ref><ref id="B206-genes-10-00770"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>M.</given-names></name><name><surname>Segersten</surname><given-names>U.</given-names></name><name><surname>Runeson</surname><given-names>M.</given-names></name><name><surname>Wester</surname><given-names>K.</given-names></name><name><surname>Busch</surname><given-names>C.</given-names></name><name><surname>Pettersson</surname><given-names>U.</given-names></name><name><surname>Lind</surname><given-names>S.B.</given-names></name><name><surname>Malmstrom</surname><given-names>P.U.</given-names></name></person-group><article-title>Tumour expression of bladder cancer-associated urinary proteins</article-title><source>BJU Int.</source><year>2013</year><volume>112</volume><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11653.x</pub-id><?supplied-pmid 23470167?><pub-id pub-id-type="pmid">23470167</pub-id></element-citation></ref><ref id="B207-genes-10-00770"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>N.</given-names></name><name><surname>Oltean</surname><given-names>S.</given-names></name></person-group><article-title>The many faces of SRPK1</article-title><source>J. Pathol.</source><year>2017</year><volume>241</volume><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/path.4846</pub-id><?supplied-pmid 27859253?><pub-id pub-id-type="pmid">27859253</pub-id></element-citation></ref><ref id="B208-genes-10-00770"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells</article-title><source>Neuro Oncol.</source><year>2015</year><volume>17</volume><fpage>407</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou219</pub-id><?supplied-pmid 25209430?><pub-id pub-id-type="pmid">25209430</pub-id></element-citation></ref><ref id="B209-genes-10-00770"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Liao</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Jin</surname><given-names>F.</given-names></name></person-group><article-title>Significance of Vesicle-Associated Membrane Protein 8 Expression in Predicting Survival in Breast Cancer</article-title><source>J. Breast Cancer</source><year>2018</year><volume>21</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.4048/jbc.2018.21.e57</pub-id><?supplied-pmid 30607161?><pub-id pub-id-type="pmid">30607161</pub-id></element-citation></ref><ref id="B210-genes-10-00770"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunnet</surname><given-names>M.</given-names></name><name><surname>Calatayud</surname><given-names>D.</given-names></name><name><surname>Schultz</surname><given-names>N.A.</given-names></name><name><surname>Hasselby</surname><given-names>J.P.</given-names></name><name><surname>Mau-Sorensen</surname><given-names>M.</given-names></name><name><surname>Brunner</surname><given-names>N.</given-names></name><name><surname>Stenvang</surname><given-names>J.</given-names></name></person-group><article-title>TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas</article-title><source>Scand. J. Gastroenterol.</source><year>2015</year><volume>50</volume><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.3109/00365521.2014.980318</pub-id><?supplied-pmid 25615400?><pub-id pub-id-type="pmid">25615400</pub-id></element-citation></ref><ref id="B211-genes-10-00770"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>R.</given-names></name><name><surname>Qiu</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Fan</surname><given-names>R.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Rab34 regulates adhesion, migration, and invasion of breast cancer cells</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>3698</fpage><lpage>3714</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0202-7</pub-id><?supplied-pmid 29622794?><pub-id pub-id-type="pmid">29622794</pub-id></element-citation></ref><ref id="B212-genes-10-00770"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>A.</given-names></name><name><surname>Qiao</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma</article-title><source>Oncol. Rep.</source><year>2017</year><volume>38</volume><fpage>2967</fpage><lpage>2974</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5957</pub-id><?supplied-pmid 29048615?><pub-id pub-id-type="pmid">29048615</pub-id></element-citation></ref><ref id="B213-genes-10-00770"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.J.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.L.</given-names></name><name><surname>Jiang</surname><given-names>C.L.</given-names></name></person-group><article-title>RAB34 was a progression- and prognosis-associated biomarker in gliomas</article-title><source>Tumour Biol.</source><year>2015</year><volume>36</volume><fpage>1573</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-2732-0</pub-id><?supplied-pmid 25501506?><pub-id pub-id-type="pmid">25501506</pub-id></element-citation></ref><ref id="B214-genes-10-00770"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artero-Castro</surname><given-names>A.</given-names></name><name><surname>Castellvi</surname><given-names>J.</given-names></name><name><surname>Garcia</surname><given-names>A.</given-names></name><name><surname>Hernandez</surname><given-names>J.</given-names></name><name><surname>Ramon y Cajal</surname><given-names>S.</given-names></name><name><surname>Lleonart</surname><given-names>M.E.</given-names></name></person-group><article-title>Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors</article-title><source>Hum. Pathol.</source><year>2011</year><volume>42</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2010.04.020</pub-id><?supplied-pmid 21040949?><pub-id pub-id-type="pmid">21040949</pub-id></element-citation></ref><ref id="B215-genes-10-00770"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sendoel</surname><given-names>A.</given-names></name><name><surname>Dunn</surname><given-names>J.G.</given-names></name><name><surname>Rodriguez</surname><given-names>E.H.</given-names></name><name><surname>Naik</surname><given-names>S.</given-names></name><name><surname>Gomez</surname><given-names>N.C.</given-names></name><name><surname>Hurwitz</surname><given-names>B.</given-names></name><name><surname>Levorse</surname><given-names>J.</given-names></name><name><surname>Dill</surname><given-names>B.D.</given-names></name><name><surname>Schramek</surname><given-names>D.</given-names></name><name><surname>Molina</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Translation from unconventional 5&#x02032; start sites drives tumour initiation</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/nature21036</pub-id><?supplied-pmid 28077873?><pub-id pub-id-type="pmid">28077873</pub-id></element-citation></ref><ref id="B216-genes-10-00770"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neklesa</surname><given-names>T.K.</given-names></name><name><surname>Davis</surname><given-names>R.W.</given-names></name></person-group><article-title>A genome-wide screen for regulators of TORC1 in response to amino acid starvation reveals a conserved Npr2/3 complex</article-title><source>PLoS Genet.</source><year>2009</year><volume>5</volume><elocation-id>e1000515</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000515</pub-id><?supplied-pmid 19521502?><pub-id pub-id-type="pmid">19521502</pub-id></element-citation></ref><ref id="B217-genes-10-00770"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>B.P.</given-names></name></person-group><article-title>Selective regulation of autophagy by the Iml1-Npr2-Npr3 complex in the absence of nitrogen starvation</article-title><source>Mol. Biol. Cell</source><year>2011</year><volume>22</volume><fpage>4124</fpage><lpage>4133</lpage><pub-id pub-id-type="doi">10.1091/mbc.e11-06-0525</pub-id><?supplied-pmid 21900499?><pub-id pub-id-type="pmid">21900499</pub-id></element-citation></ref><ref id="B218-genes-10-00770"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smardon</surname><given-names>A.M.</given-names></name><name><surname>Tarsio</surname><given-names>M.</given-names></name><name><surname>Kane</surname><given-names>P.M.</given-names></name></person-group><article-title>The RAVE complex is essential for stable assembly of the yeast V-ATPase</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>13831</fpage><lpage>13839</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200682200</pub-id><?supplied-pmid 11844802?><pub-id pub-id-type="pmid">11844802</pub-id></element-citation></ref><ref id="B219-genes-10-00770"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seol</surname><given-names>J.H.</given-names></name><name><surname>Shevchenko</surname><given-names>A.</given-names></name><name><surname>Shevchenko</surname><given-names>A.</given-names></name><name><surname>Deshaies</surname><given-names>R.J.</given-names></name></person-group><article-title>Skp1 forms multiple protein complexes, including RAVE, a regulator of V-ATPase assembly</article-title><source>Nat. Cell Biol.</source><year>2001</year><volume>3</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/35070067</pub-id><?supplied-pmid 11283612?><pub-id pub-id-type="pmid">11283612</pub-id></element-citation></ref><ref id="B220-genes-10-00770"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>N.</given-names></name><name><surname>Matsuura</surname><given-names>A.</given-names></name><name><surname>Wada</surname><given-names>Y.</given-names></name><name><surname>Ohsumi</surname><given-names>Y.</given-names></name></person-group><article-title>Acidification of vacuoles is required for autophagic degradation in the yeast, Saccharomyces cerevisiae</article-title><source>J. Biochem.</source><year>1997</year><volume>121</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a021592</pub-id><?supplied-pmid 9089409?><pub-id pub-id-type="pmid">9089409</pub-id></element-citation></ref><ref id="B221-genes-10-00770"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Geng</surname><given-names>J.</given-names></name><name><surname>Yen</surname><given-names>W.L.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Klionsky</surname><given-names>D.J.</given-names></name></person-group><article-title>Positive or negative roles of different cyclin-dependent kinase Pho85-cyclin complexes orchestrate induction of autophagy in Saccharomyces cerevisiae</article-title><source>Mol. Cell</source><year>2010</year><volume>38</volume><fpage>250</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.02.033</pub-id><?supplied-pmid 20417603?><pub-id pub-id-type="pmid">20417603</pub-id></element-citation></ref><ref id="B222-genes-10-00770"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollert</surname><given-names>T.</given-names></name><name><surname>Wunder</surname><given-names>C.</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name></person-group><article-title>Membrane scission by the ESCRT-III complex</article-title><source>Nature</source><year>2009</year><volume>458</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/nature07836</pub-id><?supplied-pmid 19234443?><pub-id pub-id-type="pmid">19234443</pub-id></element-citation></ref><ref id="B223-genes-10-00770"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>C.M.</given-names></name><name><surname>West</surname><given-names>M.</given-names></name><name><surname>Odorizzi</surname><given-names>G.</given-names></name></person-group><article-title>Doa4 function in ILV budding is restricted through its interaction with the Vps20 subunit of ESCRT-III</article-title><source>J. Cell Sci.</source><year>2013</year><volume>126</volume><fpage>1881</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1242/jcs.122499</pub-id><?supplied-pmid 23444383?><pub-id pub-id-type="pmid">23444383</pub-id></element-citation></ref><ref id="B224-genes-10-00770"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukubou</surname><given-names>H.</given-names></name><name><surname>Tsujimura</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>R.</given-names></name><name><surname>Ku</surname><given-names>Y.</given-names></name></person-group><article-title>The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation</article-title><source>Int. J. Oncol.</source><year>2010</year><volume>37</volume><fpage>821</fpage><lpage>828</lpage><?supplied-pmid 20811703?><pub-id pub-id-type="pmid">20811703</pub-id></element-citation></ref><ref id="B225-genes-10-00770"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>D.</given-names></name><name><surname>Blauer</surname><given-names>M.</given-names></name><name><surname>Hirota</surname><given-names>M.</given-names></name><name><surname>Ikonen</surname><given-names>N.H.</given-names></name><name><surname>Sand</surname><given-names>J.</given-names></name><name><surname>Laukkarinen</surname><given-names>J.</given-names></name></person-group><article-title>Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs</article-title><source>Eur. J. Cancer</source><year>2014</year><volume>50</volume><fpage>1382</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2014.01.011</pub-id><?supplied-pmid 24503026?><pub-id pub-id-type="pmid">24503026</pub-id></element-citation></ref><ref id="B226-genes-10-00770"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>P.</given-names></name><name><surname>Wan</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>F.</given-names></name><name><surname>Shen</surname><given-names>P.</given-names></name></person-group><article-title>The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells</article-title><source>Int. J. Mol. Med.</source><year>2014</year><volume>34</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2014.1772</pub-id><?supplied-pmid 24804820?><pub-id pub-id-type="pmid">24804820</pub-id></element-citation></ref><ref id="B227-genes-10-00770"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beilharz</surname><given-names>T.H.</given-names></name><name><surname>Harrison</surname><given-names>P.F.</given-names></name><name><surname>Miles</surname><given-names>D.M.</given-names></name><name><surname>See</surname><given-names>M.M.</given-names></name><name><surname>Le</surname><given-names>U.M.</given-names></name><name><surname>Kalanon</surname><given-names>M.</given-names></name><name><surname>Curtis</surname><given-names>M.J.</given-names></name><name><surname>Hasan</surname><given-names>Q.</given-names></name><name><surname>Saksouk</surname><given-names>J.</given-names></name><name><surname>Margaritis</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Coordination of Cell Cycle Progression and Mitotic Spindle Assembly Involves Histone H3 Lysine 4 Methylation by Set1/COMPASS</article-title><source>Genetics</source><year>2017</year><volume>205</volume><fpage>185</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1534/genetics.116.194852</pub-id><pub-id pub-id-type="pmid">28049706</pub-id></element-citation></ref><ref id="B228-genes-10-00770"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>T.</given-names></name><name><surname>Krogan</surname><given-names>N.J.</given-names></name><name><surname>Dover</surname><given-names>J.</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H.</given-names></name><name><surname>Tempst</surname><given-names>P.</given-names></name><name><surname>Johnston</surname><given-names>M.</given-names></name><name><surname>Greenblatt</surname><given-names>J.F.</given-names></name><name><surname>Shilatifard</surname><given-names>A.</given-names></name></person-group><article-title>COMPASS: A complex of proteins associated with a trithorax-related SET domain protein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>12902</fpage><lpage>12907</lpage><pub-id pub-id-type="doi">10.1073/pnas.231473398</pub-id><?supplied-pmid 11687631?><pub-id pub-id-type="pmid">11687631</pub-id></element-citation></ref><ref id="B229-genes-10-00770"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shilatifard</surname><given-names>A.</given-names></name></person-group><article-title>The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis</article-title><source>Annu. Rev. Biochem.</source><year>2012</year><volume>81</volume><fpage>65</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-051710-134100</pub-id><?supplied-pmid 22663077?><pub-id pub-id-type="pmid">22663077</pub-id></element-citation></ref><ref id="B230-genes-10-00770"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>E.L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Histone methylation: A dynamic mark in health, disease and inheritance</article-title><source>Nat. Rev. Genet.</source><year>2012</year><volume>13</volume><fpage>343</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nrg3173</pub-id><pub-id pub-id-type="pmid">22473383</pub-id></element-citation></ref><ref id="B231-genes-10-00770"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehe</surname><given-names>P.M.</given-names></name><name><surname>Dichtl</surname><given-names>B.</given-names></name><name><surname>Schaft</surname><given-names>D.</given-names></name><name><surname>Roguev</surname><given-names>A.</given-names></name><name><surname>Pamblanco</surname><given-names>M.</given-names></name><name><surname>Lebrun</surname><given-names>R.</given-names></name><name><surname>Rodriguez-Gil</surname><given-names>A.</given-names></name><name><surname>Mkandawire</surname><given-names>M.</given-names></name><name><surname>Landsberg</surname><given-names>K.</given-names></name><name><surname>Shevchenko</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protein interactions within the Set1 complex and their roles in the regulation of histone 3 lysine 4 methylation</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>35404</fpage><lpage>35412</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603099200</pub-id><?supplied-pmid 16921172?><pub-id pub-id-type="pmid">16921172</pub-id></element-citation></ref><ref id="B232-genes-10-00770"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname><given-names>A.G.</given-names></name><name><surname>Thiagarajan</surname><given-names>P.S.</given-names></name><name><surname>Mulkearns-Hubert</surname><given-names>E.E.</given-names></name><name><surname>Silver</surname><given-names>D.J.</given-names></name><name><surname>Hale</surname><given-names>J.S.</given-names></name><name><surname>Alban</surname><given-names>T.J.</given-names></name><name><surname>Turaga</surname><given-names>S.M.</given-names></name><name><surname>Jarrar</surname><given-names>A.</given-names></name><name><surname>Reizes</surname><given-names>O.</given-names></name><name><surname>Longworth</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression</article-title><source>Cell Stem Cell</source><year>2017</year><volume>20</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.12.001</pub-id><?supplied-pmid 28089910?><pub-id pub-id-type="pmid">28089910</pub-id></element-citation></ref><ref id="B233-genes-10-00770"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Sabbatini</surname><given-names>M.E.</given-names></name><name><surname>Colby</surname><given-names>A.H.</given-names></name><name><surname>Grinstaff</surname><given-names>M.W.</given-names></name><name><surname>Oberlies</surname><given-names>N.H.</given-names></name><name><surname>Pearce</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name></person-group><article-title>Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><elocation-id>149</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4061-y</pub-id><?supplied-pmid 29409480?><pub-id pub-id-type="pmid">29409480</pub-id></element-citation></ref><ref id="B234-genes-10-00770"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>W.J.</given-names></name><name><surname>Bao</surname><given-names>H.B.</given-names></name><name><surname>Si</surname><given-names>S.H.</given-names></name><name><surname>Fan</surname><given-names>J.L.</given-names></name><name><surname>Lin</surname><given-names>P.</given-names></name><name><surname>Cui</surname><given-names>R.J.</given-names></name><name><surname>Pan</surname><given-names>Y.J.</given-names></name><name><surname>Wen</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial-mesenchymal transition in prostate cancer cell</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>65553</fpage><lpage>65567</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11549</pub-id><?supplied-pmid 27566588?><pub-id pub-id-type="pmid">27566588</pub-id></element-citation></ref><ref id="B235-genes-10-00770"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Bao</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Jiao</surname><given-names>X.</given-names></name><name><surname>Sheng</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Retinoblastoma Binding Protein 5 Correlates with the Progression in Hepatocellular Carcinoma</article-title><source>BioMed Res. Int.</source><year>2018</year><volume>2018</volume><fpage>1073432</fpage><pub-id pub-id-type="doi">10.1155/2018/1073432</pub-id><pub-id pub-id-type="pmid">30533424</pub-id></element-citation></ref><ref id="B236-genes-10-00770"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telles</surname><given-names>E.</given-names></name><name><surname>Seto</surname><given-names>E.</given-names></name></person-group><article-title>Modulation of cell cycle regulators by HDACs</article-title><source>Front. Biosci. (Sch. Ed.)</source><year>2012</year><volume>4</volume><fpage>831</fpage><lpage>839</lpage></element-citation></ref><ref id="B237-genes-10-00770"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seto</surname><given-names>E.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name></person-group><article-title>Erasers of histone acetylation: The histone deacetylase enzymes</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2014</year><volume>6</volume><fpage>a018713</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a018713</pub-id><pub-id pub-id-type="pmid">24691964</pub-id></element-citation></ref><ref id="B238-genes-10-00770"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Carmen</surname><given-names>A.A.</given-names></name><name><surname>Kobayashi</surname><given-names>R.</given-names></name><name><surname>Suka</surname><given-names>N.</given-names></name><name><surname>Grunstein</surname><given-names>M.</given-names></name></person-group><article-title>HDA2 and HDA3 are related proteins that interact with and are essential for the activity of the yeast histone deacetylase HDA1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>4391</fpage><lpage>4396</lpage><pub-id pub-id-type="doi">10.1073/pnas.081560698</pub-id><?supplied-pmid 11287668?><pub-id pub-id-type="pmid">11287668</pub-id></element-citation></ref><ref id="B239-genes-10-00770"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alic</surname><given-names>N.</given-names></name><name><surname>Higgins</surname><given-names>V.J.</given-names></name><name><surname>Dawes</surname><given-names>I.W.</given-names></name></person-group><article-title>Identification of a Saccharomyces cerevisiae gene that is required for G1 arrest in response to the lipid oxidation product linoleic acid hydroperoxide</article-title><source>Mol. Biol. Cell</source><year>2001</year><volume>12</volume><fpage>1801</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1091/mbc.12.6.1801</pub-id><pub-id pub-id-type="pmid">11408586</pub-id></element-citation></ref><ref id="B240-genes-10-00770"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alic</surname><given-names>N.</given-names></name><name><surname>Higgins</surname><given-names>V.J.</given-names></name><name><surname>Pichova</surname><given-names>A.</given-names></name><name><surname>Breitenbach</surname><given-names>M.</given-names></name><name><surname>Dawes</surname><given-names>I.W.</given-names></name></person-group><article-title>Lipid hydroperoxides activate the mitogen-activated protein kinase Mpk1p in Saccharomyces cerevisiae</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>41849</fpage><lpage>41855</lpage><pub-id pub-id-type="doi">10.1074/jbc.M307760200</pub-id><pub-id pub-id-type="pmid">12912987</pub-id></element-citation></ref><ref id="B241-genes-10-00770"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Addinall</surname><given-names>S.G.</given-names></name><name><surname>Downey</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Zubko</surname><given-names>M.K.</given-names></name><name><surname>Dewar</surname><given-names>J.</given-names></name><name><surname>Leake</surname><given-names>A.</given-names></name><name><surname>Hallinan</surname><given-names>J.</given-names></name><name><surname>Shaw</surname><given-names>O.</given-names></name><name><surname>James</surname><given-names>K.</given-names></name><name><surname>Wilkinson</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae</article-title><source>Genetics</source><year>2008</year><volume>180</volume><fpage>2251</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1534/genetics.108.092577</pub-id><pub-id pub-id-type="pmid">18845848</pub-id></element-citation></ref><ref id="B242-genes-10-00770"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Veen</surname><given-names>A.G.</given-names></name><name><surname>Ploegh</surname><given-names>H.L.</given-names></name></person-group><article-title>Ubiquitin-like proteins</article-title><source>Annu. Rev. Biochem.</source><year>2012</year><volume>81</volume><fpage>323</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-093010-153308</pub-id><?supplied-pmid 22404627?><pub-id pub-id-type="pmid">22404627</pub-id></element-citation></ref><ref id="B243-genes-10-00770"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Judes</surname><given-names>A.</given-names></name><name><surname>Bruch</surname><given-names>A.</given-names></name><name><surname>Klassen</surname><given-names>R.</given-names></name><name><surname>Helm</surname><given-names>M.</given-names></name><name><surname>Schaffrath</surname><given-names>R.</given-names></name></person-group><article-title>Sulfur transfer and activation by ubiquitin-like modifier system Uba4*Urm1 link protein urmylation and tRNA thiolation in yeast</article-title><source>Microb. Cell</source><year>2016</year><volume>3</volume><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.15698/mic2016.11.539</pub-id><?supplied-pmid 28357324?><pub-id pub-id-type="pmid">28357324</pub-id></element-citation></ref><ref id="B244-genes-10-00770"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>Y.</given-names></name><name><surname>Nakai</surname><given-names>M.</given-names></name><name><surname>Hayashi</surname><given-names>H.</given-names></name></person-group><article-title>Thio-modification of yeast cytosolic tRNA requires a ubiquitin-related system that resembles bacterial sulfur transfer systems</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>27469</fpage><lpage>27476</lpage><pub-id pub-id-type="doi">10.1074/jbc.M804043200</pub-id><?supplied-pmid 18664566?><pub-id pub-id-type="pmid">18664566</pub-id></element-citation></ref><ref id="B245-genes-10-00770"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noma</surname><given-names>A.</given-names></name><name><surname>Sakaguchi</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name></person-group><article-title>Mechanistic characterization of the sulfur-relay system for eukaryotic 2-thiouridine biogenesis at tRNA wobble positions</article-title><source>Nucleic Acids Res.</source><year>2009</year><volume>37</volume><fpage>1335</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn1023</pub-id><?supplied-pmid 19151091?><pub-id pub-id-type="pmid">19151091</pub-id></element-citation></ref><ref id="B246-genes-10-00770"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawer</surname><given-names>H.</given-names></name><name><surname>Hammermeister</surname><given-names>A.</given-names></name><name><surname>Ravichandran</surname><given-names>K.E.</given-names></name><name><surname>Glatt</surname><given-names>S.</given-names></name><name><surname>Schaffrath</surname><given-names>R.</given-names></name><name><surname>Klassen</surname><given-names>R.</given-names></name></person-group><article-title>Roles of Elongator Dependent tRNA Modification Pathways in Neurodegeneration and Cancer</article-title><source>Genes</source><year>2018</year><volume>10</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3390/genes10010019</pub-id><?supplied-pmid 30597914?><pub-id pub-id-type="pmid">30597914</pub-id></element-citation></ref><ref id="B247-genes-10-00770"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapino</surname><given-names>F.</given-names></name><name><surname>Delaunay</surname><given-names>S.</given-names></name><name><surname>Rambow</surname><given-names>F.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Tharun</surname><given-names>L.</given-names></name><name><surname>De Tullio</surname><given-names>P.</given-names></name><name><surname>Sin</surname><given-names>O.</given-names></name><name><surname>Shostak</surname><given-names>K.</given-names></name><name><surname>Schmitz</surname><given-names>S.</given-names></name><name><surname>Piepers</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Codon-specific translation reprogramming promotes resistance to targeted therapy</article-title><source>Nature</source><year>2018</year><volume>558</volume><fpage>605</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0243-7</pub-id><?supplied-pmid 29925953?><pub-id pub-id-type="pmid">29925953</pub-id></element-citation></ref><ref id="B248-genes-10-00770"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plunkett</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Searcy</surname><given-names>C.E.</given-names></name><name><surname>Gandhi</surname><given-names>V.</given-names></name></person-group><article-title>Gemcitabine: Preclinical pharmacology and mechanisms of action</article-title><source>Semin Oncol.</source><year>1996</year><volume>23</volume><fpage>3</fpage><lpage>15</lpage><?supplied-pmid 8893876?><pub-id pub-id-type="pmid">8893876</pub-id></element-citation></ref><ref id="B249-genes-10-00770"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Soo</surname><given-names>R.A.</given-names></name><name><surname>Yong</surname><given-names>W.P.</given-names></name><name><surname>Innocenti</surname><given-names>F.</given-names></name></person-group><article-title>Clinical pharmacology and pharmacogenetics of gemcitabine</article-title><source>Drug Metab. Rev.</source><year>2009</year><volume>41</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1080/03602530902741828</pub-id><pub-id pub-id-type="pmid">19514966</pub-id></element-citation></ref><ref id="B250-genes-10-00770"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Lam</surname><given-names>W.</given-names></name><name><surname>Liou</surname><given-names>J.Y.</given-names></name><name><surname>Dutschman</surname><given-names>G.</given-names></name><name><surname>Cheng</surname><given-names>Y.C.</given-names></name></person-group><article-title>Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>5453</fpage><lpage>5459</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109025200</pub-id><pub-id pub-id-type="pmid">11741981</pub-id></element-citation></ref><ref id="B251-genes-10-00770"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flentie</surname><given-names>K.</given-names></name><name><surname>Gonzalez</surname><given-names>C.</given-names></name><name><surname>Kocher</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Marasa</surname><given-names>J.</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D.</given-names></name></person-group><article-title>Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFkappaB Activation</article-title><source>Mol. Cancer Res.</source><year>2018</year><volume>16</volume><fpage>986</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0603</pub-id><pub-id pub-id-type="pmid">29523766</pub-id></element-citation></ref><ref id="B252-genes-10-00770"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Kane</surname><given-names>G.M.</given-names></name><name><surname>Connor</surname><given-names>A.A.</given-names></name><name><surname>Gallinger</surname><given-names>S.</given-names></name></person-group><article-title>Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer</article-title><source>Trends Mol. Med.</source><year>2017</year><volume>23</volume><fpage>1121</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2017.10.007</pub-id><?supplied-pmid 29133135?><pub-id pub-id-type="pmid">29133135</pub-id></element-citation></ref><ref id="B253-genes-10-00770"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>J.C.</given-names></name><name><surname>Lopes</surname><given-names>J.M.</given-names></name></person-group><article-title>The yeast UME6 gene is required for both negative and positive transcriptional regulation of phospholipid biosynthetic gene expression</article-title><source>Nucleic Acids Res.</source><year>1996</year><volume>24</volume><fpage>1322</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1093/nar/24.7.1322</pub-id><?supplied-pmid 8614637?><pub-id pub-id-type="pmid">8614637</pub-id></element-citation></ref><ref id="B254-genes-10-00770"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae-Lee</surname><given-names>M.S.</given-names></name><name><surname>Carman</surname><given-names>G.M.</given-names></name></person-group><article-title>Phosphatidylserine synthesis in Saccharomyces cerevisiae. Purification and characterization of membrane-associated phosphatidylserine synthase</article-title><source>J. Biol. Chem.</source><year>1984</year><volume>259</volume><fpage>10857</fpage><lpage>10862</lpage><pub-id pub-id-type="pmid">6088519</pub-id></element-citation></ref><ref id="B255-genes-10-00770"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeo</surname><given-names>F.</given-names></name><name><surname>Frohlich</surname><given-names>E.</given-names></name><name><surname>Frohlich</surname><given-names>K.U.</given-names></name></person-group><article-title>A yeast mutant showing diagnostic markers of early and late apoptosis</article-title><source>J. Cell Biol.</source><year>1997</year><volume>139</volume><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1083/jcb.139.3.729</pub-id><?supplied-pmid 9348289?><pub-id pub-id-type="pmid">9348289</pub-id></element-citation></ref><ref id="B256-genes-10-00770"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modrak</surname><given-names>D.E.</given-names></name><name><surname>Cardillo</surname><given-names>T.M.</given-names></name><name><surname>Newsome</surname><given-names>G.A.</given-names></name><name><surname>Goldenberg</surname><given-names>D.M.</given-names></name><name><surname>Gold</surname><given-names>D.V.</given-names></name></person-group><article-title>Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>8405</fpage><lpage>8410</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2988</pub-id><pub-id pub-id-type="pmid">15548711</pub-id></element-citation></ref><ref id="B257-genes-10-00770"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modrak</surname><given-names>D.E.</given-names></name><name><surname>Leon</surname><given-names>E.</given-names></name><name><surname>Goldenberg</surname><given-names>D.M.</given-names></name><name><surname>Gold</surname><given-names>D.V.</given-names></name></person-group><article-title>Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines</article-title><source>Mol. Cancer Res.</source><year>2009</year><volume>7</volume><fpage>890</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0457</pub-id><pub-id pub-id-type="pmid">19531570</pub-id></element-citation></ref><ref id="B258-genes-10-00770"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frohlich</surname><given-names>F.</given-names></name><name><surname>Petit</surname><given-names>C.</given-names></name><name><surname>Kory</surname><given-names>N.</given-names></name><name><surname>Christiano</surname><given-names>R.</given-names></name><name><surname>Hannibal-Bach</surname><given-names>H.K.</given-names></name><name><surname>Graham</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ejsing</surname><given-names>C.S.</given-names></name><name><surname>Farese</surname><given-names>R.V.</given-names></name><name><surname>Walther</surname><given-names>T.C.</given-names></name></person-group><article-title>The GARP complex is required for cellular sphingolipid homeostasis</article-title><source>Elife</source><year>2015</year><volume>4</volume><fpage>e08712</fpage><pub-id pub-id-type="doi">10.7554/eLife.08712</pub-id></element-citation></ref><ref id="B259-genes-10-00770"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>Z.</given-names></name><name><surname>Fatheddin</surname><given-names>P.</given-names></name><name><surname>Graham</surname><given-names>T.R.</given-names></name></person-group><article-title>An essential subfamily of Drs2p-related P-type ATPases is required for protein trafficking between Golgi complex and endosomal/vacuolar system</article-title><source>Mol. Biol. Cell</source><year>2002</year><volume>13</volume><fpage>3162</fpage><lpage>3177</lpage><pub-id pub-id-type="doi">10.1091/mbc.e02-03-0172</pub-id><pub-id pub-id-type="pmid">12221123</pub-id></element-citation></ref><ref id="B260-genes-10-00770"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomorski</surname><given-names>T.</given-names></name><name><surname>Lombardi</surname><given-names>R.</given-names></name><name><surname>Riezman</surname><given-names>H.</given-names></name><name><surname>Devaux</surname><given-names>P.F.</given-names></name><name><surname>van Meer</surname><given-names>G.</given-names></name><name><surname>Holthuis</surname><given-names>J.C.</given-names></name></person-group><article-title>Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis</article-title><source>Mol. Biol. Cell</source><year>2003</year><volume>14</volume><fpage>1240</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1091/mbc.e02-08-0501</pub-id><pub-id pub-id-type="pmid">12631737</pub-id></element-citation></ref><ref id="B261-genes-10-00770"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Kishimoto</surname><given-names>T.</given-names></name><name><surname>Noji</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name></person-group><article-title>Protein kinases Fpk1p and Fpk2p are novel regulators of phospholipid asymmetry</article-title><source>Mol. Biol. Cell</source><year>2008</year><volume>19</volume><fpage>1783</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1091/mbc.e07-07-0646</pub-id><pub-id pub-id-type="pmid">18199685</pub-id></element-citation></ref><ref id="B262-genes-10-00770"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastide</surname><given-names>A.</given-names></name><name><surname>David</surname><given-names>A.</given-names></name></person-group><article-title>The ribosome, (slow) beating heart of cancer (stem) cell</article-title><source>Oncogenesis</source><year>2018</year><volume>7</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41389-018-0044-8</pub-id><pub-id pub-id-type="pmid">29674660</pub-id></element-citation></ref><ref id="B263-genes-10-00770"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manfrini</surname><given-names>N.</given-names></name><name><surname>Gobbini</surname><given-names>E.</given-names></name><name><surname>Baldo</surname><given-names>V.</given-names></name><name><surname>Trovesi</surname><given-names>C.</given-names></name><name><surname>Lucchini</surname><given-names>G.</given-names></name><name><surname>Longhese</surname><given-names>M.P.</given-names></name></person-group><article-title>G(1)/S and G(2)/M cyclin-dependent kinase activities commit cells to death in the absence of the S-phase checkpoint</article-title><source>Mol. Cell. Biol.</source><year>2012</year><volume>32</volume><fpage>4971</fpage><lpage>4985</lpage><pub-id pub-id-type="doi">10.1128/MCB.00956-12</pub-id><?supplied-pmid 23045388?><pub-id pub-id-type="pmid">23045388</pub-id></element-citation></ref><ref id="B264-genes-10-00770"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Reilly</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Jia</surname><given-names>D.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>CERKL regulates autophagy via the NAD-dependent deacetylase SIRT1</article-title><source>Autophagy</source><year>2019</year><volume>15</volume><fpage>453</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1080/15548627.2018.1520548</pub-id><?supplied-pmid 30205735?><pub-id pub-id-type="pmid">30205735</pub-id></element-citation></ref><ref id="B265-genes-10-00770"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>X.H.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Long</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>L.J.</given-names></name><name><surname>Cai</surname><given-names>M.Y.</given-names></name><name><surname>Wei</surname><given-names>Y.X.</given-names></name><name><surname>Ma</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Acylglycerol kinase is over-expressed in early-stage cervical squamous cell cancer and predicts poor prognosis</article-title><source>Tumour Biol.</source><year>2016</year><volume>37</volume><fpage>6729</fpage><lpage>6736</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4498-4</pub-id><?supplied-pmid 26662108?><pub-id pub-id-type="pmid">26662108</pub-id></element-citation></ref><ref id="B266-genes-10-00770"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>Y.</given-names></name></person-group><article-title>Acylglycerol kinase functions as an oncogene and an unfavorable prognostic marker of human gliomas</article-title><source>Hum. Pathol.</source><year>2016</year><volume>58</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2016.07.034</pub-id><?supplied-pmid 27574811?><pub-id pub-id-type="pmid">27574811</pub-id></element-citation></ref><ref id="B267-genes-10-00770"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-kappaB signaling pathway in hepatocellular carcinoma</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>12057</fpage><lpage>12069</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2666</pub-id><?supplied-pmid 25474138?><pub-id pub-id-type="pmid">25474138</pub-id></element-citation></ref><ref id="B268-genes-10-00770"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name></person-group><article-title>Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor</article-title><source>Mol. Cancer</source><year>2014</year><volume>13</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-13-106</pub-id><pub-id pub-id-type="pmid">24886245</pub-id></element-citation></ref><ref id="B269-genes-10-00770"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>H.</given-names></name><name><surname>Tsygankov</surname><given-names>D.</given-names></name><name><surname>Lew</surname><given-names>D.J.</given-names></name></person-group><article-title>Sensing a bud in the yeast morphogenesis checkpoint: A role for Elm1</article-title><source>Mol. Biol. Cell</source><year>2016</year><volume>27</volume><fpage>1764</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1091/mbc.e16-01-0014</pub-id><?supplied-pmid 27053666?><pub-id pub-id-type="pmid">27053666</pub-id></element-citation></ref><ref id="B270-genes-10-00770"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>E.J.</given-names></name><name><surname>Yoo</surname><given-names>N.J.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>An</surname><given-names>C.H.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name></person-group><article-title>Putative Tumor Suppressor Genes EGR1 and BRSK1 Are Mutated in Gastric and Colorectal Cancers</article-title><source>Oncology</source><year>2016</year><volume>91</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1159/000450616</pub-id><pub-id pub-id-type="pmid">27677186</pub-id></element-citation></ref><ref id="B271-genes-10-00770"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.B.</given-names></name><name><surname>Chen</surname><given-names>J.H.</given-names></name><name><surname>Wang</surname><given-names>Q.Q.</given-names></name><name><surname>Chen</surname><given-names>J.P.</given-names></name><name><surname>Xu</surname><given-names>J.F.</given-names></name><name><surname>Sheng</surname><given-names>C.Y.</given-names></name><name><surname>Ni</surname><given-names>Q.C.</given-names></name></person-group><article-title>Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: Correlation with Jab1 stability and PI3K/Akt pathway</article-title><source>Exp. Mol. Pathol.</source><year>2014</year><volume>97</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2014.07.012</pub-id><pub-id pub-id-type="pmid">25036402</pub-id></element-citation></ref><ref id="B272-genes-10-00770"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saiyin</surname><given-names>H.</given-names></name><name><surname>Na</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Lou</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>44669</fpage><lpage>44681</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.17965</pub-id><?supplied-pmid 28591720?><pub-id pub-id-type="pmid">28591720</pub-id></element-citation></ref><ref id="B273-genes-10-00770"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name></person-group><article-title>E2F1-mediated MNX1-AS1-miR-218-5p-SEC61A1 feedback loop contributes to the progression of colon adenocarcinoma</article-title><source>J. Cell. Biochem.</source><year>2019</year><volume>120</volume><fpage>6145</fpage><lpage>6153</lpage><pub-id pub-id-type="doi">10.1002/jcb.27902</pub-id><pub-id pub-id-type="pmid">30362161</pub-id></element-citation></ref><ref id="B274-genes-10-00770"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>N.N.</given-names></name><name><surname>Wang</surname><given-names>C.Y.</given-names></name><name><surname>Chen</surname><given-names>C.F.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Lai</surname><given-names>M.D.</given-names></name><name><surname>Lin</surname><given-names>Y.C.</given-names></name></person-group><article-title>Voltage-gated calcium channels: Novel targets for cancer therapy</article-title><source>Oncol. Lett.</source><year>2017</year><volume>14</volume><fpage>2059</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6457</pub-id><?supplied-pmid 28781648?><pub-id pub-id-type="pmid">28781648</pub-id></element-citation></ref><ref id="B275-genes-10-00770"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.T.</given-names></name><name><surname>Yeh</surname><given-names>I.J.</given-names></name><name><surname>Chou</surname><given-names>S.K.</given-names></name><name><surname>Yen</surname><given-names>M.C.</given-names></name><name><surname>Kuo</surname><given-names>P.L.</given-names></name></person-group><article-title>Regulatory mechanism of fatty acidCoA metabolic enzymes under endoplasmic reticulum stress in lung cancer</article-title><source>Oncol. Rep.</source><year>2018</year><volume>40</volume><fpage>2674</fpage><lpage>2682</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6664</pub-id><?supplied-pmid 30132556?><pub-id pub-id-type="pmid">30132556</pub-id></element-citation></ref><ref id="B276-genes-10-00770"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>J.</given-names></name><name><surname>Nobeyama</surname><given-names>Y.</given-names></name><name><surname>Umebayashi</surname><given-names>Y.</given-names></name><name><surname>Otsuka</surname><given-names>F.</given-names></name><name><surname>Kikuchi</surname><given-names>K.</given-names></name><name><surname>Ushijima</surname><given-names>T.</given-names></name></person-group><article-title>Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>6080</fpage><lpage>6086</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0157</pub-id><?supplied-pmid 16778180?><pub-id pub-id-type="pmid">16778180</pub-id></element-citation></ref><ref id="B277-genes-10-00770"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Upregulation of AUF1 is involved in the proliferation of esophageal squamous cell carcinoma through GCH1</article-title><source>Int. J. Oncol.</source><year>2016</year><volume>49</volume><fpage>2001</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3713</pub-id><pub-id pub-id-type="pmid">27826622</pub-id></element-citation></ref><ref id="B278-genes-10-00770"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocino-Rodriguez</surname><given-names>M.D.</given-names></name><name><surname>Santillan-Benitez</surname><given-names>J.G.</given-names></name><name><surname>Dozal-Dominguez</surname><given-names>D.S.</given-names></name><name><surname>Hernandez-Navarro</surname><given-names>M.D.</given-names></name><name><surname>Flores-Merino</surname><given-names>M.V.</given-names></name><name><surname>Sandoval-Cabrera</surname><given-names>A.</given-names></name><name><surname>Garcia Vazquez</surname><given-names>F.J.</given-names></name></person-group><article-title>Expression of AdipoR1 and AdipoR2 Receptors as Leptin-Breast Cancer Regulation Mechanisms</article-title><source>Dis. Markers</source><year>2017</year><volume>2017</volume><fpage>4862016</fpage><pub-id pub-id-type="doi">10.1155/2017/4862016</pub-id><?supplied-pmid 29311755?><pub-id pub-id-type="pmid">29311755</pub-id></element-citation></ref><ref id="B279-genes-10-00770"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Collings</surname><given-names>C.K.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Cozzolino</surname><given-names>K.A.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Liang</surname><given-names>K.</given-names></name><name><surname>Marshall</surname><given-names>S.A.</given-names></name><name><surname>Sze</surname><given-names>C.C.</given-names></name><name><surname>Hashizume</surname><given-names>R.</given-names></name><name><surname>Savas</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism</article-title><source>Genes Dev.</source><year>2017</year><volume>31</volume><fpage>2056</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.1101/gad.306092.117</pub-id><pub-id pub-id-type="pmid">29138278</pub-id></element-citation></ref><ref id="B280-genes-10-00770"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>J.B.</given-names></name><name><surname>Huh</surname><given-names>D.</given-names></name><name><surname>Noble</surname><given-names>L.B.</given-names></name><name><surname>Tavazoie</surname><given-names>S.F.</given-names></name></person-group><article-title>Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer</article-title><source>Nat. Cell Biol.</source><year>2015</year><volume>17</volume><fpage>651</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1038/ncb3148</pub-id><pub-id pub-id-type="pmid">25866923</pub-id></element-citation></ref><ref id="B281-genes-10-00770"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhise</surname><given-names>N.S.</given-names></name><name><surname>Chauhan</surname><given-names>L.</given-names></name><name><surname>Shin</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Pounds</surname><given-names>S.</given-names></name><name><surname>Lamba</surname><given-names>V.</given-names></name><name><surname>Lamba</surname><given-names>J.K.</given-names></name></person-group><article-title>MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients</article-title><source>Front. Pharmacol.</source><year>2015</year><volume>6</volume><fpage>324</fpage><pub-id pub-id-type="doi">10.3389/fphar.2015.00324</pub-id><pub-id pub-id-type="pmid">26858643</pub-id></element-citation></ref><ref id="B282-genes-10-00770"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenreiro</surname><given-names>S.</given-names></name><name><surname>Outeiro</surname><given-names>T.F.</given-names></name></person-group><article-title>Simple is good: Yeast models of neurodegeneration</article-title><source>FEMS Yeast Res.</source><year>2010</year><volume>10</volume><fpage>970</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1111/j.1567-1364.2010.00649.x</pub-id><?supplied-pmid 20579105?><pub-id pub-id-type="pmid">20579105</pub-id></element-citation></ref><ref id="B283-genes-10-00770"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billant</surname><given-names>O.</given-names></name><name><surname>Blondel</surname><given-names>M.</given-names></name><name><surname>Voisset</surname><given-names>C.</given-names></name></person-group><article-title>p53, p63 and p73 in the wonderland of S. cerevisiae</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>57855</fpage><lpage>57869</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18506</pub-id><?supplied-pmid 28915717?><pub-id pub-id-type="pmid">28915717</pub-id></element-citation></ref><ref id="B284-genes-10-00770"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Escudero</surname><given-names>I.</given-names></name><name><surname>Roelants</surname><given-names>F.M.</given-names></name><name><surname>Thorner</surname><given-names>J.</given-names></name><name><surname>Nombela</surname><given-names>C.</given-names></name><name><surname>Molina</surname><given-names>M.</given-names></name><name><surname>Cid</surname><given-names>V.J.</given-names></name></person-group><article-title>Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast</article-title><source>Biochem. J.</source><year>2005</year><volume>390</volume><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1042/BJ20050574</pub-id><?supplied-pmid 15913452?><pub-id pub-id-type="pmid">15913452</pub-id></element-citation></ref><ref id="B285-genes-10-00770"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamza</surname><given-names>A.</given-names></name><name><surname>Tammpere</surname><given-names>E.</given-names></name><name><surname>Kofoed</surname><given-names>M.</given-names></name><name><surname>Keong</surname><given-names>C.</given-names></name><name><surname>Chiang</surname><given-names>J.</given-names></name><name><surname>Giaever</surname><given-names>G.</given-names></name><name><surname>Nislow</surname><given-names>C.</given-names></name><name><surname>Hieter</surname><given-names>P.</given-names></name></person-group><article-title>Complementation of Yeast Genes with Human Genes as an Experimental Platform for Functional Testing of Human Genetic Variants</article-title><source>Genetics</source><year>2015</year><volume>201</volume><fpage>1263</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1534/genetics.115.181099</pub-id><?supplied-pmid 26354769?><pub-id pub-id-type="pmid">26354769</pub-id></element-citation></ref><ref id="B286-genes-10-00770"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Tan</surname><given-names>G.</given-names></name><name><surname>Costanzo</surname><given-names>M.</given-names></name><name><surname>Oughtred</surname><given-names>R.</given-names></name><name><surname>Hirschman</surname><given-names>J.</given-names></name><name><surname>Theesfeld</surname><given-names>C.L.</given-names></name><name><surname>Bansal</surname><given-names>P.</given-names></name><name><surname>Sahni</surname><given-names>N.</given-names></name><name><surname>Yi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An extended set of yeast-based functional assays accurately identifies human disease mutations</article-title><source>Genome Res.</source><year>2016</year><volume>26</volume><fpage>670</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1101/gr.192526.115</pub-id><?supplied-pmid 26975778?><pub-id pub-id-type="pmid">26975778</pub-id></element-citation></ref><ref id="B287-genes-10-00770"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachroo</surname><given-names>A.H.</given-names></name><name><surname>Laurent</surname><given-names>J.M.</given-names></name><name><surname>Yellman</surname><given-names>C.M.</given-names></name><name><surname>Meyer</surname><given-names>A.G.</given-names></name><name><surname>Wilke</surname><given-names>C.O.</given-names></name><name><surname>Marcotte</surname><given-names>E.M.</given-names></name></person-group><article-title>Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1126/science.aaa0769</pub-id><pub-id pub-id-type="pmid">25999509</pub-id></element-citation></ref><ref id="B288-genes-10-00770"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardiff</surname><given-names>D.F.</given-names></name><name><surname>Khurana</surname><given-names>V.</given-names></name><name><surname>Chung</surname><given-names>C.Y.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>From yeast to patient neurons and back again: Powerful new discovery platform</article-title><source>Mov. Disord.</source><year>2014</year><volume>29</volume><fpage>1231</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1002/mds.25989</pub-id><pub-id pub-id-type="pmid">25131316</pub-id></element-citation></ref><ref id="B289-genes-10-00770"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veit</surname><given-names>G.</given-names></name><name><surname>Oliver</surname><given-names>K.</given-names></name><name><surname>Apaja</surname><given-names>P.M.</given-names></name><name><surname>Perdomo</surname><given-names>D.</given-names></name><name><surname>Bidaud-Meynard</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>S.T.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Icyuz</surname><given-names>M.</given-names></name><name><surname>Sorscher</surname><given-names>E.J.</given-names></name><name><surname>Hartman</surname><given-names>J.L.</given-names><suffix>IV</suffix></name><etal/></person-group><article-title>Ribosomal Stalk Protein Silencing Partially Corrects the DeltaF508-CFTR Functional Expression Defect</article-title><source>PLoS Biol.</source><year>2016</year><volume>14</volume><elocation-id>e1002462</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002462</pub-id><pub-id pub-id-type="pmid">27168400</pub-id></element-citation></ref><ref id="B290-genes-10-00770"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>M.</given-names></name><name><surname>Kuzmin</surname><given-names>E.</given-names></name><name><surname>van Leeuwen</surname><given-names>J.</given-names></name><name><surname>Mair</surname><given-names>B.</given-names></name><name><surname>Moffat</surname><given-names>J.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name><name><surname>Andrews</surname><given-names>B.</given-names></name></person-group><article-title>Global Genetic Networks and the Genotype-to-Phenotype Relationship</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.033</pub-id><pub-id pub-id-type="pmid">30901552</pub-id></element-citation></ref><ref id="B291-genes-10-00770"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>M.A.</given-names></name><name><surname>Gamazon</surname><given-names>E.R.</given-names></name><name><surname>Al-Ejeh</surname><given-names>F.</given-names></name><name><surname>Aittomaki</surname><given-names>K.</given-names></name><name><surname>Andrulis</surname><given-names>I.L.</given-names></name><name><surname>Anton-Culver</surname><given-names>H.</given-names></name><name><surname>Arason</surname><given-names>A.</given-names></name><name><surname>Arndt</surname><given-names>V.</given-names></name><name><surname>Aronson</surname><given-names>K.J.</given-names></name><name><surname>Arun</surname><given-names>B.K.</given-names></name><etal/></person-group><article-title>Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1741</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-08053-5</pub-id><pub-id pub-id-type="pmid">30988301</pub-id></element-citation></ref><ref id="B292-genes-10-00770"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslow</surname><given-names>D.K.</given-names></name><name><surname>Cameron</surname><given-names>D.M.</given-names></name><name><surname>Collins</surname><given-names>S.R.</given-names></name><name><surname>Schuldiner</surname><given-names>M.</given-names></name><name><surname>Stewart-Ornstein</surname><given-names>J.</given-names></name><name><surname>Newman</surname><given-names>H.W.</given-names></name><name><surname>Braun</surname><given-names>S.</given-names></name><name><surname>Madhani</surname><given-names>H.D.</given-names></name><name><surname>Krogan</surname><given-names>N.J.</given-names></name><name><surname>Weissman</surname><given-names>J.S.</given-names></name></person-group><article-title>A comprehensive strategy enabling high-resolution functional analysis of the yeast genome</article-title><source>Nat. Methods</source><year>2008</year><volume>5</volume><fpage>711</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1234</pub-id><?supplied-pmid 18622397?><pub-id pub-id-type="pmid">18622397</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="genes-10-00770-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Experimental model of gemcitabine and cytarabine drug&#x02013;gene interaction networks. (<bold>A</bold>) The strategy of cytotoxic anticancer drug&#x02013;gene interaction is illustrated in the context of driver gene-mediated oncogenesis. Driver genes promote cancer and influence the expression of passenger genes (black arrows), which also leads to genomic instability and alterations in the genetic buffering network. The genetic buffering network (blue arrows) maintains cellular homeostasis and is altered in cancer cells by genomic instability, thereby creating the potential for drug&#x02013;gene interaction that increases the therapeutic window of anticancer agents (red arrows). Drug&#x02013;gene interaction can either involve driver or passenger genes directly, or the compromised genetic buffering network, which are systematically characterized by the quantitative yeast phenomic model. (<bold>B</bold>) The synthetic genetic array (SGA) method was used to introduce tet-inducible human deoxycytidine kinase (dCK) expression in the yeast knockout and knockdown (YKO/KD) collection. The phenomic model incorporates treatment of individually grown cultures of the YKO/KD collection, and 768 replicate reference (Ref) strain cultures, with increasing gemcitabine (0, 5, 10, 20, and 30 &#x003bc;g/mL) or cytarabine (0, 10, 25, 50, and 100 &#x003bc;g/mL) in a dextrose (HLD) media, with dCK induced by addition of doxycycline. Drug&#x02013;gene interaction profiles were analyzed by recursive expectation-maximization clustering (REMc) and gene ontology (GO) term analysis to characterize phenomic modules with respect to drug&#x02013;gene interaction for gemcitabine or cytarabine, and integrated with pharmacogenomics data to predict evolutionarily conserved drug&#x02013;gene interactions relevant to precision oncology. (<bold>C</bold>) Structures and metabolism of deoxycytidine analogs.</p></caption><graphic xlink:href="genes-10-00770-g001"/></fig><fig id="genes-10-00770-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Phenomic analysis of drug&#x02013;gene interaction for gemcitabine and cytarabine. Average growth curves (from fitting pixel intensity data of 768 replicate cultures to a logistic function) for the reference (RF) strain, treated with the indicated concentrations of (<bold>A</bold>) gemcitabine or (<bold>B</bold>) cytarabine. (<bold>C</bold>&#x02013;<bold>F</bold>) Cell proliferation parameter (CPP) distributions from data depicted in panels A and B, also with and without induction of deoxycytidine kinase (0 or 5 &#x003bc;g/mL doxycycline respectively), for (<bold>C</bold>&#x02013;<bold>D</bold>) gemcitabine and (<bold>E</bold>&#x02013;<bold>F</bold>) cytarabine in &#x003bc;g/mL for (<bold>C</bold>,<bold>E</bold>) L and (<bold>D</bold>,<bold>F</bold>) K. (<bold>G</bold>,<bold>H</bold>) Comparison of drug&#x02013;gene interaction scores calculated for L vs. K for (<bold>G</bold>) gemcitabine and (<bold>H</bold>) cytarabine, where score distributions of yeast knockout/knockdown (YKO/KD, black) and non-mutant parental (Ref, red) strain cultures are indicated along with thresholds for deletion enhancement and suppression (dashed lines at +/&#x02212; 2). (<bold>I</bold>&#x02013;<bold>J</bold>) Differential drug&#x02013;gene interaction using L (<bold>I</bold>) or K (<bold>J</bold>) as the CPP for gemcitabine vs. cytarabine, classified by specificity of gene-drug interaction, where &#x02018;G&#x02019;, &#x02018;C&#x02019;, and &#x02018;B&#x02019; indicate gemcitabine, cytarabine, or both, respectively. Deletion enhancement or suppression is indicated by &#x02018;_Enh&#x02019; or &#x02018;_Sup&#x02019;.</p></caption><graphic xlink:href="genes-10-00770-g002"/></fig><fig id="genes-10-00770-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Prediction of drug&#x02013;gene interaction in cancer cells by integration of yeast phenomic and human pharmacogenomic data. Recursive expectation-maximization clustering results were classified visually by their associated gene interaction profiles (see methods). (<bold>A</bold>) The order of data columns, which is consistent for all heatmaps, is indicated. K-derived interactions are in columns 2 and 4, with L-derived interactions in columns 6 and 8, for gemcitabine and cytarabine, respectively. To the left of each interaction value (indicated by &#x02018;+&#x02019;), is the corresponding &#x02018;shift&#x02019; value (indicated by &#x02018;&#x02212;&#x02018;), referring to the &#x02206;CPP for the respective YKO/KD culture relative to the reference culture average in the absence of gemcitabine or cytarabine (i.e., the effect of the YKO/KD on cell proliferation independent of drug treatment; see methods). (<bold>B&#x02013;F</bold>) Within each panel, clusters in the respective categories are displayed, left to right, in descending order, by relative strength of drug&#x02013;gene interaction effects evident by the heatmaps. (<bold>B</bold>) Enhancing gene&#x02013;drug interactions for both drugs. (<bold>C</bold>) Gemcitabine-specific enhancement. (<bold>D</bold>) Cytarabine-specific enhancement. (<bold>E</bold>) Suppressing gene&#x02013;drug interactions for both drugs. (<bold>F</bold>) Gemcitabine-specific suppression. (<bold>G</bold>) The algorithm for integrating yeast phenomic and cancer pharmacogenomics data: For all cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) database (either lung, hematopoietic and lymphoid, or across all tissues) with increased drug sensitivity, underexpressed (UES) genes were highlighted by yeast homologs that were deletion enhancing, while overexpressed (OES) genes were highlighted by yeast homologs that were deletion suppressing. (<bold>H</bold>) Yeast&#x02013;human homologs identified as described in G. The category of homology from <italic>BiomaRt</italic> is indicated in the left column of each heatmap (see homology color key) shown at right. The gene label color (at far right) indicates whether the human homolog was found in PharmacoDB for both drugs (black), cytarabine (teal), or gemcitabine (gold). <xref ref-type="app" rid="app1-genes-10-00770">Additional Files 5 (File B) and 8 (Files B&#x02013;D)</xref> contain all REMc heatmaps of the types indicated to the left and right, respectively, in panel H. <xref ref-type="app" rid="app1-genes-10-00770">Additional File 8</xref> includes information for all yeast&#x02013;human homologs from each category suggested by the study to exhibit functionally conserved gene&#x02013;drug interaction.</p></caption><graphic xlink:href="genes-10-00770-g003"/></fig><fig id="genes-10-00770-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>GO annotations associated with deletion enhancement or suppression of gemcitabine and/or cytarabine cytotoxicity. Representative GO terms are listed, which were identified by REMc/GTF (orange), GTA (purple), or both methods, for enhancement (above dashed line) or suppression (below dashed line) of gemcitabine (left, red), cytarabine (right, blue), or both media types (black). Term-specific heatmaps were manually reviewed to decide which terms should be included. Distance above or below the horizontal dashed line reflects the average interaction score for genes identified by REMc/GTF or the GTA score (see methods). See <xref ref-type="app" rid="app1-genes-10-00770">Additional Files 5 and 6</xref> for all REMc/GTF and GTA results, and <xref ref-type="app" rid="app1-genes-10-00770">Additional File 7</xref> for GO term-specific heatmaps.</p></caption><graphic xlink:href="genes-10-00770-g004"/></fig><fig id="genes-10-00770-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Drug&#x02013;gene interaction common to gemcitabine and cytarabine. Genes that similarly influence the cytotoxicity of both gemcitabine and cytarabine suggest common pathways that buffer or promote toxicity, as illustrated by: (<bold>A</bold>) GO term-specific heatmaps for DNA integrity checkpoint and its child term intra-S DNA damage checkpoint, which buffer gemcitabine and cytarabine, along with (<bold>B</bold>) genes comprising other DNA checkpoint/repair-related GO terms, such as positive regulation of DNA-dependent DNA replication initiation, and the Mre11, checkpoint clamp and RecQ helicase-Topo III complexes; (<bold>C</bold>,<bold>D</bold>) REMc clusters filtered for PharmacoDB results for yeast-human homologs that exhibited (C) deletion enhancement and UES or (D) deletion suppression and OES; and (<bold>E</bold>) deletion enhancing endosomal transport-related GO terms, including vesicle fusion with vacuole, and the CORVET/HOPS, ESCRT, GET, and Ubp3-Bre5 deubiquitination complexes. Gene labels are color-coordinated with legends in panels B and E, and as described in <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>H for panels C and D. Genes in the YKD collection are underlined.</p></caption><graphic xlink:href="genes-10-00770-g005"/></fig><fig id="genes-10-00770-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Gemcitabine-specific gene interaction. (<bold>A</bold>&#x02013;<bold>C</bold>) Cellular processes that buffer gemcitabine to a greater extent than cytarabine included: (<bold>A</bold>) autophagy-related processes; (<bold>B</bold>) histone modification and chromatin remodeling (particularly for K interaction); and (<bold>C</bold>) peptidyl-tyrosine dephosphorylation, representing the genes <italic>OCA (1&#x02013;6)</italic> (<italic>OCA5</italic> was manually added to the panel (see text); <italic>OCA3</italic>/<italic>SIW14</italic> are aliases). (<bold>D</bold>,<bold>E</bold>) When comparing gene-drug interactions of homologs across cancer pharmacogenomic and yeast phenomic experiments, human genes are predicted to (<bold>D</bold>) buffer gemcitabine toxicity if they are UES and deletion enhancing, or to (<bold>E</bold>) promote gemcitabine toxicity if they are OES and deletion suppressing. (<bold>F</bold>) Apoptosis-related genes and complexes were observed to promote toxicity of gemcitabine more than toxicity of cytarabine. Gene labels are color-coordinated with legends in panels A, B, and F, and as described in <xref ref-type="fig" rid="genes-10-00770-f003">Figure 3</xref>H for panels D and E.</p></caption><graphic xlink:href="genes-10-00770-g006"/></fig><fig id="genes-10-00770-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Cytarabine-specific gene interaction. (<bold>A</bold>) GO terms identified by GTA that revealed deletion enhancement to be greater for cytarabine than gemcitabine. (<bold>B</bold>) Human homologs of cytarabine-specific yeast gene deletion enhancers found to exhibit underexpression sensitivity for cytarabine in cancer cell lines.</p></caption><graphic xlink:href="genes-10-00770-g007"/></fig><table-wrap id="genes-10-00770-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t001_Table 1</object-id><label>Table 1</label><caption><p>GO terms enriched in REMc clusters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GO Term</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">INT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">O</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes in Term</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fig.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GTA Gem L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GTA Cyt L</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ubp3-Bre5 deubiquitination complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.57 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">UBP3:BRE5</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">19.8</td><td align="center" valign="middle" rowspan="1" colspan="1">14.32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of DNA-dependent DNA replication initiation</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-2</td><td align="center" valign="middle" rowspan="1" colspan="1">3/4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.09 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">RFM1:FKH2:SUM1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mre11 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">RAD50:XRS2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">13.7</td><td align="center" valign="middle" rowspan="1" colspan="1">26.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HOPS complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">2/7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.94 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">PEP3:VPS33</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">12.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CORVET complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">2/7</td><td align="center" valign="middle" rowspan="1" colspan="1">3.94 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">PEP3:VPS33</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RecQ helicase-Topo III complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.31 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">SGS1:RMI1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5</td><td align="center" valign="middle" rowspan="1" colspan="1">14.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GET complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" rowspan="1" colspan="1">4.68 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">GET1:GET2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">18.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DNA integrity checkpoint</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">4/40</td><td align="center" valign="middle" rowspan="1" colspan="1">3.85 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">DUN1:RAD17:RAD24:SGS1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;-glucoside transmembrane transporter activity</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.17-3</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">5.98 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">MAL31:MAL11</td><td align="center" valign="middle" rowspan="1" colspan="1">Figure 7A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">intralumenal vesicle formation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">3/7</td><td align="center" valign="middle" rowspan="1" colspan="1">2.90 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">DOA4:VPS24:BRO1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">9.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDA1 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/3</td><td align="center" valign="middle" rowspan="1" colspan="1">7.08 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">HDA1:HDA3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Swr1 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-11</td><td align="center" valign="middle" rowspan="1" colspan="1">3/12</td><td align="center" valign="middle" rowspan="1" colspan="1">3.46 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">SWC3:VPS71:SWR1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">2.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">peptidyl-tyrosine dephosphorylation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">5/20</td><td align="center" valign="middle" rowspan="1" colspan="1">2.18 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">OCA2:SIW14:OCA1:OCA4:OCA6</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>C</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Set1C/COMPASS complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">3/6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.74 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">SDC1:SWD3:BRE2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phospholipid-translocating ATPase activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sup</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-0-8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.70 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRS2:LEM3:DNF2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.9</td></tr></tbody></table><table-wrap-foot><fn><p>For each GO term, the table indicates which drugs interact with it, the interaction type (enhancing or suppressing), the ontology (&#x02018;O&#x02019;) it derives from (cellular process or component, or molecular function), the REMc cluster ID from which the term was most specific, the fraction of the genes in the term that were observed in the cluster, and the <italic>p</italic>-value for enrichment of the genes. Relevant figures and associated GTA data are also given.</p></fn></table-wrap-foot></table-wrap><table-wrap id="genes-10-00770-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t002_Table 2</object-id><label>Table 2</label><caption><p>GO terms identified by gene ontology term averaging (GTA).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Term</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">INT_Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ont</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cluster</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fig.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem GTA_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gem GTA_L</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt GTA_K</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cyt GTA_L</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">checkpoint clamp complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD17 | MEC3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.3</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;23.5</td><td align="center" valign="middle" rowspan="1" colspan="1">15.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HOPS complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.94 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">VPS16 | VPS8 | PEP3 | VPS41 | VPS33 | PEP5</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.3</td><td align="center" valign="middle" rowspan="1" colspan="1">12.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;11.4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mre11 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">5.66 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">MRE11 | RAD50 | XRS2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.8</td><td align="center" valign="middle" rowspan="1" colspan="1">13.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;39.3</td><td align="center" valign="middle" rowspan="1" colspan="1">26.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RecQ helicase-Topo III complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-14</td><td align="center" valign="middle" rowspan="1" colspan="1">3.31 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">RMI1 | SGS1 | TOP3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;24.7</td><td align="center" valign="middle" rowspan="1" colspan="1">14.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ubp3-Bre5 deubiquitination complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.2-0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.57 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">UBP3 | BRE5</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;9.2</td><td align="center" valign="middle" rowspan="1" colspan="1">19.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;16.9</td><td align="center" valign="middle" rowspan="1" colspan="1">14.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">vesicle fusion with vacuole</td><td align="center" valign="middle" rowspan="1" colspan="1">Both</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">VAM3 | VPS33</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7.4</td><td align="center" valign="middle" rowspan="1" colspan="1">13.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;11.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sec61 translocon complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">SEC61 | SBH2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HIR complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">HIR1 | HIR2 | HPC2 | HIR3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sphinganine kinase activity</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L</td><td align="center" valign="middle" rowspan="1" colspan="1">F</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">LCB4 | LCB5</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">protein localization to septin ring</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyt</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">ELM1 | HSL1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f007">Figure 7</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;17.8</td><td align="center" valign="middle" rowspan="1" colspan="1">21.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">autophagosome maturation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">VAM3 | CCZ1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.6</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Elongator holoenzyme complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">TUP1 | ELP4 | ELP2 | IKI3 | IKI1 | ELP3 | ELP6</td><td align="center" valign="middle" rowspan="1" colspan="1">
<xref ref-type="app" rid="app1-genes-10-00770">Figure S4C</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.6</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ESCRT I complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">STP22 | VPS28 | SRN2 | MVB12</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.9</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">negative regulation of macroautophagy</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">PHO85 | PHO80 | KSP1 | PCL5 | SIC1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">9.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">protein urmylation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">ELP2 | UBA4 | NCS2 | URM1 | URE2 | ELP6</td><td align="center" valign="middle" rowspan="1" colspan="1">
<xref ref-type="app" rid="app1-genes-10-00770">Figure S4C</xref>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CORVET complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">2-0.14-1</td><td align="center" valign="middle" rowspan="1" colspan="1">3.94 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">VPS16 | VPS8 | PEP3 | VPS41 | VPS33 | VPS3 | PEP5</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ESCRT-0 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS27 | HSE1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.7</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDA1 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-0</td><td align="center" valign="middle" rowspan="1" colspan="1">7.08 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">HDA3 | HDA1 | HDA2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GATOR (Iml1) complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NPR2 | NPR3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.4</td><td align="center" valign="middle" rowspan="1" colspan="1">6.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">intralumenal vesicle formation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-10</td><td align="center" valign="middle" rowspan="1" colspan="1">2.90 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">VPS20 | VPS24 | BRO1 | DOA4 | VPS4 | SNF7</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.7</td><td align="center" valign="middle" rowspan="1" colspan="1">9.0</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">positive regulation of DNA-dependent DNA replication initiation</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">P</td><td align="center" valign="middle" rowspan="1" colspan="1">1-0-2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.09 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">SUM1 | FKH2 | RFM1 | FKH1</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f005">Figure 5</xref>B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">15.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAVE complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Enh L/K</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">RAV1 | RAV2</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GARP complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Sup L</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">VPS51 | VPS53 | VPS54 | VPS52</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lem3p-Dnf1p complex</td><td align="center" valign="middle" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" rowspan="1" colspan="1">Sup L</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">DNF1 | LEM3</td><td align="center" valign="middle" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphatidylserine biosynthetic process</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gem</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sup L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DEP1 | CHO1 | UME6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><xref ref-type="fig" rid="genes-10-00770-f006">Figure 6</xref>D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3</td></tr></tbody></table><table-wrap-foot><fn><p>See <xref rid="genes-10-00770-t001" ref-type="table">Table 1</xref> for data descriptions. &#x02018;NA&#x02019; indicates terms identified by GTA only (i.e., not identified by REMc/GTF).</p></fn></table-wrap-foot></table-wrap><table-wrap id="genes-10-00770-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">genes-10-00770-t006_Table 6</object-id><label>Table 6</label><caption><p>Disease relevance of buffering interactions from the yeast phenomic model evidenced by the cancer biology literature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene (Yeast/Human)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Process/Complex</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description (Human)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside Analog Relevance</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD24/RAD17</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA damage checkpoint</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD17 checkpoint clamp loader component</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-genes-10-00770" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD50/RAD50</td><td align="center" valign="middle" rowspan="1" colspan="1">Mre11 complex</td><td align="center" valign="middle" rowspan="1" colspan="1">RAD50 double strand break repair protein</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B127-genes-10-00770" ref-type="bibr">127</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Depletion of human Rad50 sensitizes Ataxia-telangiectasia (AT) fibroblasts to gemcitabine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDA1/HDAC6</td><td align="center" valign="middle" rowspan="1" colspan="1">Hda1 complex; histone deacetylation</td><td align="center" valign="middle" rowspan="1" colspan="1">histone deacetylase 6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B160-genes-10-00770" ref-type="bibr">160</xref>,<xref rid="B165-genes-10-00770" ref-type="bibr">165</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">HDAC inhibitors enhance sensitivity to gemcitabine in pancreatic cancer cells and are associated with reduction of HDAC6; HDAC6 inhibition induces apoptosis in cytarabine treated AML cells</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">RAD54/ATRX</td><td align="center" valign="middle" rowspan="1" colspan="1">Chromatin remodeling</td><td align="center" valign="middle" rowspan="1" colspan="1">ATRX, chromatin remodeler</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B168-genes-10-00770" ref-type="bibr">168</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Glioma patients with IDH1 mutations and loss of ATRX had improved response to gemcitabine plus radiation therapy</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KEX2/PCSK7</td><td align="center" valign="middle" rowspan="1" colspan="1">serine-type endopeptidase activity</td><td align="center" valign="middle" rowspan="1" colspan="1">proprotein convertase subtilisin/kexin type 7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B179-genes-10-00770" ref-type="bibr">179</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Overexpressed in gemcitabine resistant pancreatic cancer cell lines</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">YNK1/NME5</td><td align="center" valign="middle" rowspan="1" colspan="1">Nucleoside diphosphate phosphorylation</td><td align="center" valign="middle" rowspan="1" colspan="1">NME/NM23 family member 5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B182-genes-10-00770" ref-type="bibr">182</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Depletion of NME5 sensitizes gemcitabine-resistant cancer cell lines to gemcitabine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPS30/BECN1</td><td align="center" valign="middle" rowspan="1" colspan="1">Autophagy</td><td align="center" valign="middle" rowspan="1" colspan="1">beclin 1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B170-genes-10-00770" ref-type="bibr">170</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Depletion of <italic>BECN1</italic> sensitizes pancreatic cancer stem cells to gemcitabine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCB4/5/CERKL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sphinganine kinase activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ceramide kinase like</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-genes-10-00770" ref-type="bibr">138</xref>,<xref rid="B264-genes-10-00770" ref-type="bibr">264</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CERKL stabilizes SIRT1, SIRT1 chemical inhibition sensitizes acute myeloid leukemia cells to cytarabine</td></tr></tbody></table><table-wrap-foot><fn><p>Deletion-enhancing/UES drug&#x02013;gene interactions are highlighted; most exemplify loss of buffering functions that lead to increased drug sensitivity; however, there is one instance (KEX2/PCSK7) of overexpression of the buffering gene that increases drug resistance.</p></fn></table-wrap-foot></table-wrap></floats-group></article>